

39/380447 PATENT COOPERATION TREATY

5000 PCT

**NOTIFICATION OF ELECTION**  
(PCT Rule 61.2)

From the INTERNATIONAL BUREAU

To:

Assistant Commissioner for Patents  
United States Patent and Trademark  
Office  
Box PCT  
Washington, D.C.20231  
ÉTATS-UNIS D'AMÉRIQUE

in its capacity as elected Office

Date of mailing (day/month/year) 01 March 2000 (01.03.00)	
International application No. PCT/US99/16596	Applicant's or agent's file reference P1581R2
International filing date (day/month/year) 22 July 1999 (22.07.99)	Priority date (day/month/year) 27 July 1998 (27.07.98)
<b>Applicant</b> SIDHU, Sachdev, S. et al	

1. The designated Office is hereby notified of its election made:

in the demand filed with the International Preliminary Examining Authority on:

02 February 2000 (02.02.00)

in a notice effecting later election filed with the International Bureau on:

\_\_\_\_\_

2. The election  was

was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland	Authorized officer R. Forax
Facsimile No.: (41-22) 740.14.35	Telephone No.: (41-22) 338.83.38

PATENT COOPERATION TREATY  
PCT

**INTERNATIONAL SEARCH REPORT**

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference <b>P1581R2</b>	<b>FOR FURTHER ACTION</b> see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.	
International application No. <b>PCT/US 99/ 16596</b>	International filing date (day/month/year) <b>22/07/1999</b>	(Earliest) Priority Date (day/month/year) <b>27/07/1998</b>
Applicant <b>GENENTECH, INC. et al.</b>		

This International Search Report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This International Search Report consists of a total of 4 sheets.

It is also accompanied by a copy of each prior art document cited in this report.

**1. Basis of the report**

- a. With regard to the language, the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.
  - the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).
- b. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international search was carried out on the basis of the sequence listing :
  - contained in the international application in written form.
  - filed together with the international application in computer readable form.
  - furnished subsequently to this Authority in written form.
  - furnished subsequently to this Authority in computer readable form.
  - the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
  - the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished

2.  Certain claims were found unsearchable (See Box I).

3.  Unity of invention is lacking (see Box II).

4. With regard to the title,

- the text is approved as submitted by the applicant.
- the text has been established by this Authority to read as follows:

**IMPROVED TRANSFORMATION EFFICIENCY IN PHAGE DISPLAY THROUGH MODIFICATION OF A COAT PROTEIN**

5. With regard to the abstract,

- the text is approved as submitted by the applicant.
- the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

6. The figure of the drawings to be published with the abstract is Figure No.

- as suggested by the applicant.
- because the applicant failed to suggest a figure.
- because this figure better characterizes the invention.

None of the figures.

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US 99/16596

## B x I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
  
2.  Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
  
3.  Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## B x II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1.  As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
  
2.  As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
  
3.  As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
  
4.  No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Claims 1-15.

### Remark on Protest

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

1. Claims: 1-15

Fusion protein comprising a heterologous polypeptide and a variant of a major viral coat protein, which enhances expression and/or surface display of said fusion protein or heterologous moiety, expression vector encoding said fusion protein, library comprising a plurality of said vectors, host cells expressing said protein, viruses displaying said protein, and a method of decreasing the detection limit of a phage display system using said fusion protein.

2. Claim : 21

Method for expressing a selected polypeptide involving screening of a phage-display library.

3. Claims: 16-20

Method of transformation of cells by electroporation.

4. Claims: 22-28, partially

Fusion protein of at least a portion of protein III with a heterologous polypeptide at its C-terminal, expression vector encoding said protein, library comprising a plurality of said proteins, host cell comprising said vector, and a virus displaying said protein.

5. Claims: 22-28, partially

Fusion protein of at least a portion of protein VIII with a heterologous polypeptide at its C-terminal, expression vector encoding said protein, library comprising a plurality of said proteins, host cell comprising said vector, and a virus displaying said protein.

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 99/16596

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/10 C12N15/62 C07K14/01 C12N1/00 C12N15/86

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 94 11496 A (IXSYS INC) 26 May 1994 (1994-05-26) page 39, paragraph 3 ---	1,2,5, 7-14
X	WO 92 09690 A (GENENTECH INC) 11 June 1992 (1992-06-11) abstract ---	1,2,7-14
X	DATABASE MEDLINE [Online] AN 96105339, 1995 SMITH, G.R. ET AL.: "Expression, purification, and use as an antigen of recombinant sugarcane mosaic virus coat protein." XP002127416 abstract -----	1,3,7,9, 11,12

 Further documents are listed in the continuation of box C. Patent family members are listed in annex.

## ° Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

13 January 2000

Date of mailing of the international search report

27.04.00

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Smalt, R

## INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 99/16596

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 9411496	A 26-05-1994	CA 2148838	A	26-05-1994
		EP 0675953	A	11-10-1995
		JP 8505524	T	18-06-1996
		US 5770434	A	23-06-1998
-----	-----	-----	-----	-----
WO 9209690	A 11-06-1992	AT 164395	T	15-04-1998
		CA 2095633	A	04-06-1992
		DE 69129154	D	30-04-1998
		DE 69129154	T	20-08-1998
		EP 0564531	A	13-10-1993
		ES 2113940	T	16-05-1998
		GR 3026468	T	30-06-1998
		JP 7503600	T	20-04-1995
		US 5750373	A	12-05-1998
		US 5534617	A	09-07-1996
		US 5688666	A	18-11-1997
		US 5780279	A	14-07-1998
		US 5846765	A	08-12-1998
		US 5821047	A	13-10-1998
		US 5834598	A	10-11-1998
		US 6022711	A	08-02-2000
		US 6040136	A	21-03-2000
-----	-----	-----	-----	-----

# PATENT COOPERATION TREATY

## PCT

### INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference <b>P1581R2</b>	<b>FOR FURTHER ACTION</b>	See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)
International application No. <b>PCT/US99/16596</b>	International filing date (day/month/year) <b>22/07/1999</b>	Priority date (day/month/year) <b>27/07/1998</b>
International Patent Classification (IPC) or national classification and IPC <b>C12N15/10</b>		
<p><b>Applicant</b>  <b>GENENTECH, INC. et al.</b></p>		
<p>1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.</p> <p>2. This REPORT consists of a total of 7 sheets, including this cover sheet.</p> <p><input checked="" type="checkbox"/> This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).</p> <p>These annexes consist of a total of 2 sheets.</p>		
<p>3. This report contains indications relating to the following items:</p> <ul style="list-style-type: none"> <li>I    <input checked="" type="checkbox"/> Basis of the report</li> <li>II    <input type="checkbox"/> Priority</li> <li>III    <input type="checkbox"/> Non-establishment of opinion with regard to novelty, inventive step and industrial applicability</li> <li>IV    <input checked="" type="checkbox"/> Lack of unity of invention</li> <li>V    <input checked="" type="checkbox"/> Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement</li> <li>VI    <input type="checkbox"/> Certain documents cited</li> <li>VII    <input type="checkbox"/> Certain defects in the international application</li> <li>VIII    <input checked="" type="checkbox"/> Certain observations on the international application</li> </ul>		

Date of submission of the demand <b>02/02/2000</b>	Date of completion of this report <i>20.10.00</i>
Name and mailing address of the international preliminary examining authority:  European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465	Authorized officer <b>Lanzrein, M</b> Telephone No. +49 89 2399 7358



# INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/US99/16596

## I. Basis of the report

1. This report has been drawn on the basis of (*substitute sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to the report since they do not contain amendments.*):

### Description, pages:

1-85                   as originally filed

### Claims, No.:

1-3,5-10,12-15       as originally filed

4,11                   as received on                   04/10/2000   with letter of                   04/10/2000

### Drawings, sheets:

1/26-26/26           as originally filed

2. The amendments have resulted in the cancellation of:

the description,       pages:  
 the claims,           Nos.:  
 the drawings,         sheets:

3.  This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):

4. Additional observations, if necessary:

## IV. Lack of unity of invention

1. In response to the invitation to restrict or pay additional fees the applicant has:

restricted the claims.  
 paid additional fees.  
 paid additional fees under protest.

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT**

International application No. PCT/US99/16596

neither restricted nor paid additional fees.

2.  This Authority found that the requirement of unity of invention is not complied and chose, according to Rule 68.1, not to invite the applicant to restrict or pay additional fees.

3. This Authority considers that the requirement of unity of invention in accordance with Rules 13.1, 13.2 and 13.3 is

complied with.

not complied with for the following reasons:

**see separate sheet**

4. Consequently, the following parts of the international application were the subject of international preliminary examination in establishing this report:

all parts.

the parts relating to claims Nos. .

**V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**

**1. Statement**

Novelty (N)	Yes: Claims 5-7
	No: Claims 1-4, 8-14
Inventive step (IS)	Yes: Claims 7
	No: Claims 1-6, 8-14
Industrial applicability (IA)	Yes: Claims 1-14
	No: Claims

**2. Citations and explanations**

**see separate sheet**

**VIII. Certain observations on the international application**

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:

**see separate sheet**

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT - SEPARATE SHEET**

International application No. PCT/US99/16596

Reference is made to the following document (cited by the examiner):

D1: Luzzago A. et al., *Gene* 128, 51-57, 1993.

**Re Item IV**

**Lack of unity of invention**

The present application lacks unity within the meaning of Art. 34(3) and Rule 13.1 PCT. The international preliminary examining Authority is of the opinion that the present application contains two separate alleged inventions are not so linked as to form a single general inventive concept, therefore lacking unity *a priori*:

- 1) Claims 1-4, 7-14 (completely), claim 15 (partially): fusion proteins comprising a heterologous polypeptide fused to a variant of a major coat protein of a virus/phage. Vectors, host cells, virus displaying said fusion protein, library of viruses displaying multiple fusion proteins, method for isolating target molecules, method for decreasing the detection limit of phage display.
  
- 2) Claims 5, 6 (completely), claim 15 (partially): fusion proteins comprising a heterologous polypeptide fused to a variant of a coat protein such as pIII of a filamentous phage, method for decreasing the detection limit of phage display.

In view of the prior art, alleged invention 1) lacks unity of invention *a posteriori* for the following reasons:

D1 is prejudicial to novelty of claims 1-4, 9-14 (see below Item V, 2.), i.e. fusion proteins comprising variants of a major coat protein existed. Hence, there is no common inventive concept linking the variants of invention 1) and each variant has to be considered as a separate invention.

With regard to the novelty and inventive step objections (see Item V) the IPEA has chosen not to invite the applicant to pay additional fees. However, in case of later regional filings, non-unity objections are likely to be raised.

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT - SEPARATE SHEET**

International application No. PCT/US99/16596

**Re It m V**

**Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**

1. The present application concerns fusion proteins of a filamentous phage coat protein with a heterologous sequence. The coat protein is a variant of the wild type major coat protein VIII (pVIII) or the coat protein III (pIII).  
Claimed are the fusion proteins, vectors, host cells, a virus displaying the fusion protein on the surface, a library comprising a plurality of such viruses, a method for finding target molecules and a method for improvement of phage display detection.  
The description discloses the improved properties of certain pVIII variants, i.e. the enhanced display of heterologous sequences on phage particles.
  
2. Claims 1-4, 8-14 lack novelty within the meaning of Art. 33(2) PCT in view of D1.  
D1 describes a phage library of bacteriophage f1, containing a random nonapeptide in the N-terminal-region-of-the major coat-protein-VIII.-With respect to the disclosure on p. 40 of the description of the present application, pVIII of f1 is in fact a variant of the M13 pVIII, having a single amino acid substitution N to D at position 12. Hence, the fusion proteins of D1 consist of a random nonapeptide fused N-terminally to a variant of M13 pVIII.  
It is recognized that in D1, the heterologous sequence is inserted three amino acids downstream from the N-terminus of pVIII. Since the variants claimed are not limited and include deletions, insertions, substitutions and combinations thereof (description p. 19 lines 16-26), the molecules of D1 fall under the claims, as they can be regarded as fusions of an N-terminally deleted pVIII with a heterologous sequence.  
Thus, D1 is prejudicial to novelty of claims 1-3 and also claim 4, since the amino acid substitution N12D falls under the scope of said claim. D1 also discloses vectors, host cells, a library comprising a plurality fusion proteins on the surface and methods for selecting target molecules (p. 52, right-hand column). D1 is therefore prejudicial to novelty of claims 9-14.

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT - SEPARATE SHEET**

International application No. PCT/US99/16596

3. Inventive step in the sense of Art. 33 (3) can be acknowledged for claim 7, insofar as the inventive contribution lies in the provision of further fusion proteins which *do not exhibit increased fusion protein display*. Only certain variants exhibit said increased protein display, whereas the claim is broad and covers variants which do not exhibit any unexpected technical effect other than the fact that after two or more amino acid substitutions the ability to display proteins was *retained*. Since this tolerance for mutation was unexpected and not derivable from the available prior art, inventive step in the sense of Art. 33 (3) PCT is recognized.

However, in case claim 7 is interpreted in the light of the description the inventive contribution lies in the provision of further fusion proteins which *do exhibit improved display of the heterologous polypeptide in phage display*. In this case, inventive step of said claim in its present broad form cannot be acknowledged because it appears not plausible that the large number of variants covered by the claim will all solve the problem.

4. With regard to insufficiency of disclosure of the subject-matter of claims 5 and 6 which leads to an objection under Art. 5/6 PCT (see below), an inventive step within the meaning of Art. 33(3) cannot be acknowledged for said claims because the solution to the technical problem has not been disclosed.

**Re Item VIII**

**Certain observations on the international application**

1. Claims 1, 4-6, 14, 15 do not meet the requirements of Article 6 PCT
  - 1.1 Claims 5, 6 are not sufficiently disclosed and supported by the description as required by Article 5 and 6 PCT. Said claims concern variants of a wild type coat protein, preferably protein pIII, having an alteration in the transmembrane domain or in the cytoplasmic domain. It appears that such variants are not disclosed in the description. Examples 8-25 concern variants of the major coat protein pVIII.

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT - SEPARATE SHEET**

International application No. PCT/US99/16596

Example 26 deals with a gIII C-terminal fragment which appears to consist of the wild type sequence.

- 1.2 Claim 4 appears to be unhappily drafted. For the purposes of the present examination, the claim was understood such that the variant should have the wild type sequence and at least 1 substitution taken from the list. However, since the term "variant" is not limited (see below) the claim could be understood as if the only delimiting feature was an amino acid from the list, with the rest of the sequence being random (cf. 1.1).
- 1.3 The terms "variant" and "a portion of" used in claims 1, 4, 5, 14, 15 are vague and unclear (Article 6 PCT). Said terms alone without substantially delimiting features are indefinite and may encompass virtually any polypeptide, thereby rendering the definition of the subject-matter of said claims unclear.

## CLAIMS

1. A fusion protein comprising a heterologous polypeptide fused to a major coat protein of a virus, wherein the major coat protein is a variant of a wild type major coat protein of the virus.
- 5  
2. The fusion protein of claim 1, wherein the virus is selected from the group consisting of a filamentous phage, a lambda phage, a Baculovirus, a T4 phage and a T7 phage.
- 10  
3. The fusion protein of claim 1, wherein the phage is a filamentous phage, the major coat protein is gpVIII and the heterologous polypeptide is fused to the N-terminus or the C-terminus thereof.
- 15  
4. The fusion protein of claim 1, wherein the major coat protein is a variant of a wild type filamentous phage coat protein which contains at least one amino acid residue selected from the list below in the position indicated:

	<u>Residue Number</u>	<u>Amino Acid Residue</u>
	1	E, L, V, Q, D, I, N
	2	R, H, F, W, E, K, Y, D
20	3	T, E, L, S, D, I, V, A
	4	D, R, H, E, K
	5	R, H, N, D, K, Q, E
	6	Y, W, S, I, L, F, T, V
	7	T, N, S
25	8	D, H, R, E, K
	9	E, Q, T, D, N, S
	11	W, I, V, Y, L, F
	12	R, H, N, E, D, K, Q
	13	I, L, E, Q, A, V, D, T, N, S
30	14	L, I, V
	15	D, R, N, E, K, H, Q
	16	E, V, L, T, D, I, A, S, G
	17	E, V, L, I, A, T, D
	18	L, V, I
35	19	L, T, Q, E, I, V, S, A, N, D
	20	R, D, H, N, Q, K, E
	21	W, Y, I, L, F, V
	22	W, F, Y

P1581R2

23	W, Y, I, V, H, K, F, L, R
24	I, Q, L, N, V
25	S, L, I, T, V
26	A, I, V, G, L, M
5	N, T, S
27	I, L, V
28	K, R, F, W, H, Y
29	I, V, L.
30	

10 5. A fusion protein comprising a heterologous polypeptide fused to at least a portion of a coat protein of a filamentous phage, wherein the coat protein is a variant of a wild type coat protein of the phage, the variant having an alteration in the transmembrane domain or in the cytoplasmic domain of the coat protein.

15 6. The fusion protein of claim 5, wherein the coat protein is gpIII of a filamentous phage and the heterologous polypeptide is fused to the N-terminus or the C-terminus thereof.

7. The fusion protein of claim 1, wherein the variant has 2 - 50 altered residues relative to the wild type coat protein sequence.

20 8. The fusion protein of claim 1, wherein the heterologous polypeptide is an antibody or a fragment thereof or a cytokine or a cytokine receptor.

9. A replicable expression vector comprising a gene fusion, wherein the gene fusion encodes

25 25 the fusion protein of claim 1.

10. A library comprising a plurality of the replicable expression vectors of claim 9, the expression vectors comprising a plurality of different gene fusions encoding a plurality of fusion proteins.

30 30 11. Host cells comprising the vector of claim 9.

12. A virus displaying the fusion protein of claim 1 on the surface thereof.

35 35 13. A library of virus, comprising a plurality of the virus of claim 12 displaying a plurality of different fusion proteins on the surface thereof.

14. A method, comprising:

## PATENT COOPERATION TREATY

PCT

REC'D 25 OCT 2000
WIPO
PCT

## INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference P1581R2	<b>FOR FURTHER ACTION</b>	See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)
--	---------------------------	---

International application No. PCT/US99/16596	International filing date (day/month/year) 22/07/1999	Priority date (day/month/year) 27/07/1998
---	--	--

International Patent Classification (IPC) or national classification and IPC C12N15/10	<b>RECEIVED</b> MAY 15 2001
---	--------------------------------

Applicant GENENTECH, INC. et al.	<b>TECH CENTER 1600/2001</b>
-------------------------------------	------------------------------

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.

2. This REPORT consists of a total of 7 sheets, including this cover sheet.

This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

These annexes consist of a total of 2 sheets.

3. This report contains indications relating to the following items:

- I    Basis of the report
- II    Priority
- III    Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
- IV    Lack of unity of invention
- V    Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- VI    Certain documents cited
- VII    Certain defects in the international application
- VIII    Certain observations on the international application

Date of submission of the demand 02/02/2000	Date of completion of this report 12.0.10.00
Name and mailing address of the international preliminary examining authority: European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465	Authorized officer  Lanzrein, M  Telephone No. +49 89 2399 7358



**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT**

International application No. PCT/US99/16596

**I. Basis of the report**

1. This report has been drawn on the basis of (*substitute sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to the report since they do not contain amendments.*):

**Description, pages:**

1-85                   as originally filed

**Claims, No.:**

1-3,5-10,12-15       as originally filed

4,11                   as received on                   04/10/2000   with letter of                   04/10/2000

**Drawings, sheets:**

1/26-26/26           as originally filed

2. The amendments have resulted in the cancellation of:

the description,       pages:  
 the claims,           Nos.:  
 the drawings,         sheets:

3.  This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):

4. Additional observations, if necessary:

**IV. Lack of unity of invention**

1. In response to the invitation to restrict or pay additional fees the applicant has:

restricted the claims.  
 paid additional fees.  
 paid additional fees under protest.

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT**

International application No. PCT/US99/16596

neither restricted nor paid additional fees.

2.  This Authority found that the requirement of unity of invention is not complied and chose, according to Rule 68.1, not to invite the applicant to restrict or pay additional fees.

3. This Authority considers that the requirement of unity of invention in accordance with Rules 13.1, 13.2 and 13.3 is

complied with.

not complied with for the following reasons:

**see separate sheet**

4. Consequently, the following parts of the international application were the subject of international preliminary examination in establishing this report:

all parts.

the parts relating to claims Nos. . .

**V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**

1. Statement

Novelty (N)	Yes:	Claims 5-7
	No:	Claims 1-4, 8-14
Inventive step (IS)	Yes:	Claims 7
	No:	Claims 1-6, 8-14
Industrial applicability (IA)	Yes:	Claims 1-14
	No:	Claims

2. Citations and explanations

**see separate sheet**

**VIII. Certain observations on the international application**

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:

**see separate sheet**

Reference is made to the following document (cited by the examiner):

D1: Luzzago A. et al., *Gene* 128, 51-57, 1993.

**Re Item IV**

**Lack of unity of invention**

The present application lacks unity within the meaning of Art. 34(3) and Rule 13.1 PCT. The international preliminary examining Authority is of the opinion that the present application contains two separate alleged inventions are not so linked as to form a single general inventive concept, therefore lacking unity *a priori*.

- 1) Claims 1-4, 7-14 (completely), claim 15 (partially): fusion proteins comprising a heterologous polypeptide fused to a variant of a major coat protein of a virus/phage. Vectors, host cells, virus displaying said fusion protein, library of viruses displaying multiple fusion proteins, method for isolating target molecules, method for decreasing the detection limit of phage display.
  
- 2) Claims 5, 6 (completely), claim 15 (partially): fusion proteins comprising a heterologous polypeptide fused to a variant of a coat protein such as pIII of a filamentous phage, method for decreasing the detection limit of phage display.

In view of the prior art, alleged invention 1) lacks unity of invention *a posteriori* for the following reasons:

D1 is prejudicial to novelty of claims 1-4, 9-14 (see below Item V, 2.), i.e. fusion proteins comprising variants of a major coat protein existed. Hence, there is no common inventive concept linking the variants of invention 1) and each variant has to be considered as a separate invention.

With regard to the novelty and inventive step objections (see Item V) the IPEA has chosen not to invite the applicant to pay additional fees. However, in case of later regional filings, non-unity objections are likely to be raised.

**Re Item V**

**Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**

1. The present application concerns fusion proteins of a filamentous phage coat protein with a heterologous sequence. The coat protein is a variant of the wild type major coat protein VIII (pVIII) or the coat protein III (pIII).  
Claimed are the fusion proteins, vectors, host cells, a virus displaying the fusion protein on the surface, a library comprising a plurality of such viruses, a method for finding target molecules and a method for improvement of phage display detection.  
The description discloses the improved properties of certain pVIII variants, i.e. the enhanced display of heterologous sequences on phage particles.
  
2. Claims 1-4, 8-14 lack novelty within the meaning of Art. 33(2) PCT in view of D1.  
D1 describes a phage library of bacteriophage f1, containing a random nonapeptide in the N-terminal region of the major coat protein VIII. With respect to the disclosure on p. 40 of the description of the present application, pVIII of f1 is in fact a variant of the M13 pVIII, having a single amino acid substitution N to D at position 12. Hence, the fusion proteins of D1 consist of a random nonapeptide fused N-terminally to a variant of M13 pVIII.  
It is recognized that in D1, the heterologous sequence is inserted three amino acids downstream from the N-terminus of pVIII. Since the variants claimed are not limited and include deletions, insertions, substitutions and combinations thereof (description p. 19 lines 16-26), the molecules of D1 fall under the claims, as they can be regarded as fusions of an N-terminally deleted pVIII with a heterologous sequence.  
Thus, D1 is prejudicial to novelty of claims 1-3 and also claim 4, since the amino acid substitution N12D falls under the scope of said claim. D1 also discloses vectors, host cells, a library comprising a plurality fusion proteins on the surface and methods for selecting target molecules (p. 52, right-hand column). D1 is therefore prejudicial to novelty of claims 9-14.

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT - SEPARATE SHEET**

International application No. PCT/US99/16596

3. Inventive step in the sense of Art. 33 (3) can be acknowledged for claim 7, insofar as the inventive contribution lies in the provision of further fusion proteins which *do not exhibit increased fusion protein display*. Only certain variants exhibit said increased protein display, whereas the claim is broad and covers variants which do not exhibit any unexpected technical effect other than the fact that after two or more amino acid substitutions the ability to display proteins was *retained*. Since this tolerance for mutation was unexpected and not derivable from the available prior art, inventive step in the sense of Art. 33 (3) PCT is recognized.

However, in case claim 7 is interpreted in the light of the description the inventive contribution lies in the provision of further fusion proteins which *do exhibit improved display of the heterologous polypeptide in phage display*. In this case, inventive step of said claim in its present broad form cannot be acknowledged because it appears not plausible that the large number of variants covered by the claim will all solve the problem.

4. With regard to insufficiency of disclosure of the subject matter of claims 5 and 6 which leads to an objection under Art. 5/6 PCT (see below), an inventive step within the meaning of Art. 33(3) cannot be acknowledged for said claims because the solution to the technical problem has not been disclosed.

**Re Item VIII**

**Certain observations on the international application**

1. Claims 1, 4-6, 14, 15 do not meet the requirements of Article 6 PCT
  - 1.1 Claims 5, 6 are not sufficiently disclosed and supported by the description as required by Article 5 and 6 PCT. Said claims concern variants of a wild type coat protein, preferably protein pIII, having an alteration in the transmembrane domain or in the cytoplasmic domain. It appears that such variants are not disclosed in the description. Examples 8-25 concern variants of the major coat protein pVIII.

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT - SEPARATE SHEET**

International application No. PCT/US99/16596

Example 26 deals with a gIII C-terminal fragment which appears to consist of the wild type sequence.

- 1.2 Claim 4 appears to be unhappily drafted. For the purposes of the present examination, the claim was understood such that the variant should have the wild type sequence and at least 1 substitution taken from the list. However, since the term "variant" is not limited (see below) the claim could be understood as if the only delimiting feature was an amino acid from the list, with the rest of the sequence being random (cf. 1.1).
- 1.3 The terms "variant" and "a portion of" used in claims 1, 4, 5, 14, 15 are vague and unclear (Article 6 PCT). Said terms alone without substantially delimiting features are indefinite and may encompass virtually any polypeptide, thereby rendering the definition of the subject-matter of said claims unclear.

## CLAIMS

1. A fusion protein comprising a heterologous polypeptide fused to a major coat protein of a virus, wherein the major coat protein is a variant of a wild type major coat protein of the virus.  
5
2. The fusion protein of claim 1, wherein the virus is selected from the group consisting of a filamentous phage, a lambda phage, a Baculovirus, a T4 phage and a T7 phage.
3. The fusion protein of claim 1, wherein the phage is a filamentous phage, the major coat protein is gpVIII and the heterologous polypeptide is fused to the N-terminus or the C-terminus thereof.  
10
4. The fusion protein of claim 1, wherein the major coat protein is a variant of a wild type filamentous phage coat protein which contains at least one amino acid residue selected from the list below in the position indicated:  
15

	<u>Residue Number</u>	<u>Amino Acid Residue</u>
	1	E, L, V, Q, D, I, N
	2	R, H, F, W, E, K, Y, D
20	3	T, E, L, S, D, I, V, A
	4	D, R, H, E, K
	5	R, H, N, D, K, Q, E
	6	Y, W, S, I, L, F, T, V
	7	T, N, S
25	8	D, H, R, E, K
	9	E, Q, T, D, N, S
	11	W, I, V, Y, L, F
	12	R, H, N, E, D, K, Q
	13	I, L, E, Q, A, V, D, T, N, S
30	14	L, I, V
	15	D, R, N, E, K, H, Q
	16	E, V, L, T, D, I, A, S, G
	17	E, V, L, I, A, T, D
	18	L, V, I
35	19	L, T, Q, E, I, V, S, A, N, D
	20	R, D, H, N, Q, K, E
	21	W, Y, I, L, F, V
	22	W, F, Y

P1581R2

	23	W, Y, I, V, H, K, F, L, R
	24	I, Q, L, N, V
	25	S, L, I, T, V
	26	A, I, V, G, L, M
5	27	N, T, S
	28	I, L, V
	29	K, R, F, W, H, Y
	30	I, V, L.

10 5. A fusion protein comprising a heterologous polypeptide fused to at least a portion of a coat protein of a filamentous phage, wherein the coat protein is a variant of a wild type coat protein of the phage, the variant having an alteration in the transmembrane domain or in the cytoplasmic domain of the coat protein.

15 6. The fusion protein of claim 5, wherein the coat protein is gpIII of a filamentous phage and the heterologous polypeptide is fused to the N-terminus or the C-terminus thereof.

7. The fusion protein of claim 1, wherein the variant has 2 - 50 altered residues relative to the wild type coat protein sequence.

20 8. The fusion protein of claim 1, wherein the heterologous polypeptide is an antibody or a fragment thereof or a cytokine or a cytokine receptor.

9. A replicable expression vector comprising a gene fusion, wherein the gene fusion encodes the fusion protein of claim 1.

25 10. A library comprising a plurality of the replicable expression vectors of claim 9, the expression vectors comprising a plurality of different gene fusions encoding a plurality of fusion proteins.

30 11. Host cells comprising the vector of claim 9.

12. A virus displaying the fusion protein of claim 1 on the surface thereof.

35 13. A library of virus, comprising a plurality of the virus of claim 12 displaying a plurality of different fusion proteins on the surface thereof.

14. A method, comprising:

*Elson*  
*PCT*

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 :  C12N 15/10, 15/62, C07K 14/01, C12N 1/00, 15/86		A2	(11) International Publication Number: <b>WO 00/06717</b>  (43) International Publication Date: 10 February 2000 (10.02.00)												
<p>(21) International Application Number: <b>PCT/US99/16596</b></p> <p>(22) International Filing Date: 22 July 1999 (22.07.99)</p> <p>(30) Priority Data:</p> <table> <tr> <td>60/094,291</td> <td>27 July 1998 (27.07.98)</td> <td>US</td> </tr> <tr> <td>60/103,514</td> <td>8 October 1998 (08.10.98)</td> <td>US</td> </tr> <tr> <td>60/133,296</td> <td>10 May 1999 (10.05.99)</td> <td>US</td> </tr> <tr> <td>60/134,870</td> <td>19 May 1999 (19.05.99)</td> <td>US</td> </tr> </table>		60/094,291	27 July 1998 (27.07.98)	US	60/103,514	8 October 1998 (08.10.98)	US	60/133,296	10 May 1999 (10.05.99)	US	60/134,870	19 May 1999 (19.05.99)	US	<p>(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p>	
60/094,291	27 July 1998 (27.07.98)	US													
60/103,514	8 October 1998 (08.10.98)	US													
60/133,296	10 May 1999 (10.05.99)	US													
60/134,870	19 May 1999 (19.05.99)	US													
<p>(71) Applicant (for all designated States except US): GENENTECH, INC. [US/US]; 1 DNA Way, South San Francisco, CA 94080-4990 (US).</p> <p>(72) Inventors; and</p> <p>(75) Inventors/Applicants (for US only): <del>SIDHU, Sachdev, S. [CA/US]; Apartment 203-574 - 3rd Street, San Francisco, CA 94107 (US)</del>, WEISS, Gregory, A. [US/US]; <del>733</del> Fairfield Road #3, Burlingame, CA 94010 (US) <del>/ WELLS, James, A. [US/US]; 1342 Columbus Avenue, Burlingame, CA 94010 (US)</del>.</p> <p>(74) Agents: SCHWARTZ, Timothy, R. et al.; Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080-4990 (US).</p>		<p><b>Published</b> Without international search report and to be republished upon receipt of that report.</p>													

(54) Title: IMPROVED TRANSFORMATION EFFICIENCY IN PHAGE DISPLAY THROUGH MODIFICATION OF A COAT PROTEIN

(57) Abstract

The transformation yield of electroporation is increased by using higher DNA concentrations and DNA affinity purification. Fusion proteins of a viral coat protein variant and a heterologous polypeptide are useful in phage display systems.

***FOR THE PURPOSES OF INFORMATION ONLY***

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		

09/380 447 PCT



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 :  C12N 15/10, 15/62, C07K 14/01, C12N 1/00, 15/86		A3	(11) International Publication Number: <b>WO 00/06717</b>  (43) International Publication Date: 10 February 2000 (10.02.00)												
<p>(21) International Application Number: PCT/US99/16596</p> <p>(22) International Filing Date: 22 July 1999 (22.07.99)</p> <p>(30) Priority Data:</p> <table> <tr> <td>60/094,291</td> <td>27 July 1998 (27.07.98)</td> <td>US</td> </tr> <tr> <td>60/103,514</td> <td>8 October 1998 (08.10.98)</td> <td>US</td> </tr> <tr> <td>60/133,296</td> <td>10 May 1999 (10.05.99)</td> <td>US</td> </tr> <tr> <td>60/134,870</td> <td>19 May 1999 (19.05.99)</td> <td>US</td> </tr> </table> <p>(71) Applicant (for all designated States except US): GENENTECH, INC. [US/US]; 1 DNA Way, South San Francisco, CA 94080-4990 (US).</p> <p>(72) Inventors; and</p> <p>(75) Inventors/Applicants (for US only): SIDHU, Sachdev, S. [CA/US]; Apartment 203, 574 - 3rd Street, San Francisco, CA 94107 (US). WEISS, Gregory, A. [US/US]; 733 Fairfield Road #3, Burlingame, CA 94010 (US). WELLS, James, A. [US/US]; 1342 Columbus Avenue, Burlingame, CA 94010 (US).</p> <p>(74) Agents: SCHWARTZ, Timothy, R. et al.; Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080-4990 (US).</p>		60/094,291	27 July 1998 (27.07.98)	US	60/103,514	8 October 1998 (08.10.98)	US	60/133,296	10 May 1999 (10.05.99)	US	60/134,870	19 May 1999 (19.05.99)	US	<p>(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p><b>Published</b> With international search report.</p> <p>(88) Date of publication of the international search report: 29 June 2000 (29.06.00)</p>	
60/094,291	27 July 1998 (27.07.98)	US													
60/103,514	8 October 1998 (08.10.98)	US													
60/133,296	10 May 1999 (10.05.99)	US													
60/134,870	19 May 1999 (19.05.99)	US													
<p>(54) Title: IMPROVED TRANSFORMATION EFFICIENCY IN PHAGE DISPLAY THROUGH MODIFICATION OF A COAT PROTEIN</p> <p>(57) Abstract</p> <p>The transformation yield of electroporation is increased by using higher DNA concentrations and DNA affinity purification. Fusion proteins of a viral coat protein variant and a heterologous polypeptide are useful in phage display systems.</p>															

***FOR THE PURPOSES OF INFORMATION ONLY***

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

## IMPROVED TRANSFORMATION EFFICIENCY IN PHAGE DISPLAY THROUGH MODIFICATION OF A COAT PROTEIN

### FIELD OF THE INVENTION

5        The invention relates to fusion proteins of a polypeptide and a coat protein of a virus, where a coat protein is not a wild type coat protein. The invention also relates to replicable expression vectors which contain a gene encoding the fusion protein, host cells containing the expression vectors, a virus which displays the fusion protein on the surface of the virus, libraries of the virus displaying a plurality of different fusion proteins on viral surfaces and methods of using 10 these compositions.

The invention also relates to a method of transforming cells by electroporating cells to improve transformation efficiency. In various preferred embodiments, the transformation is performed in the presence of a high concentration of DNA; in the presence of a high concentration of cells; with highly purified DNA; with specific host cells; or with combinations of these. When 15 used to prepare libraries, for example phage display libraries, these improvements allow for the construction of larger libraries in a single electroporation step than has been previously possible. The invention is also directed to a method of producing a product polypeptide by transforming host cells using the method of the invention.

### DISCUSSION OF THE BACKGROUND

20        Bacteriophage (phage) display is a technique by which variant polypeptides are displayed as fusion proteins to the coat protein on the surface of bacteriophage particles (Scott, J.K. and Smith, G. P. (1990) *Science* 249: 386). The utility of phage display lies in the fact that large 25 libraries of selectively randomized protein variants (or randomly cloned cDNAs) can be rapidly and efficiently sorted for those sequences that bind to a target molecule with high affinity. Display of peptide (Cwirla, S. E. et al. (1990) *Proc. Natl. Acad. Sci. USA*, 87:6378) or protein (Lowman, H.B. et al. (1991) *Biochemistry*, 30:10832; Clackson, T. et al. (1991) *Nature*, 352: 624; Marks, J. D. et al. (1991), *J. Mol. Biol.*, 222:581; Kang, A.S. et al. (1991) *Proc. Natl. Acad. Sci. USA*, 88:8363) libraries on phage have been used for screening millions of polypeptides for ones with 30 specific binding properties (Smith, G. P. (1991) *Current Opin. Biotechnol.*, 2:668). Sorting phage libraries of random mutants requires a strategy for constructing and propagating a large number of variants, a procedure for affinity purification using the target receptor, and a means of evaluating the results of binding enrichments. U.S. 5,223,409; U.S. 5,403,484; U.S. 5,571,689; U.S. 5,663,143.

35        Typically, variant polypeptides are fused to a gene III protein, which is displayed at one end of the viron. Alternatively, the variant polypeptides may be fused to the gene VIII protein, which is the major coat protein of the viron. Such polyvalent display libraries are constructed by replacing the phage gene III with a cDNA encoding the foreign sequence fused to the amino

terminus of the gene III protein. This can complicate efforts to sort high affinity variants from libraries because of the avidity effect; phage can bind to the target through multiple point attachment. Moreover, because the gene III protein is required for attachment and propagation of phage in the host cell, e.g., *E. coli*, the fusion protein can dramatically reduce infectivity of the 5 progeny phage particles.

To overcome these difficulties, monovalent phage display was developed in which a protein or peptide sequence is fused to a portion of a gene III protein and expressed at low levels in the presence of wild-type gene III protein so that particles display mostly wild-type gene III protein and one copy or none of the fusion protein (Bass, S. et al. (1990) *Proteins*, 8:309; Lowman, H.B. 10 and Wells, J.A. (1991) *Methods: a Companion to Methods in Enzymology*, 3:205). Monovalent display has advantages over polyvalent phage display in that progeny phagemid particles retain full infectivity. Avidity effects are reduced so that sorting is on the basis of intrinsic ligand affinity, and phagemid vectors, which simplify DNA manipulations, are used. See also U.S. 5,750,373 and U.S. 5,780,279. Others have also used phagemids to display proteins, particularly antibodies. U.S. 15 5,667,988; U.S. 5,759,817; U.S. 5,770,356; and U.S. 5,658,727.

A two-step approach has been used to select high affinity ligands from peptide libraries displayed on M13 phage. Low affinity leads were first selected from naive, polyvalent libraries displayed on the major coat protein (protein VIII). The low affinity selectants were subsequently transferred to the gene III minor coat protein and matured to high affinity in a monovalent format. 20 Unfortunately, extension of this methodology from peptides to proteins has been difficult. Display levels on protein VIII vary with fusion length and sequence. Increasing fusion size generally decreases display. Thus, while monovalent phage display has been used to affinity mature many different proteins, polyvalent display on protein VIII has not been applicable to most protein scaffolds.

25 Although most phage display methods have used filamentous phage, lambdoid phage display systems (WO 95/34683; U.S. 5,627,024), T4 phage display systems (Ren, Z-J. et al. (1998) Gene 215:439; Zhu, Z. (1997) CAN 33:534; Jiang, J. et al. (1997) can 128:44380; Ren, Z-J. et al. (1997) CAN 127:215644; Ren, Z-J. (1996) Protein Sci. 5:1833; Efimov, V. P. et al. (1995) Virus Genes 10:173) and T7 phage display systems (Smith, G. P. and Scott, J.K. (1993) Methods in 30 Enzymology, 217, 228-257; U.S. 5,766,905) are also known.

Many other improvements and variations of the basic phage display concept have now 35 been developed. These improvements enhance the ability of display systems to screen peptide libraries for binding to selected target molecules and to display functional proteins with the potential of screening these proteins for desired properties. Combinatorial reaction devices for phage display reactions have been developed (WO 98/14277) and phage display libraries have been used to analyze and control bimolecular interactions (WO 98/20169; WO 98/20159) and properties of constrained helical peptides (WO 98/20036). WO 97/35196 describes a method of isolating an affinity ligand in which a phage display library is contacted with one solution in which

the ligand will bind to a target molecule and a second solution in which the affinity ligand will not bind to the target molecule, to selectively isolate binding ligands. WO 97/46251 describes a method of biopanning a random phage display library with an affinity purified antibody and then isolating binding phage, followed by a micropanning process using microplate wells to isolate high affinity binding phage. The use of *Staphylococcus aureus* protein A as an affinity tag has also been reported (Li et al. (1998) Mol Biotech., 9:187). WO 97/47314 describes the use of substrate subtraction libraries to distinguish enzyme specificities using a combinatorial library which may be a phage display library. A method for selecting enzymes suitable for use in detergents using phage display is described in WO 97/09446. Additional methods of selecting specific binding proteins are described in U.S. 5,498,538; U.S. 5,432,018; and WO 98/15833.

Methods of generating peptide libraries and screening these libraries are also disclosed in U.S. 5,723,286; U.S. 5,432,018; U.S. 5,580,717; U.S. 5,427,908; and U.S. 5,498,530. See also U.S. 5,770,434; U.S. 5,734,018; U.S. 5,698,426; U.S. 5,763,192; and U.S. 5,723,323.

Methods which alter the infectivity of phage are also known. WO 95/34648 and U.S. 5,516,637 describe a method of displaying a target protein as a fusion protein with a pilin protein of a host cell, where the pilin protein is preferably a receptor for a display phage. U.S. 5,712,089 describes infecting a bacteria with a phagemid expressing a ligand and then superinfecting the bacteria with helper phage containing wild type protein III but not a gene encoding protein III followed by addition of a protein III-second ligand where the second ligand binds to the first ligand displayed on the phage produced. See also WO 96/22393. A selectively infective phage system using non-infectious phage and an infectivity mediating complex is also known (U.S. 5,514,548).

Phage systems displaying a ligand have also been used to detect the presence of a polypeptide binding to the ligand in a sample (WO/9744491), and in an animal (U.S. 5,622,699). Methods of gene therapy (WO 98/05344) and drug delivery (WO 97/12048) have also been proposed using phage which selectively bind to the surface of a mammalian cell.

Further improvements have enabled the phage display system to express antibodies and antibody fragments on a bacteriophage surface, allowing for selection of specific properties, i.e., binding with specific ligands (EP 844306; U.S. 5,702,892; U.S. 5,658,727) and recombination of antibody polypeptide chains (WO 97/09436). A method to generate antibodies recognizing specific peptide - MHC complexes has also been developed (WO 97/02342). See also U.S. 5,723,287; U.S. 5,565,332; and U.S. 5,733,743.

U.S. 5,534,257 describes an expression system in which foreign epitopes up to about 30 residues are incorporated into a capsid protein of a MS-2 phage. This phage is able to express the chimeric protein in a suitable bacterial host to yield empty phage particles free of phage RNA and other nucleic acid contaminants. The empty phage are useful as vaccines.

The degree of expression of polypeptides as fusion proteins on the surface of bacteriophage particles is variable and depends, to some extent, on the size of the polypeptide. Conventional phage display systems use wild type phage coat proteins and fuse the heterologous

polypeptide to the amino terminus of the wild type amino acid sequence or an amino terminus resulting from truncation of the wild type coat protein sequence. Segments of linker amino acids have also been added to the amino terminus of the wild type coat protein sequence to improve selection and target binding.

5 Notwithstanding numerous modifications and improvements in phage technology, a need continues to exist for improved methods of displaying polypeptides as fusion proteins in phage display methods.

Methods of transforming cells to introduce new DNA are of great practical interest in molecular biology and modern genetic engineering. Early methods involved chemical treatment of 10 bacteria with solutions of metal ions, generally calcium chloride, followed by heating to produce competent bacteria capable of functioning as recipient bacteria and able to take up heterologous DNA derived from a variety of sources. These early protocols provided transformation yields of about  $10^5$  -  $10^6$  transformed colonies per  $\mu$ gram of plasmid DNA. Subsequent improvements using different cations, longer treatment times and other chemical agents have allowed improvements in 15 transformation efficiency of up to about  $10^8$  colonies/ $\mu$ gram of DNA. Sambrook et al., *Molecular Cloning: A Laboratory Manual*, 2nd edition, (1989) Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, page 1.74.

Cells can also be transformed using high-voltage electroporation. Electroporation is suitable to introduce DNA into eukaryotic cells (e.g. animal cells, plant cells, etc.) as well as 20 bacteria, e.g., *E. coli*. Sambrook et al., *ibid*, pages 1.75, 16.54-16.55. Different cell types require different conditions for optimal electroporation and preliminary experiments are generally conducted to find acceptable levels of expression or transformation. For mammalian cells, voltages of 250-750 V/cm result in 20-50% cell survival. An electric pulse length of 20-100 ms at a temperature ranging from room temperature to 0°C and below using a DNA concentration of 1- 25 40  $\mu$ gram/mL are typical parameters. Transfection efficiency is reported to be higher using linear DNA and when the cells are suspended in buffered salt solutions than when suspended in nonionic solutions. Sambrook et al., above, pages 16.54-16.55.

Dower et al., 1988, *Nucleic Acids Research*, 16:6127-6145 extensively studied high-efficiency transformation of *E. coli* by high-voltage electroporation. This study evaluated 30 numerous parameters, including electrical variables such as the effect of field strength and pulse length, the effect of DNA concentration and cell concentration on the recovery of transformants, accuracy, reproducibility, etc. and provided a protocol for high-efficiency electrotransformation of *E. coli* cells. The optimized protocol of Dower et al. uses cells concentrated in a range of at least 2 and up to  $4 \times 10^{10}$ /mL, a DNA concentration of from about 1 to 10  $\mu$ grams/mL, 12.5-16.7 kV/cm, 35 3-25  $\mu$ F and the electroporation is conducted at 0°C (ice temperature). These studies were conducted with highly purified closed circular plasmid DNA, which is known to give high transformation efficiencies. Dower et al. report transformation efficiencies of  $10^9$  -  $10^{10}$

transformants/ $\mu$ gram of DNA achieved by highly optimizing these parameters. For library formation, Dower et al. suggests using a DNA concentration of less than 10 nanogram/mL and a cell concentration of greater than  $3 \times 10^{10}$  to minimize co-transformants. See also U.S. 4,910,140 and U.S. 5,186,800 to Dower et al. and U.S. 4,849,355 to Wong.

5 Several attempts have been made to improve the design of electroporation apparatus (see, for example, U.S. 5,173,158; U.S. 5,098,843; U.S. 5,422,272; U.S. 5,232,856; and U.S. 5,283,194) and to improve electroporation of specific cells (see U.S. 5,128,257). U.S. 5,124,259 describes an improved buffer for electroporation. U.S. 4,956,288 describes a method for producing cells containing foreign DNA in high copy numbers.

10 The attainment of higher transformation efficiencies by optimizing the electroporation parameters has been difficult. The use of higher voltages and longer pulses results in an increase in cell death, decreasing the total number of transformed cells. Highly optimized electroporation still results in about 50-75% cell death. Dower et al. represents an important investigation of the parameters of electroporation and the protocol described in this paper has formed the basis of more 15 recent electroporation procedures

An important emerging use of cell transformations, including electroporation, is the preparation of peptide and protein variant libraries. In these applications, a replicable transcription vector, for example a plasmid, is reacted with a restriction enzyme to open the plasmid DNA, desired coding DNA is ligated into the plasmid to form a library of vectors each encoding a 20 different variant, and cells are transformed with the library of transformation vectors in order to prepare a library of polypeptide variants differing in amino acid sequence at one or more residues. The library of peptides can then be selectively panned for peptides which have or do not have particular properties. A common property is the ability of the variant peptides to bind to a cell surface receptor, an antibody, a ligand or other binding partner, which may be bound to a solid 25 support. Variants may also be selected for their ability to catalyze specific reactions, to inhibit reactions, to inhibit enzymes, etc.

In one application, bacteriophage (phage), such as filamentous phage, are used to create phage display libraries by transforming host cells with phage vector DNA encoding a library of peptide variants. J.K. Scott and G.P. Smith, *Science*, (1990), 249:386-390. Phagemid vectors may 30 also be used for phage display. Lowman and Wells, 1991, *Methods: A Companion to Methods in Enzymology*, 3:205-216. The preparation of phage and phagemid display libraries of peptides and proteins, e.g. antibodies, is now well known in the art. These methods generally require transforming cells with phage or phagemid vector DNA to propagate the libraries as phage particles having one or more copies of the variant peptides or proteins displayed on the surface of 35 the phage particles. See, for example, Barbas et al., *Proc. Natl. Acad. Sci., USA*, (1991), 88:7978-7982; Marks et al., *J. Mol. Biol.*, (1991), 222:581-597; Hoogenboom and Winter, *J. Mol. Biol.*, (1992), 227:381-388; Barbas et al., *Proc. Natl. Acad. Sci., USA*, (1992), 89:4457-4461; Griffiths et al., *EMBO Journal*, (1994), 13:3245-3260; de Kruif et al., *J. Mol. Biol.*, (1995), 248:97-105;

Bonnycastle et al., *J. Mol. Biol.*, (1996), 258:747-762; and Vaughan et al., *Nature Biotechnology* (1996), 14:309-314. The library DNA is prepared using restriction and ligation enzymes in one of several well known mutagenesis procedures, for example, cassette mutagenesis or oligonucleotide-mediated mutagenesis.

5 A recurring problem with transformation by electroporation, in particular with phage or phagemid vector DNA libraries, is the low transformation efficiency which has generally been in the range of  $10^7$  -  $10^8$  transformations/ $\mu$ gram of DNA. The low transformation efficiency has limited the size of libraries which can be prepared with a single electroporation step. Vaughan et al., above, describe a modified procedure in which several hundred electroporations were  
10 conducted to achieve a library with about  $10^{10}$  recombinants.

Reaction mixtures obtained by enzymatic manipulation of DNA and RNA contain proteins, salts, etc., which are contaminants of the desired DNA or RNA. To obtain the purified nucleic acid, these mixtures are usually extracted with phenol/chloroform or similar solvent and then the DNA is precipitated with ethanol and resuspended in an appropriate amount of water or  
15 buffer to provide the DNA concentrations recommended by Dower et al. Bonnycastle et al., above, describe extracting a ligation reaction with chloroform/phenol/isoamyl alcohol followed by resuspension of the DNA in water and desalting by filtration over an exclusion membrane. This procedure allowed electroporation of electrocompetent MC1061 *E. coli* cells using a DNA concentration of about 20  $\mu$ grams/mL.

20 Despite two decades of research into electroporation and parameters affecting transformation efficiency, a need continues to exist for improved electroporation processes, in particular, for the transformation of cells with libraries of phage and phagemid DNA vectors.

#### SUMMARY OF THE INVENTION

25 Conventional phage display methods use wild type coat protein sequences, presumably to enhance stability of the phage particles and to increase the frequency of incorporation of fusion proteins into the coat of stable phage particles. It has now been discovered that stable viral particles can be prepared which incorporate fusion proteins containing a heterologous polypeptide of interest fused to a coat protein of the virus, preferably a major coat protein, where the coat  
30 protein is not a wild type coat protein of the virus, that is, where the coat protein has one or more amino acid substitutions, deletions or additions. This result is unexpected since prior phage display techniques have utilized wild type coat protein sequences and the incorporation of heterologous polypeptides as fusion proteins into phage particles is expected to have a generally deleterious effect on normal phage packaging and phage particle production.

35 One object of the present invention is to provide a fusion protein containing a heterologous polypeptide fused to a coat protein of a virus where the coat protein does not have the wild type coat protein sequence. A further object is to provide a replicable expression vector

containing a gene fusion which encodes this fusion protein. A further object is to provide host cells containing the replicable expression vector.

Another object of the invention is to provide a library of the replicable expression vectors where the vectors contain a plurality of different gene fusions encoding a plurality of variant fusion proteins. A further object is to provide a library of virus particles which display a plurality of variant fusion proteins where the fusion proteins contain a coat protein variant which does not have the wild type coat protein sequence, and the host cells containing the vector libraries.

An additional object of the invention is to provide a method of constructing the libraries of expression vectors and virus particles.

10 A further object is to provide a method of modulating the number of fusion proteins which are displayed on the surface of a phage or phagemid particle through the use of the fusion protein of the invention.

Another object of the present invention is to provide an improved method of transforming cells by electroporating competent cells in the presence of heterologous DNA.

15 A further object of the invention is to provide an improved strain of *E. coli* cells which have improved characteristics and allow higher transformation yields with electroporation.

20 A further object is to provide a method of producing a product polypeptide by culturing a host cell transformed with a replicable expression vector where the host cells have been transformed using the method of the present invention, and product polypeptides produced by this process.

One embodiment of the invention is a method, which includes constructing a library containing a plurality of replicable expression vectors, each expression vector containing a transcription regulatory element operably linked to a gene fusion encoding a fusion protein, where the gene fusion contains a first gene encoding a first polypeptide and a second gene encoding a 25 phage major coat protein, where the library contains a plurality of second genes encoding variant phage major coat proteins. The method may further include transforming suitable host cells with the library of vectors and culturing the transformed cells under conditions suitable to form the fusion proteins. Preferably, the vector is phage or phagemid DNA and the culturing is sufficient to form phage or phagemid particles which display fusion proteins on the surfaces thereof. The 30 method may also include contacting the phage or phagemid particles with a target molecule so that at least a portion of the particles bind to the target molecule, and separating the particles that bind from those that do not bind. The method may further include selecting a bound particle, constructing a second library containing a plurality of replicable expression vectors, each expression vector containing a transcription regulatory element operably linked to a second gene 35 fusion encoding a second fusion protein, where the second gene fusion contains a third gene encoding a second polypeptide and a fourth gene encoding the major coat protein variant of the fusion protein displayed on the surface of the selected bound particle, where the library contains a

plurality of third genes encoding variant second polypeptides. The first polypeptide and the third polypeptide may be the same or different.

In another embodiment, the invention is a method including the steps:

- 5 (a) constructing a first library containing a plurality of first replicable expression vectors, each expression vector comprising a transcription regulatory element operably linked to a first gene fusion encoding a first fusion protein, wherein the first gene fusion comprises
  - a first gene encoding a first polypeptide and
  - a second gene encoding a phage major coat protein, and
- 10 wherein the first library contains a plurality of first vectors encoding second genes encoding variant phage major coat proteins;
- (b) transforming suitable host cells with the first library of vectors and culturing the transformed cells under conditions suitable to form phage or phagemid particles;
- 15 (c) contacting the phage or phagemid particles with a target molecule so that at least a portion of the particles bind to the target molecule;
- (d) separating particles that bind from those that do not bind;
- (e) selecting a particle;
- (f) constructing a second replicable expression vector comprising a transcription regulatory element operably linked to a second gene fusion encoding a second fusion protein, wherein the second gene fusion comprises
  - a third gene encoding a second polypeptide and
  - a fourth gene encoding the major coat protein variant of the fusion protein displayed on the surface of the selected bound particle;
- 20 (g) transforming suitable host cells with the second vector, culturing the transformed cells under conditions suitable to form phage or phagemid particles displaying the second fusion protein on the surface thereof; and
- (h) separating particles that bind from those that do not bind.

The method may also include constructing a second library of second vectors containing a plurality of third genes encoding variant second polypeptides. The method may further include steps:

- 30 (i) selecting a particle;
- (j) constructing a third expression vector comprising a transcription regulatory element operably linked to the third gene of the particle selected in step (i); and
- (k) transforming suitable host cells with the third vector obtained in step (j) and culturing the transformed cells under conditions suitable for forming the second polypeptide.

35 These and other objects which will become apparent in the course of the following descriptions of exemplary embodiments have been achieved by the present method of transforming cells by electroporating competent cells in the presence of heterologous DNA, where the DNA is purified by affinity purification, and is preferably present at a concentration of about 1

picogram/mL to about 500  $\mu$ gram/mL. The DNA is generally present at a concentration of a few to several hundred nanograms/mL or greater, preferably about 1 to about 50  $\mu$ grams/mL or greater, even more preferably about 70  $\mu$ grams/mL or greater, and may be present at a concentration of greater than 100  $\mu$ grams/mL to about 500  $\mu$ grams/mL.

5 In part, the present invention is also based on the discovery that prior art methods of preparing DNA for electroporation, for example the preparation of clonable recombinant DNA, using phenol extractions and ethanol precipitation, have generally resulted in DNA solutions having unacceptably high conductance. Electroporation instruments are generally configured to have a sample cell in parallel with a capacitor and a resistor (R2) to control the electric pulse  
10 duration through the sample. Ideally, the resistance of the sample (R1) should be much greater than that of R2 so that the electric pulse decays mainly through R2. In a preferred electroporation, where essentially the entire discharge occurs through R2, the time constant would approach the theoretical maximum where R1 is infinite. DNA is an ionic molecule, and thus DNA electroporation samples have an inherent conductance. Furthermore, DNA preparations containing  
15 electrically charged impurities such as proteins, salts, buffers, etc., introduce additional conductance. The volume of a DNA preparation (and thus the mass of DNA) which can be introduced into an electroporation reaction is limited by the conductance of the preparation. As the conductance of the sample increases, R1 decreases and becomes significant in comparison to R2, i.e. a significant proportion of the electric pulse is discharged through R1. This results in a  
20 decrease in the time constant and a decrease in the transformation efficiency. Further increases in sample conductance result in electric arcing across the electrodes and a failure of the electroporation. The high conductance of DNA solutions prepared using prior art methods practically limits electroporation reactions to low DNA concentrations, since higher concentrations results in electrical arcing. The invention solves this problem, in part, by providing a method of  
25 electroporating cells with affinity purified DNA and/or at DNA concentrations much greater than was thought possible. It has been discovered that the DNA in prior art DNA preparations contributes only a small proportion of the total conductance; the majority of the conductance in these preparations is due to ionic impurities. The present invention uses affinity DNA purification to reduce ionic impurities and thus reduce the conductance associated with a unit mass of DNA.  
30 Although the prior art generally suggests using purified DNA for electroporation and several standard purifications have been used, for example, DNA precipitation and membrane filtration, the use of affinity purification has not been utilized and the very high DNA concentrations which can be used in the method of the invention and the resulting high transformation yields are surprising.

35 The invention provides an improved method of transforming cells by highly purifying DNA, for example recombinant clonable DNA, preferably closed circular DNA, more preferably phage or phagemid vector DNA. The invention enables one to prepare DNA solutions of high concentration, preferably an aqueous solution having very low conductance, for example a non-

buffer aqueous or water/glycerol solution at concentrations up to hundreds of micrograms of DNA per mL through the use of affinity purification of DNA to remove impurities which increase the conductance and shorten the time constant during electroporation. Electroporation using the higher DNA concentrations of this invention improves the transformation yield, but does not result in 5 unacceptably higher cell death or loss of host cell viability. The method of the invention increases the amount of heterologous DNA, for example recombinant clonable DNA, which can be transformed into a cell. This increase in DNA entering the host cell provides a greater number of transformants per electroporation and allows one to prepare larger combinatorial libraries which overcomes the prior art problem of small library size using recombinant DNA.

10 The method of the invention also provides improved transformation yield using host cell concentrations higher than those used in the prior art to further improve transformation yield and combinatorial library size.

15 The invention also provides a novel *E. coli* strain containing a phage F' factor which is particularly useful for the preparation of phage and phagemid libraries of variant peptides, proteins and antibodies for use in phage display systems.

#### BRIEF DESCRIPTION OF THE DRAWINGS

Figures 1A, 1B, and 1C: Protein VIII variants selected for increased display of fusion proteins. Figure 1A shows a Zone-1 library encompassing protein VIII residues 1 through 10. 20 Figure 1B shows a Zone-2 library encompassing protein VIII residues 11 through 20. Figure 1C shows a Zone-3 library encompassing protein VIII residues 21 through 30. The possible variations at each position within the library are shown followed by wild-type and selected sequences. The DNA sequence is shown above in italics with the deduced amino acid sequence below in normal text (the amber stop codon (TAG) is suppressed as glutamine in *E. coli* XL1-Blue). DNA degeneracies are represented in the IUB code (K = G/T, N = A/C/G/T, R = A/G, S = G/C, W = A/T, Y = C/T). \*Selected for streptavidin (SAV) display. All others were selected for hGH display.

Figure 2: Phage ELISAs for hGH display with protein VIII and selected protein VIII variants. The hGHbp was used as target ( $K_d = 1.6$  nM, Pearce, K.H. Jr., et al. (1997) J. Biol. Chem 30 272:20595-20602). Display was measured for hGH-protein VIII (circles), hGH- protein VIII (1a) (squares), hGH- protein VIII (2a) (diamonds), and hGH- protein VIII (3a) (triangles). Phage were produced from cultures which were either uninduced (unfilled) or induced with 10 uM IPTG (filled). The sequences for the protein VIII variants are shown in Figure 1.

Figure 3: Phage ELISAs for display of hGH mutants. The hGHbp was used as target. 35 Display was measured for wild-type hGH (circles,  $K_d = 1.6$  nM), hGH(R64A) (squares,  $K_d = 13.8$  nM), hGH(Y164A/R178A) (diamonds,  $K_d = 169$  nM), and hGH(K172A/R178A), (triangles,  $K_d = 820$  nM). hGH was fused to either wild-type protein VIII (unfilled) or protein VIII(1a) (filled). Phage were produced from cultures induced with 10 uM IPTG.

Figures 4A and 4B: Phage ELISAs for SAV display. Figure 4A shows results using anti-SAV polyclonal antibody as target. Figure 4B shows results using Biotin-BSA conjugate as target. Display was measured for SAV-protein VIII (circles), SAV-protein VIII (2e) (triangles), SAV-protein VIII (2f) (diamonds), and SAV- protein VIII (2a) (squares). Phage were produced from uninduced cultures.

Figure 5: Phage ELISAs for hGH display with protein VIII variants combining mutations in different zones. An anti-hGH monoclonal antibody was used as target. Display was measured for hGH displayed as a fusion with protein VIII (filled circles), protein VIII(1a) (filled squares), protein VIII(2a) (filled diamonds), protein VIII(3a) (filled triangles), protein VIII containing the mutations of protein VIII(1a) and protein VIII(2a) (unfilled circles), or protein VIII containing the mutations of protein VIII(2a) and protein VIII(3a) (unfilled squares).

Figure 6: Phage ELISAs for hGH display with protein VIII variants derived from protein VIII(2a). An anti-hGH monoclonal antibody was used as target. Display was measured for hGH displayed as a fusion with either protein VIII(2a) (filled circles) or with protein VIII(2a) containing the following mutation: E12N (unfilled squares), D16A (unfilled circles), or I17S (unfilled triangles).

Figures 7A and 7B: Linkers selected for hGH display or SAV display. 7A) Linkers selected for display of hGH. Linkers were of the form (Gly)<sub>3</sub>(Xaa)<sub>14</sub>(Gly)<sub>2</sub>, where (Xaa)<sub>14</sub> is the selected sequence shown. 7B) Linkers selected for display of SAV.

Figures 8A and 8B: Phage ELISAs for protein display with selected linkers. 8A) hGH displayed on protein VIII using either a Gly/Ser linker (phagemid pS349, circles) or the linker selectant Link1 (Fig. 7A, squares). Phage were produced from cultures which were either uninduced (unfilled) or induced with 10 uM IPTG (filled). The hGHbp was used as target. 8B) SAV displayed on wild type protein VIII using a Gly/Ser linker (unfilled circles) or on variant protein VIII(2e) using either a Gly/Ser linker (unfilled squares), link18 (filled circles), link29 (filled squares), link34 (filled diamonds), or link37 (filled triangles). The Gly/Ser sequence was identical to the Gly/Ser linker encoded by pS349. The sequences of the other linkers are shown in Figure 7B. Biotinylated BSA was used as target.

Figure 9: Phage ELISAs for hGH display with protein VIII and selected protein VIII variants. The hGHbp was used as target ( $K_d = 1.6 \text{ nM}$ , Pearce, K.H. Jr. et al., (1997) J. Biol. Chem. 272:20595-20602). Display was measured for hGH-protein VIII expressed from phagemid pS1607 (see Example 11) (circles), hGH-protein VIII(1a) (squares), hGH-protein VIII(2a) (diamonds), and hGH-protein VIII(3a) (triangles). Phage were produced from cultures which were either uninduced (unfilled) or induced with 10 uM IPTG (filled). The sequences for the protein VIII variants are show in Figure 1.

Figure 10: Phage ELISAs for Fab display with protein VIII and a protein VIII mutant. A monoclonal antibody specific for a peptide flag fused to the N-terminus of the Fab heavy chain was

used as target. Display was measured for Fab-protein VIII (circles) or Fab-protein VIII(S13A/S17I).

Figure 11: Phage ELISAs for hGH display with protein VIII variants combining mutations in different zones. An anti-hGH monoclonal antibody was used as target. hGH was fused to wild-type protein VIII (wt), a protein VIII selectant from zone 1, 2, or 3 (1a, 2a, or 3a, respectively) or protein VIII variants combining mutations from these selectants (e.g. 1a+2a combines 1a residues 1 through 10 with 2a residues 11 through 20 and wild type residues 21 through 50). Sequences for the protein VIII selectants are shown in Figure 1.

Figure 12: Site directed mutagenesis of protein VIII variants highlights key positions for enhanced display and enables modulated hGH display. hGH was fused to variants derived from A) zone 1 selectant 1a, B) zone 2 selectant 2a, or C) zone 3 selectant 3a. For each protein VIII selectant, the effect of every possible single back mutation to the wild-type sequence is shown (e.g. D1A indicates the protein VIII variant obtained by introducing the mutation D1A into selectant 1a. In addition, D) double and triple back mutations were introduced into zone 2 selectant 2a to further modulate hGH display. Sequences for the protein VIII selectants are shown in Figure 1.

Figure 13: Phage ELISAs for the display of a peptide fused to the C-terminus of protein VIII using poly-glycine linkers. A hexapeptide (HHHHHA, referred to as a pentaHis flag) was fused to the C-terminus of protein VIII with intervening linkers containing varying numbers of Gly residues as indicated (linker length, X-axis). There is a large increase in display when the linker length is increased from eight to nine residues. The phage were used at a concentration of  $2 \times 10^{12}$  phage/mL. An anti-(His)5 antibody (Qiagen) was used as the capture target. See Example 22.

Figure 14: Phage ELISAs for the display of a peptide fused to the C-terminus of protein VIII using an optimized linker sequence. A polyHis flag was fused to the C-terminus of protein VIII with intervening linkers as follows: (Gly)8 (open circles), (Gly)9 (squares), (Gly)10 (diamonds), (Gly)12 (triangles), or optimized linker-1 (filled circles). The highest levels of display were observed with the optimized linker. Phage were serially diluted 5-fold from a starting concentration of  $10^{13}$  phage/mL. An anti-(His)5 antibody (Qiagen) was used as the capture target. See Examples 22 and 23.

Figure 15: P12 variants selected for the display of a polyHis flag as a C-terminal fusion. The variable region of each P12 is shown. The complete sequence for each P12 is as follows: MSKSTFKKKFLK-(x)19-ETASAQLSNFAAKAPDDGEA (SEQ ID NO. 1). Where "(x)19" is the nineteen residue sequence inserted in the library construction as shown in the figure. The possible variations at each position within the library are shown followed by the selected sequences. The DNA sequence is shown with the deduced amino acid sequence below. The numerical designation for each sequence is shown to the left. The numbering above refers to the position of each codon within the nineteen residue library insertion. See Example 24.

Figure 16: Phage ELISAs for the display of a polyHis flag as a C-terminal fusion with P12 variants. An anti-(His)4 antibody was used as the capture target (unfilled bars). As a negative

control, phage binding to a BSA-blocked plate was also measured (filled bars). The phage were used at a concentration of  $10^{13}$  phage/mL. See Example 24.

Figure 17: Phage ELISAs for hGH or hGHsm display with P12-7. Display was measured for hGHsm fused to the C-terminus of P12-7 (phagemid pS1258, open circles), hGH fused to the C-terminus of P12-7 (phagemid pW930a, open squares), hGHsm fused to the C-terminus of P12-1 (phagemid pS1239b, filled circles), hGH fused to the C-terminus of P12-1 (phagemid pS1239a, filled squares), or hGH fused to the N-terminus of protein VIII (phagemid pS1607, filled diamonds). An anti-hGH monoclonal antibody was used as target. See Example 25.

Figure 18: Phage ELISAs for the display of a peptide fused to the C-terminus of the protein III C-terminal domain using selected linkers. A hexaHis flag was displayed with intervening linker sequences as follows: linker-g3-1 (open circles), linker-g3-2 (open squares), linker-g3-3, (open diamonds). Display was also measured for polyHis flags displayed as either N-terminal fusions with protein VIII (filled circles) or as C-terminal fusions with protein VIII using optimized linker-1 (filled diamonds). Phage derived from a phagemid not encoding a polyHis flag were also included as a negative control (filled squares). See Example 26.

#### DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

##### DEFINITIONS

The term "affinity purification" means the purification of a molecule based on a specific attraction or binding of the molecule to a chemical or binding partner to form a combination or complex which allows the molecule to be separated from impurities while remaining bound or attracted to the partner moiety.

The term "antibody" is used in the broadest sense and specifically covers single monoclonal antibodies (including agonist and antagonist antibodies), antibody compositions with polyepitopic specificity, affinity matured antibodies, humanized antibodies, chimeric antibodies, as well as antibody fragments (*e.g.*, Fab, F(ab')<sub>2</sub>, scFv and Fv), so long as they exhibit the desired biological activity. An affinity matured antibody will typically have its binding affinity increased above that of the isolated or natural antibody or fragment thereof by from 2 to 500 fold. Preferred affinity matured antibodies will have nanomolar or even picomolar affinities to the receptor antigen. Affinity matured antibodies are produced by procedures known in the art. Marks, J. D. *et al.* *Bio/Technology* 10:779-783 (1992) describes affinity maturation by VH and VL domain shuffling. Random mutagenesis of CDR and/or framework residues is described by: Barbas, C. F. *et al.* *Proc Nat. Acad. Sci., USA* 91:3809-3813 (1994), Schier, R. *et al.* *Gene* 169:147-155 (1995), Yelton, D. E. *et al.* *J. Immunol.* 155:1994-2004 (1995), Jackson, J.R. *et al.*, *J. Immunol.* 154(7):3310-9 (1995), and Hawkins, R.E. *et al.*, *J. Mol. Biol.* 226:889-896 (1992). Humanized antibodies are known. Jones *et al.*, *Nature*, 321:522-525 (1986); Reichmann *et al.*, *Nature*, 332:323-329 (1988); and Presta, *Curr. Op. Struct. Biol.*, 2:593-596 (1992)).

An "Fv" fragment is the minimum antibody fragment which contains a complete antigen recognition and binding site. This region consists of a dimer of one heavy and one light chain variable domain in tight, non-covalent association. It is in this configuration that the three CDRs of each variable domain interact to define an antigen binding site on the surface of the V<sub>H</sub>-V<sub>L</sub> dimer. Collectively, the six CDRs confer antigen binding specificity to the antibody. However, even a single variable domain (or half of an Fv comprising only three CDRs specific for an antigen) has the ability to recognize and bind antigen, although at a lower affinity than the entire binding site.

The "Fab" fragment also contains the constant domain of the light chain and the first constant domain (CH1) of the heavy chain. Fab' fragments differ from Fab fragments by the addition of a few residues at the carboxy terminus of the heavy chain CH1 domain including one or more cysteines from the antibody hinge region. Fab'-SH is the designation herein for Fab' in which the cysteine residue(s) of the constant domains bear a free thiol group. F(ab')<sub>2</sub> antibody fragments originally were produced as pairs of Fab' fragments which have hinge cysteines between them. Other, chemical couplings of antibody fragments are also known.

"Single-chain Fv" or "sFv" antibody fragments comprise the V<sub>H</sub> and V<sub>L</sub> domains of antibody, wherein these domains are present in a single polypeptide chain. Generally, the Fv polypeptide further comprises a polypeptide linker between the V<sub>H</sub> and V<sub>L</sub> domains which enables the sFv to form the desired structure for antigen binding. For a review of sFv see Pluckthun in *The Pharmacology of Monoclonal Antibodies*, vol. 113, Rosenberg and Moore eds. Springer-Verlag, New York, pp. 269-315 (1994).

The term "diabodies" refers to small antibody fragments with two antigen-binding sites, which fragments comprise a heavy chain variable domain (V<sub>H</sub>) connected to a light chain variable domain (V<sub>L</sub>) in the same polypeptide chain (V<sub>H</sub> - V<sub>L</sub>). By using a linker that is too short to allow pairing between the two domains on the same chain, the domains are forced to pair with the complementary domains of another chain and create two antigen-binding sites. Diabodies are described more fully in, for example, EP 404,097; WO 93/11161; and Hollinger *et al.*, *Proc. Natl. Acad. Sci. USA* 90:6444-6448 (1993).

The expression "linear antibodies" refers to the antibodies described in Zapata *et al.* *Protein Eng.* 8(10):1057-1062 (1995). Briefly, these antibodies comprise a pair of tandem Fd segments (V<sub>H</sub>-C<sub>H1</sub>-V<sub>H</sub>-C<sub>H1</sub>) which form a pair of antigen binding regions. Linear antibodies can be bispecific or monospecific.

"Cell," "cell line," and "cell culture" are used interchangeably herein and such designations include all progeny of a cell or cell line. Thus, for example, terms like "transformants" and "transformed cells" include the primary subject cell and cultures derived therefrom without regard for the number of transfers. It is also understood that all progeny may not be precisely identical in DNA content, due to deliberate or inadvertent mutations. Mutant

progeny that have the same function or biological activity as screened for in the originally transformed cell are included. Where distinct designations are intended, it will be clear from the context.

The terms "competent cells" and "electroporation competent cells" mean cells which are in 5 a state of competence and able to take up DNAs from a variety of sources. The state may be transient or permanent. Electroporation competent cells are able to take up DNA during electroporation.

"Control sequences" when referring to expression means DNA sequences necessary for the expression of an operably linked coding sequence in a particular host organism. The control 10 sequences that are suitable for prokaryotes, for example, include a promoter, optionally an operator sequence, a ribosome binding site, and possibly, other as yet poorly understood sequences. Eukaryotic cells are known to utilize promoters, polyadenylation signals, and enhancers.

The term "coat protein" means a protein, at least a portion of which is present on the surface of the virus particle. From a functional perspective, a coat protein is any protein which 15 associates with a virus particle during the viral assembly process in a host cell, and remains associated with the assembled virus until it infects another host cell. The coat protein may be the major coat protein or may be a minor coat protein. A "major" coat protein is a coat protein which is present in the viral coat at 10 copies of the protein or more. A major coat protein may be present in tens, hundreds or even thousands of copies per virion.

20 The "detection limit" for a chemical entity in a particular assay is the minimum concentration of that entity which can be detected above the background level for that assay. For example, in the phage ELISA of Example 5, the "detection limit" for a particular phage displaying a particular protein (e.g. hGH) is the phage concentration at which the particular phage produces an ELISA signal above that produced by a control phage not displaying the protein.

25 The terms "electroporation" and "electroporating" mean a process in which foreign matter (protein, nucleic acid, etc.) is introduced into a cell by applying a voltage to the cell under conditions sufficient to allow uptake of the foreign matter into the cell. The foreign matter is typically DNA.

An "F factor" or "F' episome" is a DNA which, when present in a cell, allows 30 bacteriophage to infect the cell. The episome may contain other genes, for example selection genes, marker genes, etc. Common F' episomes are found in well known *E. coli* strains including CJ236, CSH18, DH5alphaF', JM101 (same as in JM103, JM105, JM107, JM109, JM110), KS1000, XL1-BLUE and 71-18. These strains and the episomes contained therein are commercially available (New England Biolabs) and many have been deposited in recognized 35 depositories such as ATCC in Manassas, VA.

A "fusion protein" is a polypeptide having two portions covalently linked together, where each of the portions is a polypeptide having a different property. The property may be a biological

property, such as activity in vitro or in vivo. The property may also be a simple chemical or physical property, such as binding to a target molecule, catalysis of a reaction, etc. The two portions may be linked directly by a single peptide bond or through a peptide linker containing one or more amino acid residues. Generally, the two portions and the linker will be in reading frame 5 with each other.

"Heterologous DNA" is any DNA that is introduced into a host cell. The DNA may be derived from a variety of sources including genomic DNA, cDNA, synthetic DNA and fusions or combinations of these. The DNA may include DNA from the same cell or cell type as the host or recipient cell or DNA from a different cell type, for example, from a mammal or plant. The DNA 10 may, optionally, include selection genes, for example, antibiotic resistance genes, temperature resistance genes, etc.

"Ligation" is the process of forming phosphodiester bonds between two nucleic acid fragments. For ligation of the two fragments, the ends of the fragments must be compatible with each other. In some cases, the ends will be directly compatible after endonuclease digestion. 15 However, it may be necessary first to convert the staggered ends commonly produced after endonuclease digestion to blunt ends to make them compatible for ligation. For blunting the ends, the DNA is treated in a suitable buffer for at least 15 minutes at 15°C with about 10 units of the Klenow fragment of DNA polymerase I or T4 DNA polymerase in the presence of the four deoxyribonucleotide triphosphates. The DNA is then purified by phenol-chloroform extraction and 20 ethanol precipitation. The DNA fragments that are to be ligated together are put in solution in about equimolar amounts. The solution will also contain ATP, ligase buffer, and a ligase such as T4 DNA ligase at about 10 units per 0.5 µg of DNA. If the DNA is to be ligated into a vector, the vector is first linearized by digestion with the appropriate restriction endonuclease(s). The linearized fragment is then treated with bacterial alkaline phosphatase or calf intestinal phosphatase 25 to prevent self-ligation during the ligation step.

A "mutation" is a deletion, insertion, or substitution of a nucleotide(s) relative to a reference nucleotide sequence, such as a wild type sequence.

A "silent mutation" is a mutation which does not change the amino acid sequence of the translated polypeptide product of a given DNA sequence.

30 A "non-silent mutation" is a mutation which changes the amino acid sequence of the translated polypeptide product of a given DNA sequence.

35 "Operably linked" when referring to nucleic acids means that the nucleic acids are placed in a functional relationship with another nucleic acid sequence. For example, DNA for a presequence or secretory leader is operably linked to DNA for a polypeptide if it is expressed as a proprotein that participates in the secretion of the polypeptide; a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the sequence; or a ribosome binding site is operably linked to a coding sequence if it is positioned so as to facilitate translation.

Generally, "operably linked" means that the DNA sequences being linked are contiguous and, in the case of a secretory leader, contiguous and in reading phase. However, enhancers do not have to be contiguous. Linking is accomplished by ligation at convenient restriction sites. If such sites do not exist, the synthetic oligonucleotide adapters or linkers are used in accord with conventional practice.

"Phage display" is a technique by which variant polypeptides are displayed as fusion proteins to a coat protein on the surface of phage, e.g. filamentous phage, particles. A utility of phage display lies in the fact that large libraries of randomized protein variants can be rapidly and efficiently sorted for those sequences that bind to a target molecule with high affinity. Display of peptides and proteins libraries on phage has been used for screening millions of polypeptides for ones with specific binding properties. Polyvalent phage display methods have been used for displaying small random peptides and small proteins through fusions to either gene III or gene VIII of filamentous phage. Wells and Lowman, *Curr. Opin. Struct. Biol.*, 1992, 3:355-362 and references cited therein. In monovalent phage display, a protein or peptide library is fused to a gene III or a portion thereof and expressed at low levels in the presence of wild type gene III protein so that phage particles display one copy or none of the fusion proteins. Avidity effects are reduced relative to polyvalent phage so that sorting is on the basis of intrinsic ligand affinity, and phagemid vectors are used, which simplify DNA manipulations. Lowman and Wells, *Methods: A companion to Methods in Enzymology*, 1991, 3:205-216.

A "phagemid" is a plasmid vector having a bacterial origin of replication, e.g., ColE1, and a copy of an intergenic region of a bacteriophage. The phagemid may be based on any known bacteriophage, including filamentous bacteriophage and lambdoid bacteriophage. The plasmid will also generally contain a selectable marker for antibiotic resistance. Segments of DNA cloned into these vectors can be propagated as plasmids. When cells harboring these vectors are provided with all genes necessary for the production of phage particles, the mode of replication of the plasmid changes to rolling circle replication to generate copies of one strand of the plasmid DNA and package phage particles. The phagemid may form infectious or non-infectious phage particles. This term includes phagemids which contain a phage coat protein gene or fragment thereof linked to a heterologous polypeptide gene as a gene fusion such that the heterologous polypeptide is displayed on the surface of the phage particle. Sambrook et al., above, 4.17.

The term "phage vector" means a double stranded replicative form of a bacteriophage containing a heterologous gene and capable of replication. The phage vector has a phage origin of replication allowing phage replication and phage particle formation. The phage is preferably a filamentous bacteriophage, such as an M13, f1, fd, Pf3 phage or a derivative thereof, or a lambdoid phage, such as lambda, 21, phi80, phi81, 82, 424, 434, etc., or a derivative thereof.

"Preparation" of DNA from cells means isolating the plasmid DNA from a culture of the host cells. Commonly used methods for DNA preparation are the large- and small-scale plasmid preparations described in sections 1.25-1.33 of Sambrook et al., *supra*. After preparation of the

DNA, it can be purified by methods well known in the art such as that described in section 1.40 of *Sambrook et al., supra.*

“Oligonucleotides” are short-length, single- or double-stranded polydeoxynucleotides that are chemically synthesized by known methods (such as phosphotriester, phosphite, or phosphoramidite chemistry, using solid-phase techniques such as described in EP 266,032 published 4 May 1988, or via deoxynucleoside H-phosphonate intermediates as described by Froehler *et al.*, *Nucl. Acids Res.*, 14:5399-5407 (1986)). Further methods include the polymerase chain reaction defined below and other autoprimer methods and oligonucleotide syntheses on solid supports. All of these methods are described in Engels *et al.*, *Agnew. Chem. Int. Ed. Engl.*, 28:716-10 734 (1989). These methods are used if the entire nucleic acid sequence of the gene is known, or the sequence of the nucleic acid complementary to the coding strand is available. Alternatively, if the target amino acid sequence is known, one may infer potential nucleic acid sequences using known and preferred coding residues for each amino acid residue. The oligonucleotides are then purified on polyacrylamide gels.

15 “Polymerase chain reaction” or “PCR” refers to a procedure or technique in which minute amounts of a specific piece of nucleic acid, RNA and/or DNA, are amplified as described in U.S. Patent No. 4,683,195 issued 28 July 1987. Generally, sequence information from the ends of the region of interest or beyond needs to be available, such that oligonucleotide primers can be designed; these primers will be identical or similar in sequence to opposite strands of the template 20 to be amplified. The 5' terminal nucleotides of the two primers may coincide with the ends of the amplified material. PCR can be used to amplify specific RNA sequences, specific DNA sequences from total genomic DNA, and cDNA transcribed from total cellular RNA, bacteriophage or plasmid sequences, etc. See generally Mullis *et al.*, *Cold Spring Harbor Symp. Quant. Biol.*, 51:263 (1987); Erlich, ed., *PCR Technology*, (Stockton Press, NY, 1989). As used herein, PCR is 25 considered to be one, but not the only, example of a nucleic acid polymerase reaction method for amplifying a nucleic acid test sample comprising the use of a known nucleic acid as a primer and a nucleic acid polymerase to amplify or generate a specific piece of nucleic acid.

DNA is "purified" when the DNA is separated from non-nucleic acid impurities. The impurities may be polar, non-polar, ionic, etc.

30 “Recovery” or “isolation” of a given fragment of DNA from a restriction digest means separation of the digest on polyacrylamide or agarose gel by electrophoresis, identification of the fragment of interest by comparison of its mobility versus that of marker DNA fragments of known molecular weight, removal of the gel section containing the desired fragment, and separation of the gel from DNA. This procedure is known generally. For example, see Lawn *et al.*, *Nucleic Acids Res.*, 9:6103-6114 (1981), and Goeddel *et al.*, *Nucleic Acids Res.*, 8:4057 (1980).

A chemical group or species having a “specific binding affinity for DNA” means a molecule or portion thereof which forms a non-covalent bond with DNA which is stronger than the bonds formed with other cellular components including proteins, salts, and lipids.

A "survivor" is a cell which remains viable after a transformation process.

A "transcription regulatory element" will contain one or more of the following components: an enhancer element, a promoter, an operator sequence, a repressor gene, and a transcription termination sequence. These components are well known in the art. U.S. 5,667,780.

5 A "transformant" is a cell which has taken up and maintained DNA as evidenced by the expression of a phenotype associated with the DNA (e.g., antibiotic resistance conferred by a protein encoded by the DNA).

"Transformation" means a process whereby a cell takes up DNA and becomes a "transformant". The DNA uptake may be permanent or transient.

10 "Transformation efficiency" means the number of transformants produced per unit mass of DNA following a transformation procedure (e.g. transformants per microgram of DNA).

"Transformation frequency" means the ratio of the number of transformants to the number of survivors.

15 "Transformation yield" means the number of transformants produced in a single electroporation reaction.

20 A "variant" or "mutant" of a starting polypeptide, such as a fusion protein or a heterologous polypeptide (heterologous to a phage), is a polypeptide that 1) has an amino acid sequence different from that of the starting polypeptide and 2) was derived from the starting polypeptide through either natural or artificial (manmade) mutagenesis. Such variants include, for example, deletions from, and/or insertions into and/or substitutions of, residues within the amino acid sequence of the polypeptide of interest. Any combination of deletion, insertion, and substitution may be made to arrive at the final variant or mutant construct, provided that the final construct possesses the desired functional characteristics. The amino acid changes also may alter post-translational processes of the polypeptide, such as changing the number or position of glycosylation sites. Methods for generating amino acid sequence variants of polypeptides are described in U. S. 5,534,615, expressly incorporated herein by reference.

25 Generally, a variant coat protein will possess at least 20% or 40% sequence identity and up to 70% or 85% sequence identity, more preferably up to 95% or 99.9% sequence identity, with the wild type coat protein. Percentage sequence identity is determined, for example, by the Fitch *et al.*, 30 *Proc. Natl. Acad. Sci. USA* 80:1382-1386 (1983), version of the algorithm described by Needleman *et al.*, *J. Mol. Biol.* 48:443-453 (1970), after aligning the sequences to provide for maximum homology. Amino acid sequence variants of a polypeptide are prepared by introducing appropriate nucleotide changes into DNA encoding the polypeptide, or by peptide synthesis. An "altered residue" is a deletion, insertion or substitution of an amino acid residue relative to a reference 35 amino acid sequence, such as a wild type sequence.

A "functional" mutant or variant is one which exhibits a detectable activity or function which is also detectably exhibited by the wild type protein. For example, a "functional" mutant or variant of the major coat protein is one which is stably incorporated into the phage coat at levels

which can be experimentally detected. Preferably, the phage coat incorporation can be detected in a range of about 1 fusion per 1000 virus particles up to about 1000 fusions per virus particle.

A "hyper-functional" mutant or variant is a functional mutant or variant whose activity exceeds that of the wild type. For example, a hyper-functional mutant or variant of the major coat protein is one which is stably incorporated into the phage coat at levels greater than those of the wild type protein in an identical context.

A "hypo-functional" mutant or variant is a functional mutant or variant whose activity is less than that of the wild type. For example, a hypo-functional mutant or variant of the major coat protein is one which is stably incorporated into the phage coat at levels less than those of the wild type protein in an identical context.

A "wild type" sequence or the sequence of a "wild type" protein, such as a coat protein, is the reference sequence from which variant polypeptides are derived through the introduction of mutations. In general, the "wild type" sequence for a given protein is the sequence that is most common in nature. Similarly, a "wild type" gene sequence is the sequence for that gene which is most commonly found in nature. Mutations may be introduced into a "wild type" gene (and thus the protein it encodes) either through natural processes or through man induced means. The products of such processes are "variant" or "mutant" forms of the original "wild type" protein or gene.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTSA. Novel methods and cells

The present invention provides a method of transforming cells by electroporating competent cells in the presence of heterologous DNA, where the DNA has been purified by DNA affinity purification. Preferably, for library construction in bacteria, the DNA is present at a concentration of 25 micrograms/mL or greater. Preferably, the DNA is present at a concentration of about 30 micrograms/mL or greater, more preferably at a concentration of about 70 micrograms/mL or greater and even more preferably at a concentration of about 100 micrograms/mL or greater even up to several hundreds of micrograms/mL. Generally, the method of the invention will utilize DNA concentrations in the range of about 50 to about 500 micrograms/mL. It has been discovered that by highly purifying the heterologous DNA, a time constant during electroporation greater than 3.0 milliseconds (ms) is possible even when the DNA concentration is very high, which results in a high transformation efficiency. Over the DNA concentration range of about 50 microgram/mL to about 400 microgram/mL, the method of the invention allows the use of time constants in the range of about 3.6 to about 4.4 ms using standard electroporation instruments. The invention therefore provides a method with greater dynamic range in DNA concentration than previously known.

The high DNA concentrations used in the method of the invention are obtained by highly purifying DNA used to transform the competent cells. In the method of the invention, the DNA is purified to remove contaminants which increase the conductance of the DNA solution used in the electroporating process. The DNA may be purified by any known method, however, a preferred purification method is the use of DNA affinity purification. The purification of DNA, e.g., recombinant linear or plasmid DNA, using DNA binding resins and affinity reagents is well known and any of the known methods can be used in this invention (Vogelstein, B. and Gillespie, D., 1979, *Proc. Natl. Acad. Sci. USA*, 76:615; Callen, W., 1993, Strategies, 6:52-53). Commercially available DNA isolation and purification kits are also available from several sources including Stratagene (CLEARCUT Miniprep Kit), and Life Technologies (GLASSMAX DNA Isolation Systems). Suitable nonlimiting methods of DNA purification include column chromatography (U.S. 5,707,812), the use of hydroxylated silical polymers (U.S. 5,693,785), rehydrated silica gel (U.S. 4,923,978), boronated silicates (U.S. 5,674,997), modified glass fiber membranes (U.S. 5,650,506; U.S. 5,438,127), fluorinated adsorbents (U.S. 5,625,054; U.S. 5,438,129), diatomaceous earth (U.S. 5,075,430), dialysis (U.S. 4,921,952), gel polymers (U.S. 5,106,966) and the use of chaotropic compounds with DNA binding reagents (U.S. 5,234,809). After purification, the DNA is eluted or otherwise resuspended in water, preferably distilled or deionized water, for use in electroporation at the concentrations of the invention. The use of low salt buffer solutions is also contemplated where the solution has low electrical conductivity, i.e., is compatible with the use of the high DNA concentrations of the invention with time constants greater than about 3.0 ms.

Any cells which can be transformed by electroporation may be used as host cells in the method of the present invention. Suitable host cells which can be transformed with heterologous DNA in the method of the invention include animal cells (Neumann et al., *EMBO J.*, (1982), 1:841; Wong and Neumann, *Biochem. Biophys. Res. Commun.*, (1982), 107:584; Potter et al., *Proc. Natl. Acad. Sci., USA*, (1984) 81:7161; Sugden et al., *Mol. Cell. Biol.*, (1985), 5:410; Toneguzzo et al., *Mol. Cell. Biol.*, (1986), 6:703; Pur-Kaspa et al., *Mol. Cell. Biol.*, (1986), 6:716), plant cells (Fromm et al., *Proc. Natl. Acad. Sci., USA*, (1985), 82:5824; Fromm et al., *Nature*, (1986), 319:791; Ecker and Davis, *Proc. Natl. Acad. Sci., USA*, (1986) 83:5372) and bacterial cells (Chu et al., *Nucleic Acids Res.*, (1987), 15:1311; Knutson and Yee, *Anal. Biochem.*, (1987), 164:44).

Prokaryotes are the preferred host cells for this invention. See also Andreason and Evans, *Biotechniques*, (1988), 6:650 which describes parameters which effect transfection efficiencies for varying cell lines. Suitable bacterial cells include *E. coli* (Dower et al., above; Taketo, *Biochim. Biophys. Acta*, (1988), 149:318), *L. casei* (Chassy and Flickinger, *FEMS Microbiol. Lett.*, (1987), 44:173), *Strept. lactis* (Powell et al., *Appl. Environ. Microbiol.*, (1988), 54:655; Harlander, *Streptococcal Genetics*, ed . J. Ferretti and R. Curtiss, III), page 229, American Society for Microbiology, Washington, D.C., (1987)), *Strept. thermophilus* (Somkuti and Steinberg, *Proc. 4th Eur. Cong. Biotechnology*, 1987, 1:412); *Campylobacter jejuni* (Miller et al., *Proc. Natl. Acad. Sci., USA*, (1988) 85:856), and other bacterial strains (Fielder and Wirth, *Anal. Biochem.*, (1988), 170:38) including bacilli such as *Bacillus subtilis*, other enterobacteriaceae such as *Salmonella typhimurium* or *Serratia marcesans*, and various *Pseudomonas* species which may all be used as hosts. Suitable *E. coli* strains include JM101, *E. coli* K12 strain 294 (ATCC number 31,446), *E. coli* strain W3110 (ATCC number 27,325), *E. coli* X1776 (ATCC number 31,537), *E. coli* XL-1Blue (Stratagene), and *E. coli* B; however many other strains of *E. coli*, such as XL1-Blue MRF', SURE, ABLE C, ABLE K, WM1100, MC1061, HB101, CJ136, MV1190, JS4, JS5, NM522, NM538, NM539, TG1 and many other species and genera of prokaryotes may be used as well.

Cells are made competent using known procedures. Sambrook et al., above, 1.76-1.81, 16.30.

The heterologous DNA is preferably in the form of a replicable transcription or expression vector, such as a plasmid, phage or phagemid which can be constructed with relative ease and readily amplified. These vectors generally contain a promoter, a signal sequence, phenotypic selection genes, origins of replication, and other necessary components which are known to those of ordinary skill in this art. Construction of suitable vectors containing these components as well as the gene encoding one or more desired cloned polypeptides are prepared using standard recombinant DNA procedures as described in Sambrook et al., above. Isolated DNA fragments to be combined to form the vector are cleaved, tailored, and ligated together in a specific order and orientation to generate the desired vector.

22

The gene encoding the desired polypeptide (i.e., a peptide or a polypeptide with a rigid secondary structure) can be obtained by methods known in the art (see generally, Sambrook *et al.*). If the sequence of the gene is known, the DNA encoding the gene may be chemically synthesized (Merrfield, *J. Am. Chem. Soc.*, 85 :2149 (1963)). If the sequence of the gene is not known, or if the 5 gene has not previously been isolated, it may be cloned from a cDNA library (made from RNA obtained from a suitable tissue in which the desired gene is expressed) or from a suitable genomic DNA library. The gene is then isolated using an appropriate probe. For cDNA libraries, suitable probes include monoclonal or polyclonal antibodies (provided that the cDNA library is an expression library), oligonucleotides, and complementary or homologous cDNAs or fragments 10 thereof. The probes that may be used to isolate the gene of interest from genomic DNA libraries include cDNAs or fragments thereof that encode the same or a similar gene, homologous genomic DNAs or DNA fragments, and oligonucleotides. Screening the cDNA or genomic library with the selected probe is conducted using standard procedures as described in chapters 10-12 of Sambrook *et al.*, above.

15 An alternative means to isolating the gene encoding the protein of interest is to use polymerase chain reaction methodology (PCR) as described in section 14 of Sambrook *et al.*, above. This method requires the use of oligonucleotides that will hybridize to the gene of interest; thus, at least some of the DNA sequence for this gene must be known in order to generate the oligonucleotides.

20 After the gene has been isolated, it may be inserted into a suitable vector (preferably a plasmid) for amplification, as described generally in Sambrook *et al.*

25 The DNA is cleaved using the appropriate restriction enzyme or enzymes in a suitable buffer. In general, about 0.2-1 µg of plasmid or DNA fragments is used with about 1-2 units of the appropriate restriction enzyme in about 20 µl of buffer solution. Appropriate buffers, DNA concentrations, and incubation times and temperatures are specified by the manufacturers of the restriction enzymes. Generally, incubation times of about one or two hours at 37°C are adequate, although several enzymes require higher temperatures. After incubation, the enzymes and other contaminants are removed by extraction of the digestion solution with a mixture of phenol and chloroform, and the DNA is recovered from the aqueous fraction by precipitation with ethanol or 30 other DNA purification technique.

To ligate the DNA fragments together to form a functional vector, the ends of the DNA fragments must be compatible with each other. In some cases, the ends will be directly compatible after endonuclease digestion. However, it may be necessary to first convert the sticky ends commonly produced by endonuclease digestion to blunt ends to make them compatible for ligation. 35 To blunt the ends, the DNA is treated in a suitable buffer for at least 15 minutes at 15 °C with 10 units of the Klenow fragment of DNA polymerase I (Klenow) in the presence of the four deoxynucleotide triphosphates. The DNA is then purified by phenol-chloroform extraction and ethanol precipitation or other DNA purification technique.

The cleaved DNA fragments may be size-separated and selected using DNA gel electrophoresis. The DNA may be electrophoresed through either an agarose or a polyacrylamide matrix. The selection of the matrix will depend on the size of the DNA fragments to be separated. After electrophoresis, the DNA is extracted from the matrix by electroelution, or, if low-melting agarose has been used as the matrix, by melting the agarose and extracting the DNA from it, as described in sections 6.30-6.33 of Sambrook et al., *supra*.

The DNA fragments that are to be ligated together (previously digested with the appropriate restriction enzymes such that the ends of each fragment to be ligated are compatible) are put in solution in about equimolar amounts. The solution will also contain ATP, ligase buffer 10 and a ligase such as T4 DNA ligase at about 10 units per 0.5 µg of DNA. If the DNA fragment is to be ligated into a vector, the vector is at first linearized by cutting with the appropriate restriction endonuclease(s). The linearized vector is then treated with alkaline phosphatase or calf intestinal phosphatase. The phosphatasing prevents self-ligation of the vector during the ligation step.

After ligation, the vector with the foreign gene now inserted is purified as described above 15 and transformed into a suitable host cell such as those described above by electroporation using known and commercially available electroporation instruments and the procedures outlined by the manufacturers and described generally in Dower et al., above. The invention provides high transformation yields, a single electroporation reaction typically yields greater than  $1 \times 10^{10}$  transformants. However, more than one (a plurality) electroporation may be conducted to increase 20 the amount of DNA which is transformed into the host cells. Repeated electroporations are conducted as described in the art. See Vaughan et al., above. The number of additional electroporations may vary as desired from several (2,3,4,...10) up to tens (10, 20, 30,...100) and even hundreds (100, 200, 300,...1000). Repeated electroporations may be desired to increase the size of a combinatorial library, e.g. an antibody library, transformed into the host cells. With a 25 plurality of electroporations, it is possible to produce a library having at least  $1.0 \times 10^{12}$ , even  $2.0 \times 10^{12}$ , different members (clones, DNA vectors such as phage, phagemids, plasmids, etc., cells, etc.).

Electroporation may be carried out using methods known in the art and described, for example, in U.S. 4,910,140; U.S. 5,186,800; U.S. 4,849,355; , U.S. 5,173,158; U.S. 5,098,843; 30 U.S. 5,422,272; U.S. 5,232,856; U.S. 5,283,194; U.S. 5,128,257; U.S. 5,750,373; U.S. 4,956,288 or any other known batch or continuous electroporation process together with the improvements of the invention.

Typically, electrocompetent cells are mixed with a solution of DNA at the desired concentration at ice temperatures. An aliquot of the mixture is placed into a cuvette and placed in 35 an electroporation instrument, e.g., GENE PULSER (Biorad) having a typical gap of 0.2 cm. Each cuvette is electroporated as described by the manufacturer. Typical settings are: voltage = 2.5 kV, resistance = 200 ohms, capacitance = 25 mF. The cuvette is then immediately removed, SOC media (Maniatis) is added, and the sample is transferred to a 250 mL baffled flask. The contents of

several cuvettes may be combined after electroporation. The culture is then shaken at 37°C to culture the transformed cells.

The transformed cells are generally selected by growth on an antibiotic, commonly tetracycline (tet) or ampicillin (amp), to which they are rendered resistant due to the presence of tet and/or amp resistance genes in the vector.

After selection of the transformed cells, these cells are grown in culture and the vector DNA (plasmid or other vector with the foreign gene inserted) may then be isolated. Vector DNA can be isolated using methods known in the art. Two suitable methods are the small scale preparation of DNA and the large-scale preparation of DNA as described in sections 1.25-1.33 of 10 Sambrook et al., *supra*. The isolated DNA can be purified by methods known in the art such as that described in section 1.40 of Sambrook et al., above and as described above.. This purified DNA is then analyzed by restriction mapping and/or DNA sequencing. DNA sequencing is generally performed by either the method of Messing et al., *Nucleic Acids Res.*, 9:309 (1981) or by the method of Maxam et al., *Meth. Enzymol.*, 65:499 (1980).

15 This invention also contemplates fusing the gene encoding the desired polypeptide (gene 1) to a second gene (gene 2) such that a fusion protein is generated during transcription. Gene 2 is typically a coat protein gene of a filamentous phage, preferably phage M13 or a related phage, and the gene is preferably the coat protein III gene or the coat protein VIII gene, or a fragment thereof. See U.S. 5,750,373; WO 95/34683. Fusion of genes 1 and 2 may be accomplished by inserting 20 gene 2 into a particular site on a plasmid that contains gene 1, or by inserting gene 1 into a particular site on a plasmid that contains gene 2 using the standard techniques described above.

Alternatively, gene 2 may be a molecular tag for identifying and/or capturing and purifying the transcribed fusion protein. For example, gene 2 may encode for Herpes simplex virus glycoprotein D (Paborsky et al., 1990, *Protein Engineering*, 3:547-553) which can be used to affinity purify the fusion protein through binding to an anti-gD antibody. Gene 2 may also code for a polyhistidine, e.g., (his)<sub>6</sub> (Sporeno et al., 1994, *J. Biol. Chem.*, 269:10991-10995; Stuber et al., 1990, *Immunol. Methods*, 4:121-152, Waeber et al., 1993, *FEBS Letters*, 324:109-112), which can be used to identify and/or purify the fusion protein through binding to a metal ion (Ni) column (QIAEXPRESS Ni-NTA protein Purification System, Quiagen, Inc.). Other affinity tags known in 30 the art may be used and encoded by gene 2.

Insertion of a gene into a plasmid requires that the plasmid be cut at the precise location that the gene is to be inserted. Thus, there must be a restriction endonuclease site at this location (preferably a unique site such that the plasmid will only be cut at a single location during restriction endonuclease digestion). The plasmid is digested, phosphatased, and purified as 35 described above. The gene is then inserted into this linearized plasmid by ligating the two DNAs together. Ligation can be accomplished if the ends of the plasmid are compatible with the ends of the gene to be inserted. If the restriction enzymes are used to cut the plasmid and isolate the gene to be inserted create blunt ends or compatible sticky ends, the DNAs can be ligated together

directly using a ligase such as bacteriophage T4 DNA ligase and incubating the mixture at 16°C for 1-4 hours in the presence of ATP and ligase buffer as described in section 1.68 of Sambrook *et al.*, above. If the ends are not compatible, they must first be made blunt by using the Klenow fragment of DNA polymerase I or bacteriophage T4 DNA polymerase, both of which require the four deoxyribonucleotide triphosphates to fill-in overhanging single-stranded ends of the digested DNA. Alternatively, the ends may be blunted using a nuclease such as nuclease S1 or mung-bean nuclease, both of which function by cutting back the overhanging single strands of DNA. The DNA is then religated using a ligase as described above. In some cases, it may not be possible to blunt the ends of the gene to be inserted, as the reading frame of the coding region will be altered. To overcome this problem, oligonucleotide linkers may be used. The linkers serve as a bridge to connect the plasmid to the gene to be inserted. These linkers can be made synthetically as double stranded or single stranded DNA using standard methods. The linkers have one end that is compatible with the ends of the gene to be inserted; the linkers are first ligated to this gene using ligation methods described above. The other end of the linkers is designed to be compatible with the plasmid for ligation. In designing the linkers, care must be taken to not destroy the reading frame of the gene to be inserted or the reading frame of the gene contained on the plasmid. In some cases, it may be necessary to design the linkers such that they code for part of an amino acid, or such that they code for one or more amino acids.

Between gene 1 and gene 2, DNA encoding a termination codon may be inserted, such termination codons are UAG( amber), UAA (ocher) and UGA (opal). (*Microbiology*, Davis *et al.* Harper & Row, New York, 1980, pages 237, 245-47 and 274). The termination codon expressed in a wild type host cell results in the synthesis of the gene 1 protein product without the gene 2 protein attached. However, growth in a suppressor host cell results in the synthesis of detectable quantities of fused protein. Such suppressor host cells contain a tRNA modified to insert an amino acid in the termination codon position of the mRNA thereby resulting in production of detectable amounts of the fusion protein. Such suppressor host cells are well known and described, such as *E. coli* suppressor strain (Bullock *et al.*, *BioTechniques* 5:376-379 [1987]). Any acceptable method may be used to place such a termination codon into the mRNA encoding the fusion polypeptide.

The suppressible codon may be inserted between the first gene encoding a polypeptide, and a second gene encoding at least a portion of a phage coat protein. Alternatively, the suppressible termination codon may be inserted adjacent to the fusion site by replacing the last amino acid triplet in the polypeptide or the first amino acid in the phage coat protein. When the plasmid containing the suppressible codon is grown in a suppressor host cell, it results in the detectable production of a fusion polypeptide containing the polypeptide and the coat protein. When the plasmid is grown in a non-suppressor host cell, the polypeptide is synthesized substantially without fusion to the phage coat protein due to termination at the inserted suppressible triplet encoding UAG, UAA, or UGA. In the non-suppressor cell the polypeptide is

synthesized and secreted from the host cell due to the absence of the fused phage coat protein which otherwise anchored it to the host cell.

Gene 1 may encode a mammalian protein, and preferably the protein will be selected from human growth hormone(hGH), N-methionyl human growth hormone, bovine growth hormone, 5 parathyroid hormone, thyroxine, insulin A-chain, insulin B-chain, proinsulin, relaxin A-chain, relaxin B-chain, prorelaxin, glycoprotein hormones such as follicle stimulating hormone(FSH), thyroid stimulating hormone(TSH), leutinizing hormone(LH), glycoprotein hormone receptors, calcitonin, glucagon, factor VIII, an antibody, lung surfactant, urokinase, streptokinase, human tissue-type plasminogen activator (t-PA), bombesin, coagulation cascade factors including factor 10 VII, factor IX, and factor X, thrombin, hemopoietic growth factor, tumor necrosis factor-alpha and -beta, enkephalinase, human serum albumin, mullerian-inhibiting substance, mouse gonadotropin-associated peptide, a microbial protein, such as betalactamase, tissue factor protein, inhibin, activin, vascular endothelial growth factor (VEGF), receptors for hormones or growth factors; integrin, thrombopoietin (TPO), protein A or D, rheumatoid factors, nerve growth factors such as 15 NGF- alpha, platelet-growth factor, transforming growth factors (TGF) such as TGF-alpha and TGF-beta, insulin-like growth factor-I and -II, insulin-like growth factor binding proteins, CD-4, DNase, latency associated peptide, erythropoietin (EPO), osteoinductive factors, interferons such as interferon-alpha, -beta, and -gamma, colony stimulating factors (CSFs) such as M-CSF, GM-CSF, and G-CSF, interleukins (ILs) such as IL-1, IL-2, IL-3, IL-4, IL-6, IL-8, IL-10, IL-12, 20 superoxide dismutase; decay accelerating factor, viral antigen, HIV envelope proteins such as GP120, GP140, atrial natriuretic peptides A, B, or C, immunoglobulins, as well as variants and fragments of any of the above-listed proteins.

The first gene may encode a peptide containing as few as 4-10 amino acid residues and up to about 50 –80 residues. These smaller peptides are useful in determining the antigenic properties 25 of the peptides, in mapping the antigenic sites of proteins, etc. The first gene may also encode a polypeptide of one or more subunits containing more than about 100 amino acid residues which may be folded to form a plurality of rigid secondary structures displaying a plurality of amino acids capable of interacting with the target. Preferably the first gene will be mutated at codons corresponding to only the amino acids capable of interacting with the target so that the integrity of 30 the rigid secondary structures will be preserved.

Phage display of proteins, peptides and mutated variants thereof, including constructing a family of variant replicable vectors containing a transcription regulatory element operably linked to a gene fusion encoding a fusion polypeptide, transforming suitable host cells, culturing the transformed cells to form phage particles which display the fusion polypeptide on the surface of the 35 phage particle, contacting the recombinant phage particles with a target molecule so that at least a portion of the particle bind to the target, separating the particles which bind from those that do not are known and may be used with the transformation method of the invention. See U.S. 5,750,373; WO 97/09446; U.S. 5,514,548; U.S. 5,498,538; U.S. 5,516,637; U.S. 5,432,018; WO 96/22393;

U.S. 5,658,727; U.S. 5,627,024; WO 97/29185; O'Boyle et al., 1997, *Virology*, 236:338-347; Soumillion et al., 1994, *Appl. Biochem. Biotech.*, 47:175-190; O'Neil and Hoess, 1995, *Curr. Opin. Struct. Biol.*, 5:443-449; Makowski, 1993, *Gene*, 128:5-11; Dunn, 1996, *Curr. Opin. Struct. Biol.*, 7:547-553; Choo and Klug, 1995, *Curr. Opin. Struct. Biol.*, 6:431-436; Bradbury and Cattaneo, 5 1995, *TINS*, 18:242-249; Cortese et al., 1995, *Curr. Opin. Struct. Biol.*, 6:73-80; Allen et al., 1995, *TIBS*, 20:509-516; Lindquist and Naderi, 1995, *FEMS Micro. Rev.*, 17:33-39; Clarkson and Wells, 1994, *Tibtech*, 12:173-184; Barbas, 1993, *Curr. Opin. Biol.*, 4:526-530; McGregor, 1996, *Mol. Biotech.*, 6:155-162; Cortese et al., 1996, *Curr. Opin. Biol.*, 7:616-621; McLafferty et al., 1993, *Gene*, 128:29-36.

10 In a particularly preferred embodiment, gene 1 encodes the light chain or the heavy chain of an antibody or fragments thereof, such Fab, F(ab')<sub>2</sub>, Fv, diabodies, linear antibodies, etc. Gene 1 may also encode a single chain antibody (scFv). The preparation of libraries of antibodies or fragments thereof is well known in the art and any of the known methods may be used to construct a family of transformation vectors which may be transformed into host cells using the method of 15 the invention. Libraries of antibody light and heavy chains in phage (Huse et al., 1989, *Science*, 246:1275) and as fusion proteins in phage or phagemid are well known and can be prepared according to known procedures. See Vaughan et al., Barbas et al., Marks et al., Hoogenboom et al., Griffiths et al., de Kruif et al., noted above, and WO 98/05344; WO 98/15833; WO 97/47314; WO 97/44491; WO 97/35196; WO 95/34648; U.S. 5,712,089; U.S. 5,702,892; U.S. 5,427,908; U.S. 20 5,403,484; U.S. 5,432,018; U.S. 5,270,170; WO 92/06176; U.S. 5,702,892. Reviews have also published. Hoogenboom, 1997, *Tibtech*, 15:62-70 ; Neri et al., 1995, *Cell Biophysics*, 27:47; Winter et al., 1994, *Annu. Rev. Immunol.*, 12:433-455; Soderlind et al., 1992, *Immunol. Rev.*, 130:109-124; Jefferies, 1998, *Parasitology*, 14:202-206.

Specific antibodies contemplated as being encoded by gene 1 include antibodies which 25 bind to human leukocyte surface markers, cytokines and cytokine receptors, enzymes, etc. Specific leukocyte surface markers include CD1a-c, CD2, CD2R, CD3-CD10, CD11a-c, CDw12, CD13, CD14, CD15, CD15s, CD16, CD16b, CDw17, CD18-C41, CD42a-d, CD43, CD44, CD44R, CD45, CD45A, CD45B, CD45O, CD46-CD48, CD49a-f, CD50-CD51, CD52, CD53-CD59, CDw60, CD61, CD62E, CD62L, CD62P, CD63, CD64, CDw65, CD66a-e, CD68-CD74, CDw75, 30 CDw76, CD77, CDw78, CD79a-b, CD80-CD83, CDw84, CD85-CD89, CDw90, CD91, CDw92, CD93-CD98, CD99, CD99R, CD100, CDw101, CD102-CD106, CD107a-b, CDw108, CDw109, CD115, CDw116, CD117, CD119, CD120a-b, CD121a-b, CD122, CDw124, CD126-CD129, and 35 CD130. Other antibody binding targets include cytokines and cytokine superfamily receptors, hematopoietic growth factor superfamily receptors and preferably the extracellular domains thereof, which are a group of closely related glycoprotein cell surface receptors that share considerable homology including frequently a WSXWS domain and are generally classified as members of the cytokine receptor superfamily (see e.g. Nicola et al., *Cell*, 67:1-4 (1991) and Skoda, R.C. et al. *EMBO J.* 12:2645-2653 (1993)). Generally, these targets are receptors for

interleukins (IL) or colony-stimulating factors (CSF). Members of the superfamily include, but are not limited to, receptors for: IL-2 (b and g chains) (Hatakeyama *et al.*, *Science*, 244:551-556 (1989); Takeshita *et al.*, *Science*, 257:379-382 (1991)), IL-3 (Itoh *et al.*, *Science*, 247:324-328 (1990); Gorman *et al.*, *Proc. Natl. Acad. Sci. USA*, 87:5459-5463 (1990); Kitamura *et al.*, *Cell*, 66:1165-1174 (1991a); Kitamura *et al.*, *Proc. Natl. Acad. Sci. USA*, 88:5082-5086 (1991b)), IL-4 (Mosley *et al.*, *Cell*, 59:335-348 (1989), IL-5 (Takaki *et al.*, *EMBO J.*, 9:4367-4374 (1990); Tavernier *et al.*, *Cell*, 66:1175-1184 (1991)), IL-6 (Yamasaki *et al.*, *Science*, 241:825-828 (1988); Hibi *et al.*, *Cell*, 63:1149-1157 (1990)), IL-7 (Goodwin *et al.*, *Cell*, 60:941-951 (1990)), IL-9 (Renault *et al.*, *Proc. Natl. Acad. Sci. USA*, 89:5690-5694 (1992)), granulocyte-macrophage colony-stimulating factor (GM-CSF) (Gearing *et al.*, *EMBO J.*, 8:3667-3676 (1991); Hayashida *et al.*, *Proc. Natl. Acad. Sci. USA*, 244:9655-9659 (1990)), granulocyte colony-stimulating factor (G-CSF) (Fukunaga *et al.*, *Cell*, 61:341-350 (1990a); Fukunaga *et al.*, *Proc. Natl. Acad. Sci. USA*, 87:8702-8706 (1990b); Larsen *et al.*, *J. Exp. Med.*, 172:1559-1570 (1990)), EPO (D'Andrea *et al.*, *Cell*, 57:277-285 (1989); Jones *et al.*, *Blood*, 76:31-35 (1990)), Leukemia inhibitory factor (LIF) (Gearing *et al.*, *EMBO J.*, 10:2839-2848 (1991)), oncostatin M (OSM) (Rose *et al.*, *Proc. Natl. Acad. Sci. USA*, 88:8641-8645 (1991)) and also receptors for prolactin (Boutin *et al.*, *Proc. Natl. Acad. Sci. USA*, 88:7744-7748 (1988); Edery *et al.*, *Proc. Natl. Acad. Sci. USA*, 86:2112-2116 (1989)), growth hormone (GH) (Leung *et al.*, *Nature*, 330:537-543 (1987)), ciliary neurotrophic factor (CNTF) (Davis *et al.*, *Science*, 253:59-63 (1991) and c-Mpl (M. Souyri *et al.*, *Cell* 63:1137 (1990); I. Vigon *et al.*, *Proc. Natl. Acad. Sci.* 89:5640 (1992)). Still other targets for antibodies made by the invention are erb2, erb3, erb4, IL-10, IL-12, IL-13, IL-15, etc.

Gene 1, encoding the desired polypeptide, may be altered at one or more selected codons. An alteration is defined as a substitution, deletion, or insertion of one or more codons in the gene encoding the polypeptide that results in a change in the amino acid sequence of the polypeptide as compared with the unaltered or native sequence of the same polypeptide. Preferably, the alterations will be by substitution of at least one amino acid with any other amino acid in one or more regions of the molecule. The alterations may be produced by a variety of methods known in the art. These methods include but are not limited to oligonucleotide-mediated mutagenesis and cassette mutagenesis.

Oligonucleotide -mediated mutagenesis is preferred method for preparing substitution, deletion, and insertion variants of gene 1. This technique is well known in the art as described by Zoller *et al.*, *Nucleic Acids Res.*, 10: 6487-6504 (1987). Briefly, gene 1 is altered by hybridizing an oligonucleotide encoding the desired mutation to a DNA template, where the template is the single-stranded form of the plasmid containing the unaltered or native DNA sequence of gene 1. After hybridization, a DNA polymerase is used to synthesize an entire second complementary strand of the template will thus incorporate the oligonucleotide primer, and will code for the selected alteration in gene 1.

Generally, oligonucleotides of at least 25 nucleotides in length are used. An optimal oligonucleotide will have 12 to 15 nucleotides that are completely complementary to the template on either side of the nucleotide(s) coding for the mutation. This ensures that the oligonucleotide will hybridize properly to the single-stranded DNA template molecule. The oligonucleotides are 5 readily synthesized using techniques known in the art such as that described by Crea et al., *Proc. Nat'l. Acad. Sci. USA*, 75: 5765 (1978).

The DNA template is generated by those vectors that are either derived from bacteriophage M13 vectors (the commercially available M13mp18 and M13mp19 vectors are suitable), or those vectors that contain a single-stranded phage origin of replication as described by Viera et al., *Meth. Enzymol.*, 153: 3 (1987). Thus, the DNA that is to be mutated can be inserted into one of these 10 vectors in order to generate single-stranded template. Production of the single-stranded template is described in sections 4.21-4.41 of Sambrook et al., above.

To alter the native DNA sequence, the oligonucleotide is hybridized to the single stranded template under suitable hybridization conditions. A DNA polymerizing enzyme, usually T7 DNA 15 polymerase or the Klenow fragment of DNA polymerase I, is then added to synthesize the complementary strand of the template using the oligonucleotide as a primer for synthesis. A heteroduplex molecule is thus formed such that one strand of DNA encodes the mutated form of gene 1, and the other strand (the original template) encodes the native, unaltered sequence of gene 1. This heteroduplex molecule is then transformed into a suitable host cell, usually a prokaryote 20 such as *E. coli* JM101. After growing the cells, they are plated onto agarose plates and screened using the oligonucleotide primer radiolabelled with 32-Phosphate to identify the bacterial colonies that contain the mutated DNA.

The method described immediately above may be modified such that a homoduplex 25 molecule is created wherein both strands of the plasmid contain the mutation(s). The modifications are as follows: The single-stranded oligonucleotide is annealed to the single-stranded template as described above. A mixture of three deoxyribonucleotides, deoxyriboadenosine (dATP), deoxyriboguanosine (dGTP), and deoxyribothymidine (dTTP), is combined with a modified thio-deoxyribocytosine called dCTP-(aS) (which can be obtained from Amersham). This mixture is 30 added to the template-oligonucleotide complex. Upon addition of DNA polymerase to this mixture, a strand of DNA identical to the template except for the mutated bases is generated. In addition, this new strand of DNA will contain dCTP-(aS) instead of dCTP, which serves to protect it from restriction endonuclease digestion. After the template strand of the double-stranded heteroduplex is nicked with an appropriate restriction enzyme, the template strand can be digested with ExoIII nuclease or another appropriate nuclease past the region that contains the site(s) to be 35 mutagenized. The reaction is then stopped to leave a molecule that is only partially single-stranded. A complete double-stranded DNA homoduplex is then formed using DNA polymerase in the presence of all four deoxyribonucleotide triphosphates, ATP, and DNA ligase. This

homoduplex molecule can then be transformed into a suitable host cell such as *E. coli* JM101, as described above.

Mutants with more than one amino acid to be substituted may be generated in one of several ways. If the amino acids are located close together in the polypeptide chain, they may be 5 mutated simultaneously using one oligonucleotide that codes for all of the desired amino acid substitutions. If, however, the amino acids are located some distance from each other (separated by more than about ten amino acids), it is more difficult to generate a single oligonucleotide that encodes all of the desired changes. Instead, one of two alternative methods may be employed.

In the first method, a separate oligonucleotide is generated for each amino acid to be 10 substituted. The oligonucleotides are then annealed to the single-stranded template DNA simultaneously, and the second strand of DNA that is synthesized from the template will encode all of the desired amino acid substitutions. The alternative method involves two or more rounds of mutagenesis to produce the desired mutant. The first round is as described for the single mutants: wild-type DNA is used for the template, an oligonucleotide encoding the first desired amino acid 15 substitution(s) is annealed to this template, and the heteroduplex DNA molecule is then generated. The second round of mutagenesis utilizes the mutated DNA produced in the first round of mutagenesis as the template. Thus, this template already contains one or more mutations. The oligonucleotide encoding the additional desired amino acid substitution(s) is then annealed to this template, and the resulting strand of DNA now encodes mutations from both the first and second 20 rounds of mutagenesis. This resultant DNA can be used as a template in a third round of mutagenesis, and so on.

Cassette mutagenesis is also a preferred method for preparing substitution, deletion, and 25 insertion variants of gene 1. The method is based on that described by Wells et al., *Gene*, 34:315 (1985). The starting material is the plasmid (or other vector) comprising gene 1, the gene to be mutated. The codon(s) in gene 1 to be mutated are identified. There must be a unique restriction endonuclease site on each side of the identified mutation site(s). If no such restriction sites exist, 30 they may be generated using the above-described oligonucleotide-mediated mutagenesis method to introduce them at appropriate locations in gene 1. After the restriction sites have been introduced into the plasmid, the plasmid is cut at these sites to linearize it. A double-stranded oligonucleotide encoding the sequence of the DNA between the restriction sites but containing the desired 35 mutation(s) is synthesized using standard procedures. The two strands are synthesized separately and then hybridized together using standard techniques. This double-stranded oligonucleotide is referred to as the cassette. This cassette is designed to have 3' and 5' ends that are compatible with the ends of the linearized plasmid, such that it can be directly ligated to the plasmid. This plasmid now contains the mutated DNA sequence of gene 1.

In a preferred embodiment, gene 1 is linked to gene 2 encoding at least a portion of a phage coat protein. Preferred coat protein genes are the genes encoding coat protein 3 and coat protein 8 of filamentous phage specific for *E. coli*, such as M13, f1 and fd phage. Transfection of

host cells containing a replicable expression vector which encodes the gene fusion of gene 1 and gene 2 and production of phage particles according to standard procedures provides phage particles in which the polypeptide encoded by gene 1 is displayed on the surface of the phage particle.

Although published protocols suggest using a final cell concentration of about  $10^{10}$  colony forming units (cfu)/mL, the present invention allows one to obtain cell concentrations of  $5 \times 10^{10}$  cfu/mL of viable living cells and greater for use in electroporation. Preferably, the viable cells are concentrated to about  $1 \times 10^{11}$  to about  $4 \times 10^{11}$  cfu/mL in the method of the invention. Preferred cells which may be concentrated to this range are the SS320 cells described below. Although Dower et al. indicate that the yield of transformants should increase with the number of cells present during electroporation, it is believed that cell concentrations above about  $5 \times 10^{10}$  cells/mL have not been used in practice. It has now been discovered that some cells, in particular, *E. coli* strains, can be concentrated to concentrations far greater than has been previously suggested. A crucial factor in determining the maximum final concentration of a given strain is the resistance of the strain to the standard washing steps used in the preparation of electrocompetent cells. It has been discovered that the proportion of cells surviving the washing procedure varies. As a part of this invention, it has been discovered that prior methods of preparing cells for electroporation often result in higher numbers of non-viable cells and lower transformation yields. In this embodiment, cells are grown in culture in standard culture broth, optionally for about 6-48 hrs (or to  $OD_{600} = 0.6 - 0.8$ ) at about 37°C, and then the broth is centrifuged and the supernatant removed (e.g. decanted). Initial purification is preferably by resuspending the cell pellet in a buffer solution (e.g. HEPES pH 7.4) followed by recentrifugation and removal of supernatant. The resulting cell pellet is resuspended in dilute glycerol (e.g. 5 – 20% v/v) and again recentrifuged to form a cell pellet and the supernatant removed. The final cell concentration is obtained by resuspending the cell pellet in water or dilute glycerol to the desired concentration. As noted above, it has been discovered that these washing steps have an effect on cell survival, that is on the number of viable cells in the concentrated cell solution used for electroporation. It is preferred to use cells which survive the washing and centrifugation steps in a high survival ratio relative to the number of starting cells prior to washing. Most preferably, the ratio of the number of viable cells after washing to the number of viable cells prior to washing is 1.0, i.e., there is no cell death. However, the survival ratio may be about 0.8 or greater, preferably about 0.9 – 1.0.

A particularly preferred recipient cell is the electroporation competent *E. coli* strain of the present invention, which is *E. coli* strain MC1061 containing a phage F' episome. Any F' episome which enables phage replication in the strain may be used in the invention. Suitable episomes are available from strains deposited with ATCC or are commercially available (CJ236, CSH18, DH5alphaF', JM101, JM103, JM105, JM107, JM109, JM110), KS1000, XL1-BLUE, 71-18 and others). Strain SS320 was prepared by mating MC1061 cells with XL1-BLUE cells under conditions sufficient to transfer the fertility episome (F' plasmid) of XL1-BLUE into the MC1061

cells. In general, mixing cultures of the two cell types and growing the mixture in culture medium for about one hour at 37°C is sufficient to allow mating and episome transfer to occur. The new resulting *E. coli* strain has the genotype of MC1061 which carries a streptomycin resistance chromosomal marker and the genotype of the F' plasmid which confers tetracycline resistance.

5 The progeny of this mating is resistant to both antibiotics and can be selectively grown in the presence of streptomycin and tetracycline. Strain SS320 has been deposited with the American Type Culture Collection (ATCC), 10801 University Boulevard, Manassas, Virginia, USA on June 18, 1998 and assigned Deposit Accession No. 98795.

This deposit of strain SS320 was made under the provisions of the Budapest Treaty on the  
10 International Recognition of the Deposit of Microorganisms for the Purpose of Patent Procedure and the Regulations thereunder (Budapest Treaty). This assures maintenance of a viable culture for 30 years from the date of deposit. The organisms will be made available by ATCC under the terms of the Budapest Treaty, and subject to an agreement between Genentech, Inc. and ATCC, which assures permanent and unrestricted availability of the progeny of the cultures to the public upon  
15 issuance of the pertinent U.S. patent or upon laying open to the public of any U.S. or foreign patent application, whichever comes first, and assures availability of the progeny to one determined by the U.S. Commissioner of Patents and Trademarks to be entitled thereto according to 35 USC §122 and the Commissioner's rules pursuant thereto (including 37 CFR §1.14 with particular reference to 886 OG 638).

20 The assignee of the present application has agreed that if the cultures on deposit should die or be lost or destroyed when cultivated under suitable conditions, they will be promptly replaced on notification with a viable specimen of the same culture. Availability of the deposited cultures is not to be construed as a license to practice the invention in contravention of the rights granted under the authority of any government in accordance with its patent laws.

25 SS320 cells have properties which are particularly favorable for electroporation. It has been discovered that SS320 cells are particularly robust and are able to survive multiple washing steps with higher cell viability than most other electroporation competent cells. The ability of SS320 cells to survive washing steps allows one to prepare cell concentrations which are greater than the cell concentrations suggested by the Dower et al. protocol. Other strains suitable for use  
30 with the higher cell concentrations include TB1, MC1061, etc. These higher cell concentrations provide greater transformation efficiency for the process of the invention.

The use of higher DNA concentrations during electroporation (about 10X) increases the transformation efficiency and increases the amount of DNA transformed into the host cells. The use of higher cell concentrations also increases the efficiency (about 10X). The larger amount of  
35 transferred DNA produces larger libraries having greater diversity and representing a greater number of unique members of a combinatorial library. The method of the invention is useful to increase the size of an expressible combinatorial library by a factor of about 100X with a single

electroporation event which allows one to select, amplify and identify rare library members present in amounts 100X lower than with comparable conventional methods.

Dower et al. have demonstrated that saturation (transformation of most survivors of an electroporation) can be achieved with closed circular DNA concentrations of about 10 microgram/mL. However, the construction of libraries, for example a library of fusion genes encoding fusion polypeptides, necessarily involves the introduction of DNA fragments representing the library into a suitable vector to provide a family or library of vectors. In the case of cassette mutagenesis, the synthetic DNA is a double stranded cassette while in fill-in mutagenesis the synthetic DNA is single stranded DNA. In either case, the synthetic DNA is incorporated into a vector to yield a reaction product containing closed circular double stranded DNA which can be transformed into a cell to produce the library. However, processes used to incorporate synthetic DNA into closed circular DNA are generally less than 100% efficient, and often the desired closed circular product represents only a small fraction of the total DNA. To achieve saturation with a ligation or fill-in reaction product may require significantly higher DNA concentrations than those necessary when using pure closed circular DNA. Prior methods do not allow or suggest using DNA concentrations which are sufficient to achieve saturation in the electroporation reactions using DNA incorporating synthetic DNA fragments into transformation vectors, e.g. plasmids, phage vectors, phagemid vectors, etc.

For example, the reaction of Example 6 below, demonstrates that using the method of the invention, a DNA concentration of 19 microgram/mL results in transformation of 53% of surviving cells. In this example, the fill-in reaction was very efficient yielding about 95% of the desired closed circular DNA product as evidenced by agarose gel electrophoresis. The DNA concentration can be increased to hundreds (e.g., 300 – 500 microgram/mL) of micrograms/mL without adversely affecting either the cell survival or the transformation. The maximum number of transformants is obtained at a DNA concentration 20-fold lower than the maximum DNA concentration tested and even the largest DNA concentration tested had no detrimental effect on the electroporation reaction. The invention provides a useable dynamic range of DNA concentration in electroporation which far exceeds that possible with prior methods. Using the method of the invention, inefficient transformation vector formation reactions which yield only small amounts of the desired clonable DNA, for example only 10-50%, or even 1-10%, can be made to saturate the electroporation survivors by using DNA concentrations up to about 400 -500 micrograms/mL.

The method of the invention also allows the facile introduction of two or more vectors into a single cell, even with a DNA reaction preparation in which the desired vector (e.g. closed circular DNA) represents only a fraction of the total DNA in the preparation. This makes possible the simultaneous introduction of multiple foreign genes in separate vectors, for example, two or more libraries into a single transformant. The introduction multiple members of a library into a single cell expands the library diversity beyond the number of transformants. For example, if on average

a transformant in an electroporation reaction maintains two plasmids, the library diversity will be twice the number of transformants.

The saturation concentration for a given DNA preparation can be defined as the concentration beyond which further increases in DNA concentration do not result in increased transformation yields.

At the saturation concentration, all cells capable of taking up and maintaining DNA have been transformed. Dower et al., above, have shown that transformation efficiency is directly proportional to DNA concentration. An increase in DNA concentration should result in corresponding increases in the average number of unique plasmids per survivor. For example, if at a given DNA concentration, electroporation results in survivors carrying one unique plasmid each on average, then doubling the DNA concentration will result in the survivors carrying two unique plasmids each on average.

The current invention allows for the use of DNA concentrations in electroporation at least an order of magnitude above that possible with prior art methods. This in turn allows for the simultaneous introduction of two or more unique plasmids (containing different library members) into a single cell during a single electroporation reaction, even with DNA preparations which have been enzymatically manipulated.

Several members of a single library can be introduced into a single cell and thus the library diversity can be expanded beyond the number of transformants. For example, if on average a transformant produced in a given electroporation reaction maintains two plasmids, the library diversity will be twice the number of transformants. In the case of phage display libraries, packaging of phage DNA or phagemids maintained within the same transformant will result in a random display of the different fusion proteins produced from the different phage DNA or phagemids. Thus, some of the fusion proteins will be displayed in association with their cognate DNA sequences while others will be associated with completely unrelated sequences which happened to co-transform by random chance.

In the case of highly polyvalent display (e.g., peptide display on protein-8) where the number of incorporated fusion proteins per phage particle greatly exceeds the number of co-transformed phage DNA or phagemids, each phage particle will display its cognate fusion protein along with other unrelated fusion proteins. This will result in an increase in background during the first round of sorting due to the capture of fusion proteins associated with phage containing unrelated DNA. If the phage captured in the first round are amplified by infection into *E. coli* at a low multiplicity of infection so that each *E. coli* cell is infected by only one phage, the correlation between displayed fusion protein and its DNA sequence will be restored. The second round of sorting will then eliminate DNA sequences which do not encode proteins with affinity for the target.

In the case of monovalent display (e.g., protein display on protein-3) where the ratio of fusion protein to phage is less than one, each displayed fusion protein may associate either with its

cognate DNA sequence or with an unrelated co-transformed DNA sequence. Provided that the number of phage used in the first sort is large enough to ensure that at least some DNA sequences are linked with the fusion proteins they encode, phage displaying fusion proteins with affinity for a given target (and containing the cognate DNA sequence) will be selectable. As in the case of 5 polyvalent display, incorrect linkage between fusion protein and phage DNA will result in the first round capture of incorrect DNA sequences, but these sequences can be eliminated in the second round as described above.

The use of DNA concentrations far above the saturation concentration also allows for the 10 co-transformation of a cell with plasmids from different libraries in a single electroporation. Thus the current invention can be used to facilitate and simplify any methodology which requires that a single cell maintain two or more plasmids from distinct libraries, since two or more libraries can be introduced simultaneously rather than serially.

For example, Griffiths et al. (*EMBO Journal* 13(14):3245-3260, 1994) used the process of 15 combinatorial infection and *in vivo* recombination to increase the size of a phage antibody repertoire. The process involved the separate electroporation of light chain and heavy chain repertoires to produce two distinct libraries; a third step combined the two libraries to yield the desired antibody library. The DNA concentrations achievable with the current invention enables the co-transformation of the two libraries in a single electroporation.

The transformed cells are generally selected by growth on an antibiotic, commonly 20 tetracycline (tet) or ampicillin (amp), to which they are rendered resistant due to the presence of tet and/or amp resistance genes in the vector.

Suitable phage and phagemid vectors for use in this invention include all known vectors 25 for phage display. Additional examples include pComb8 (Gram, H., Marconi, L. A., Barbas, C. F., Collet, T. A., Lerner, R. A., and Kang, A.S. (1992) *Proc. Natl. Acad. Sci. USA* 89:3576-3580); pC89 (Felici, F., Catagnoli, L., Musacchio, A., Jappelli, R., and Cesareni, G. (1991) *J. Mol. Biol.* 222:310-310); pIF4 (Bianchi, E., Folgori, A., Wallace, A., Nicotra, M., Acali, S., Phalipon, A., Barbato, G., Bazzo, R., Cortese, R., Felici, F., and Pessi, A. (1995) *J. Mol. Biol.* 247:154-160); PM48, PM52, and PM54 (Iannolo, G., Minenkova, O., Petruzzelli, R., and Cesareni, G. (1995) *J. Mol. Biol.* ,248:835-844); fdH (Greenwood, J., Willis, A. E., and Perham, R. N. (1991) *J. Mol. Biol.*, 220:821-827); pfd8SHU, pfd8SU, pfd8SY, and fdISPLAY8 ( Malik, P. and Perham, R. N. 30 (1996) *Gene*, 171:49-51); "88" (Smith, G. P. (1993) *Gene*, 128:1-2); f88.4 (Zhong, G., Smith, G. P., Berry, J. and Brunham, R. C. (1994) *J. Biol. Chem.*, 269:24183-24188); p8V5 (Affymax); MB1, MB20, MB26, MB27, MB28, MB42, MB48, MB49, MB56: Markland, W., Roberts, B. L., Saxena, M. J., Guterman, S. K., and Ladner, R. C. (1991) *Gene*, 109:13-19). Similarly, any known helper 35 phage may be used when a phagemid vector is employed in the phage display system. Examples of suitable helper phage include M13-KO7 (Pharmacia), M13-VCS (Stratagene), and R408 (Stratagene).

After selection of the transformed cells, these cells are grown in culture and the vector DNA may then be isolated. Phage or phagemid vector DNA can be isolated using methods known in the art, for example, as described in Sambrook et al., *Molecular Cloning: A Laboratory Manual*, 2nd edition, (1989) Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.

5 The isolated DNA can be purified by methods known in the art such as that described in section 1.40 of Sambrook et al., above and as described above. This purified DNA can then be analyzed by DNA sequencing. DNA sequencing may be performed by the method of Messing et al., *Nucleic Acids Res.*, 9:309 (1981), the method of Maxam et al., *Meth. Enzymol.*, 65:499 (1980), or by any other known method.

10 The invention also contemplates producing product polypeptides which have been obtained by culturing a host cell transformed with a replicable expression vector, where the replicable expression vector contains DNA encoding a product polypeptide operably linked to a control sequence capable of effecting expression of the product polypeptide in the host cell; where the DNA encoding the product polypeptide has been obtained by:

15 (a) constructing a family of variant replicable plasmids containing a transcription regulatory element operably linked to a gene fusion encoding a fusion protein, wherein the gene fusion contains a first gene encoding a polypeptide and a second gene encoding at least a portion of a phage coat protein, where the variant replicable plasmids contain variant first genes encoding variant polypeptides;

20 (b) transforming suitable host cells with the plasmids using the method of the invention;

(c) optionally, when the plasmid is a phagemid which requires a helper phage to produce phage particles, infecting the transformed host cells with an amount of helper phage encoding the phage coat protein sufficient to produce recombinant phagemid particles which display the fusion protein on the surface of the particles, preferably where no more than a minor amount of the 25 phagemid particles display one or more copies of the fusion protein on the surface of the phagemid particles;

(d) culturing the transformed infected host cells under conditions suitable for forming recombinant phage particles containing at least a portion of the plasmid and capable of transforming the host cells;

30 (e) contacting the recombinant phage particles with a target molecule so that at least a portion of the phage particles bind to the target molecule;

(f) separating phage particles that bind to the target molecule from those that do not bind;

(g) selecting one of the variant polypeptides encoded in a phage particle which binds or does not bind to the target molecule as the product polypeptide and cloning DNA encoding the 35 product polypeptide into the replicable expression vector; and recovering the expressed product polypeptide; and product polypeptides produced by the process.

U.S. 5,750,373 describes generally how to produce and recover a product polypeptide by culturing a host cell transformed with a replicable expression vector (e.g., a phagemid) where the

DNA encoding the polypeptide has been obtained by steps (a)-(f) above using conventional helper phage where a minor amount (<20%, preferably <10%, more preferably < 1% ) of the phage particles display the fusion protein on the surface of the particle. Any suitable helper phage may be used to produce recombinant phagemid particles, e.g., VCS, etc. The present invention provides  
5 an improved method by transforming the host cells by electroporation using the high DNA concentrations and other embodiments of the invention. One of the variant polypeptides obtained by the phage display process may be selected for larger scale production by recombinant expression in a host cell. Culturing of a host cell transformed with a replicable expression vector which contains DNA encoding a product polypeptide which is the selected variant operably linked  
10 to a control sequence capable of effecting expression of the product polypeptide in the host cell and then recovering the product polypeptide using known methods is part of this invention.

B. Novel coat proteins, coat fusion proteins, vectors, cells and methods

The expression of polypeptides on the surface of bacteriophage has been developed and refined over several years. In particular, systems have been developed for displaying recombinant peptides, proteins, antigens and antibodies on the surface of filamentous bacteriophage. A number of filamentous phage have been identified which are able to infect gram negative bacteria, such as *E. coli*. These phage have a single stranded covalently closed DNA genome containing only about 10 genes encased in a cylinder of coat proteins. Due to the relative simplicity of these viruses and  
15 the ease with which they can be genetically manipulated, filamentous phage have been well studied. All strains of filamentous phage have a similar virion structure and life cycle. Upon infection, viral DNA enters the cell and is converted to a double stranded replicative form by host enzymes. Progeny DNA is replicated by a rolling circle mechanism and is assembled with a viral replication assembly protein into an elongated DNA/protein complex. The virion is extruded  
20 through the membrane of the host cell where the replication assembly protein is replaced by coat proteins. The virion sheath contains several thousand identical  $\alpha$ -helical proteins as the major coat protein.  
25

Foreign DNA can be inserted as a separate gene in a viral intergenic region. When the heterologous DNA is inserted as a separate gene, the virus or a virus-derived plasmid (phagemid)  
30 becomes a cloning vector. When the heterologous DNA is inserted as a gene fusion with a coat protein of the virus, the virus or phagemid is capable of displaying the polypeptide encoded by the heterologous DNA as a fusion protein on the surface of the virion. Fusion proteins containing variants of the major coat protein of any bacteriophage which is suitable for use in a known phage display system are within the scope of the present invention. Class I and class II filamentous phage  
35 are included within the scope of the invention. Class I includes strains Ff, IK<sub>E</sub> and IF<sub>I</sub>; class II includes strains Pf<sub>I</sub>, Pf<sub>3</sub> and Xf. The Ff phage include the virtually identical strains fd, f<sub>I</sub> and M13.

The structure and function of the major coat protein of filamentous bacteriophage have been studied in order to understand the interactions between phage DNA and the coat proteins, as well as to understand the forces which effect packing of the coat proteins into bacteriophage particles. Point mutations in the major coat proteins of filamentous bacteriophage have been prepared to assist in these studies. Hunter, E.J. et al., (1987) *Nature*, 327:252; Greenwood, J. et al., (1991) *J. Mol. Biol.* 217: 223; Deber, C.M. et al., (1993) *Proc. Natl. Acad. Sci. USA*, 90:11648; Symmons, M.S. et al., (1995) *J. Mol. Biol.* 245:86; Williams, K.A. et al., (1995) *J. Mol. Biol.* 252:6; Spruijt, R. B. et al., (1996) *Biochemistry* 35:10383; Marvin, D.A. (1998) *Current Opinion in Structural Biology* 8:150; Haigh, N.G. and Webster, R.E., (1998) *J. Mol. Biol.*, 279:19. These studies suggest that some point mutations are tolerated by phage and result in packaging of phage particles containing the mutant major coat proteins. None of these studies involve fusion proteins of heterologous polypeptides to variant phage coat proteins, however. Furthermore, it is known that the inclusion of fusion proteins in a phage coat may hinder phage packaging giving rise to poor phage yields and/or may prevent display of the fusion protein on the surface of the phage even when a wild type coat protein sequence is used (Smith, G. P. (1985), *Science*, 228:1315). Whereas small peptides (10 - 15 amino acid residues) can generally be displayed in up to about 800 - 1000 copies per virion, full length proteins are displayed in many fewer numbers (1 - 10 copies per virion). Malik, P. et al. (1996) *J. Mol. Biol.* 260:9.

The sequences of several known mature major coat proteins of filamentous bacteriophage aligned with the mature M13 coat protein VIII are shown in the Table below. Segments of the coat proteins were aligned with M13 protein VIII so as to provide maximum identity with the M13 protein without the introduction of any deletions or insertions. Numbering above the sequences refers to the residues of mature M13 protein VIII. Protein sequences are taken from the Dayhoff protein database (accession numbers: M13, COAB\_BPFD; F1, COAB\_BPFD; Fd, COAB\_BPFD; Zj-2, COAB\_BPZJ2; If-1, COAT\_BPIF1; I2-2, COAB\_BPI22; Ike, COAB\_BPIKE). Homologous residues are indicated with dashes. A sequence having a single deletion is also known (WO 92/18619). It can be seen that there is considerable homology among the sequences of these coat proteins, particularly among the M13, f1, fd and Zj-2 coat proteins and among the If1, I22 and Ike coat proteins.

## Table

(SEQ ID NOS. 2 - 8)

Filamentous phage particles are formed when the phage genes are transcribed, translated and replicated in a host cell. Phage coat proteins are directed to the periplasm and temporarily lodge in the cell membrane with a portion of the coat protein in the periplasm (the periplasmic domain), a portion of the coat protein in the cytoplasm (the cytoplasmic domain), and a portion of the coat protein spanning the cell membrane (the transmembrane domain). Phage particles are formed when the coat proteins assemble around the phage DNA as the phage particle passes through the cell membrane. The M13 major coat protein contains 50 residues which can be divided into three regions: The periplasmic domain contains residues 1 to 20, the transmembrane domain contains residues 21 to 39, and the cytoplasmic domain contains residues 40 to 50 (Marvin, D.A. (1998) *Current Opinion in Structural Biology* 8:150). The other major coat proteins in the table above have a similar domain structure.

Surprisingly, applicants have also discovered that fusion proteins of heterologous polypeptides to variants of the major coat proteins of bacteriophage are well tolerated in phage display systems. This result was unexpected since previous phage display systems have used the wild type coat protein sequences, generally of M13 or fragments thereof, T4, T7 or lambda phage coat proteins. In one aspect of the present invention, phage display and selection have been used to obtain bacteriophage displaying fusion proteins on the surface thereof where the fusion protein is a heterologous polypeptide fused to a phage major coat protein variant having one or more amino acid substitutions, deletions or additions. Fusion proteins having a heterologous polypeptide linked to a variant of the coat proteins in the Table above are within the scope of this invention.

Preferred variants of M13, f1 and fd coat protein VIII contain at least one amino acid residue selected from the lists below in the position indicated:

	<u>Residue Number</u>	<u>Sample Substitutions</u>	<u>Preferred Amino Acids</u>
25	1	E, L, V, Q (neg. charged, hydrophobic, polar)	D, I, N
	2	R, H, F, W, E (charged, large aromatic)	K, Y, D
	3	T, E, L (small polar, neg. charged, hydrophobic)	S, D, I, V, A
	4	D, R, H (charged)	E, K
30	5	R, H, N, D (charged, polar)	K, Q, E
	6	Y, W, S, I, L (aromatic, small polar, hydrophobic)	F, T, V
	7	T, N (small polar)	S
	8	D, H (charged)	R, E, K
	9	E, Q, T (neg. charged, polar)	D, N, S
35	11	W, I, V (aromatic, hydrophobic)	Y, L, F
	12	R, H, N (charged, polar)	E, D, K, Q
	13	I, L, E, Q (neg. charged, polar)	A, V, D, T, N, S
	14	L (hydrophobic)	I, V

15	D, R, N (charged, polar)	E, K, H, Q
16	E, V, L, T (neg. charged, hydrophobic, polar)	D, I, A, S, G
17	E, V, L (neg. charged, hydrophobic, polar)	I, A, T, D
18	L (hydrophobic)	V, I
5 19	L, T, Q, E (hydrophobic, polar, neg. charged)	I, V, S, A, N, D
20	R, D, H (charged)	N, Q, K, E
21	W, Y, I (aromatic, hydrophobic)	L, F, V
22	W (aromatic)	F, Y
23	W, Y, I, V, H, K (aromatic, hydrophobic, pos. charged)	F, L, R
10 24	I, Q (hydrophobic, polar)	L, N, V
25	S (hydrophobic, polar)	L, I, T, V
26	A, I, V (hydrophobic)	G, L, M
27	N (small polar)	T, S
28	I, L (hydrophobic)	V
15 29	K, R, F, W (aromatic, pos. charged)	H, Y
30	I, V (hydrophobic)	L

In these tables, the letter code refers to amino acid residues as follows: A (Ala) alanine; B (Asx) asparagine or aspartic acid; C (Cys) cysteine; D (Asp) aspartic acid; E (glu) glutamic acid; F (Phe) phenylalanine; G (Gly) glycine; H (His) histidine; I (Ile) isoleucine; K (Lys) lysine; L (Leu) leucine; M (Met) methionine; N (Asn) asparagine; O (Xaa) stop codon; P (Pro) proline; Q (Gln) glutamine; R (Arg) arginine; S (Ser) serine; T (Thr) threonine; V (Val) valine; W (Trp) tryptophan; X (Xaa) unknown or non-standard; Y (Tyr) tyrosine; Z (Glx) glutamine or glutamic acid.

As a part of this invention, it has been discovered that the amino acid sequence of phage major coat proteins can be modified to produce variants of the major coat protein which are useful as components of fusion proteins in phage display systems and methods. Fusion proteins containing variants of the major coat protein of a bacteriophage influence the ability of phage to package the fusion proteins into complete virus particles (virions). That is, variants of the major coat proteins can be used to alter the number of fusion proteins incorporated into a virus particle. Hyper-functional variants of the major coat protein can be used to increase the number of fusion proteins incorporated into a virus particle. Conversely, hypo-functional variants can be used to decrease fusion protein incorporation. In this way, the present invention provides a method for tailoring the incorporation of fusion proteins into virus particles to achieve a desired level of valency. This is particularly important for fusion proteins in which the heterologous polypeptide is relatively large, for example, where the heterologous polypeptide contains 50 or more amino acids, preferably 100 or more amino acids, and even more preferably 200 or more amino acid residues and also where the heterologous polypeptide is a protein having secondary and tertiary structure. The method of the invention, therefore, provides a means of overcoming the deficiencies of prior

art phage display methods which utilize the major coat protein of a bacteriophage and which generally obtain only limited incorporation of the fusion protein into the virus coat. The fusion polypeptides of the invention are able to function in known phage display systems by substituting for the conventionally used wild type coat protein fusions with heterologous polypeptides. The 5 fusion polypeptides of the invention will function in a similar manner to conventional fusion proteins in each of the known phage display systems, in which the fusion is with the major coat protein of the virus, further allowing one to select the degree of valency or number of fusion proteins displayed on the surface of the phage with more reliability. For example, the phage and phagemid vectors and the phage display systems described in U.S. 5,223,409; U.S. 5,403,484; U.S. 10 5,571,689; U.S. 5,750,373, and U.S. 5,780,279 (and others noted above) can be modified to use the fusion proteins of the invention to improve display of peptides, proteins, antibodies and fragments thereof on the surface of phage. The phage is preferably a DNA phage.

In addition to filamentous phage, the invention is suitable for use in phage display systems using lambda phage, Baculovirus, T4 phage and T7 phage. In each of these display systems, the 15 coat protein used to display a heterologous polypeptide is mutated to form variants of the coat protein using the method of the invention and variants having the desired degree of display (hyper-functional or hypo-functional variants) are selected. The selected variant coat protein is then used to form a fusion protein with a heterologous polypeptide which is to be displayed on the surface of the virus particles. The scope of this invention includes the method(s) of the invention using these 20 phage as well as fusion proteins, replicable expression vectors containing a gene encoding the fusion protein, virus particles containing the fusion proteins or vectors, host cells containing the virus particles, fusion proteins or vectors, libraries containing a plurality of different individuals of these fusion proteins, vectors, virions, cells, etc.

Polypeptides may be displayed on lambdoid phage using coat proteins in either the head or 25 the tail portions of the phage particle (U.S. 5,627,024). Suitable head proteins include proteins pE, pD, pB, pW, pFI, pB\* (a cleavage product of pB), pXI, and pX.2; suitable tail proteins include pJ, pV, pG, pM, and pT. The structure and location of these coat proteins is well known. See Georgeopoulos, et al. and Katsura in "Lambda II", R. W. Hendrix et al. eds. Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y., 1983. Preferred lambda proteins for use in the invention 30 are the tail coat proteins, particularly pV. U.S. 5,627,024 describes how to display polypeptides on lambda phage, preferably using pV. The fusion proteins of the invention, therefore, include at least a portion of variants of pE, pD, pB, pW, pFI, pB\*, pXI, pX.2, pJ, pV, pG, pM, and pT fused to a heterologous polypeptide.

35 Polypeptides can also be displayed on T4 phage. The structure of the T4 virion is well studied. See Eiserling in "Bacteriophage T4", C. K. Mathews et al. eds. American Society for Microbiology, Washington, D.C., 1983, pp 11-24. Peptides and full length proteins may be displayed as fusions with the SOC (small outer capsid protein) and the HOC (highly antigenic outer capsid protein) coat proteins of T4 phage. Further, the minor T4 fibrous protein fibrin

encoded by the wax (whisker's antigen control) gene can be lengthened at the C terminus with a heterologous polypeptide to form a fusion protein which is displayed on the T4 whisker protein.

See Ren, Z-J. et al. (1998) Gene 215:439; Zhu, Z. (1997) CAN 33:534; Jiang, J et al. (1997) can 128:44380; Ren, Z-J. et al. (1997) CAN 127:215644; Ren, Z-J. (1996) Protein Sci. 5:1833; and

5 Efimov, V. P. et al. (1995) Virus Genes 10:173.

T7 phage may also be used to display polypeptides and proteins. Smith, G. P. and Scott, J.K. (1993) Methods in Enzymology, 217, 228-257; U.S. 5,766,905. Commercial kits (T7Select1-1 and T7Select415-1 from Novagen) are available for display of polypeptides as fusion proteins with the 10B capsid protein (397 amino acids) and with the 10A capsid protein (344 amino acids).

10 These systems are easy to use and have the capacity to display peptides up to about 50 amino acids in size in high copy number (415 per phage), and proteins up to about 1200 amino acids in low copy number (0.1-1 per phage). T7 is a double stranded DNA phage that has been extensively studied (Dunn, J.J. and Studier, F.W. (1983) J. Mol. Biol. 166:477-535; Steven, A.C. and Trus, B.L. (1986) Electron Microscopy of Proteins 5:1-35). Phage assembly takes place inside the host 15 (E. coli) cell and mature phage are released by cell lysis. Fusion proteins of heterologous polypeptides to variants of T7 coat proteins, such as 10B and 10A, vectors containing a gene encoding the fusion protein, etc. are within the of the invention. Preferably, fusion proteins are prepared by altering, preferably by mutating to a non-wild type amino acid, one or more of residues 1-348 of capsid protein 10B.

20 The invention also includes fusion proteins of heterologous polypeptides with Baculovirus coat protein variants. Baculovirus expression vectors, particularly those based on *Autographa californica* nuclear polyhedrosis virus, are easily generated and are now widely used for the expression of heterologous polypeptides in cultured insect cells and insect larvae (Weyer, U. and Possee, R. D. (1991) *J. Gen. Virol.* 72:2967). These viruses contain a double stranded, circular genome, where foreign genes can be inserted easily. Tarui, H. et al. (1995) *J. Fac. Agr. Kyushu Univ.*, 40:45. It is possible to display a glycosylated eukaryotic protein on the surface of baculovirus particles, using a fusion with the baculovirus major coat protein gp64 or at least by fusing the heterologous polypeptides to the membrane anchorage domain of gp64 only. The efficiency of various promoters (polyhedrin, basic, gp64-promoter) have been examined, including 25 the "very late" polyhedrin promoter and the "early and late" gp64 promoter. In order to express a foreign gene on the surface of baculoviruses efficiently, it is necessary to choose a regulating promoter, that on one hand will transcribe sufficient amounts of the target protein, and on the other hand start transcription early enough in the viral replication cycle, to guarantee efficient packaging, complete glycosylation and correct folding.

30 As a further aspect of the invention, it has been discovered that phage display technology can be applied to the major coat protein itself to generate useful major coat protein variants and fusion proteins thereof. In this aspect of the invention, a library of replicable expression vectors is constructed where the expression vector includes a transcription regulatory element operably

linked to a gene fusion encoding a fusion protein where the gene fusion contains a first gene encoding a first polypeptide and a second gene encoding a variant of the major coat protein of the bacteriophage used in the phage display system. That is, a library is constructed in which the second gene encodes for a plurality of variant phage major coat proteins and the phage display system or method is used to select for the variant sequence or sequences which give the desired degree of fusion protein surface display of a polypeptide. The degree of randomization of the major coat protein to produce the variants is optional. That is, libraries may be constructed in which each amino acid residue in the coat protein may be randomized to any amino acid or each residue may be limited to a subset of amino acids to produce a more limited library having predetermined constraints. It is also possible to construct a library in which a subset of residues are allowed to vary within a subset of amino acids, i.e. selected residues are incompletely randomized. For example, it is possible to limit the range of variants for a particular amino acid residue to polar amino acids, hydrophobic amino acids, hydrophilic amino acids, aromatic amino acids, positively or negatively charged amino acids, sterically small or large amino acids, or to a particular desired combination of amino acids to obtain a smaller library having particular constraints. Any combination of amino acids may be used to prepare the desired libraries.

It is also possible to produce libraries in which amino acids residues within desired segments of the major coat protein are varied to obtain a library of major coat protein variants having amino acid additions, substitutions or deletions within defined regions of the coat protein. As an example, the major coat protein may be divided into an arbitrary number of zones, generally 2-10 zones, and a library constructed of variants within one or more of the zones. The mature major coat proteins of M13, f1 and fd phage, for example, contain 50 amino acids and might be divided into 10 zones of 5 amino acid residues each or into zones with unequal numbers of residues in each zone, e.g. zones containing 15, 10, 9, and 8 residues. Zones corresponding to the cytoplasmic, transmembrane and periplasmic regions of the coat protein may be used. A separate library may be constructed for each of the zones in which amino acid alterations are desired. If fusion proteins are desired in which the major coat protein variant has an amino acid alteration in zone 1, for example, a single library may be constructed in which one or more of the amino acid residues within zone 1 is varied. Alternatively, one may wish to produce fusion proteins in which 2 zones contain amino acid alterations. Two libraries, each library containing alterations within one of the 2 zones, can be prepared.

The variant coat protein fusions will contain one or more alterations including substitutions, additions or deletions relative to the wild type coat protein sequence. Surprisingly, a large number of alterations are possible and are tolerated by the phage while retaining the ability to display polypeptides on the phage surface. Further, the chemical nature of the residue may be changed, i.e. a hydrophobic residue may be altered to a hydrophilic residue or vice versa. Variants containing 2 - 49, preferably 5 - 40, more preferably 7 - 20, altered residues are possible. As demonstrated by the construction of protein P12 below, any of the amino acids of a major coat

protein may be varied, including varying all residues of the coat protein. Fusion proteins containing any mature coat protein sequence or portion thereof which varies from the wild type sequence of the coat protein or portion thereof is within the scope of the invention. Major coat protein variants containing 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 5 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49 or 50 variant residues are possible. Variants containing substitutions or only a few deletions are preferred since these variants will have about the same length as the wild type coat protein sequence. Variants which do not enable surface display of the heterologous polypeptide are selected against during the phage display, panning and selection process.

10 The construction of such libraries for the M13 major coat protein is described in Example 3; the selection of protein VIII variants which increase the display of hGH or SAV is shown in Example 4. For library construction, the 50-residue protein VIII was divided into five zones encompassing approximately ten contiguous residues each. A library was constructed for each zone of the protein VIII moiety within the hGH-protein VIII fusion encoded by pS349. Most 15 positions were not fully mutated, but variation was allowed at all non-lysine residues. Each library, encoding  $10^9$  possible protein VIII variants, contained at least  $3 \times 10^9$  independent transformants.

The libraries were separately cycled through five rounds of binding selection on hGHbp-coated plates. Sequencing of individual clones revealed selectants from libraries encompassing 20 zones 1, 2, and 3 (Fig. 2). The zone 4 and zone 5 sorts yielded contaminants from other libraries. The results suggest that zones 1, 2, and 3 are more tolerant to mutations and thus more suitable for use in the invention, but the results do not exclude the use of mutations in zones 4 and 5 for the purposes of the invention, and mutations in these zones are within the scope of the invention. Repeating the experiment with additional precautions to avoid contamination between libraries will 25 yield variants with mutations in zones 4 and 5 which increase or decrease heterologous protein display.

Selectants were extremely divergent from the wild type sequence, containing seven mutations on average. For zones 1 and 3, a strong consensus was not obtained. Three of four zone 30 2 selectants were identical, but subsequent clones selected for streptavidin display (see below) yielded little consensus. Only one residue (Ala10) was completely conserved as wild type, six residues (Ala7, Leu14, Ala18, Ile22, Met28, and Val30) showed consensus to wild type. Eight positions showed consensus to a mutant sequence (E2K, D4E, P6F, K8R, F11Y, G23R, A27T, and V29Y).

All selectants increased hGH display; Figure 2 shows phage ELISA data for the best 35 selectant from each zone. hGH display with the protein VIII variants produced detectable ELISA signals with phage concentrations in the sub-picomolar range. In contrast, hGH display with wild type protein VIII produced detectable ELISA signals with phage concentrations in the nanomolar

46

range. Thus, the protein VIII variants increase the signal strength (and decrease the detection limit) by at least three orders of magnitude.

Selection for SAV display was conducted with pooled libraries for zone 1, zone 2, and zone 3 of the protein VIII moiety within the SAV- protein VIII fusion gene. All selectants were 5 from the zone 2 library, but consensus was minimal (Fig. 1B). All selectants increased SAV display. Phage ELISA data for the two best selectants is shown in Fig. 4; the variants provide a 50-fold increase in signal strength when assayed for binding to either anti-SAV antibody or to biotinylated BSA.

In Example 8, hGH mutants with reduced binding affinity for hGHbp were displayed as 10 fusions to either wild type protein VIII or variant protein VIII(1a). Phage ELISA data are shown in Figure 3. As expected, reductions in binding affinity produce corresponding reductions in signal strength. When displayed on wild type protein VIII, the lowest affinity interaction ( $K_d = 820$  nM, 500-fold weaker than wild type) is barely detectable. The same interaction provides an extremely 15 strong signal when displayed on the protein VIII variant. In fact, display of the lowest affinity interaction on the protein VIII variant provides an ELISA signal at least two orders of magnitude greater than that of wild type hGH linked to wild type protein VIII.

Variants with alterations in more than one zone are possible as noted above. Such variants may be obtained by first obtaining a variant with mutations in a single zone (e.g., zone 1) and then 20 using this variant as a template for a second round of selection in which another zone is mutated (e.g., zone 2). Thus, variants obtained by this process will have mutations in two zones (e.g., zones 1 and 2). Alternatively, site-directed mutagenesis can be used to combine mutations from different variants into a single variant. For example, the mutations from a variant with mutations in zone 1 can be introduced into a variant with mutations in zone 2 to produce a new variant with mutations 25 in both zones 1 and 2. This process shown in Example 9.

Obviously, both methods can be extended further to any number of zones which may eventually encompass the entire major coat protein sequence. Thus, it is possible to derive variants 30 of the major coat protein with only minimal homology to the wild type. The potential for extreme variation in sequence in turn provides for extreme variation in function; variants ranging from extremely hyper-functional to extremely hypo-functional can be readily obtained. Thus, the invention can be used to tailor the display level of any heterologous protein fused to a coat protein. It is important to note that while the invention allows for the production of proteins with only limited homology to wild type coat protein, the new proteins are still variants of wild type protein (see definitions above) and are thus within the scope of this invention.

If a variant major coat protein which improves display of a heterologous polypeptide on 35 the surface of phage particles contains multiple mutations relative to wild type, it is also possible to obtain variants which display the heterologous polypeptide at levels intermediate between the levels obtained with the new variant and wild type major coat protein. This can be accomplished by separately back mutating each mutated amino acid of the variant back to the wild type sequence

or to another altered residue. These back mutations will generally reduce display levels of the heterologous polypeptide to levels varying between display levels obtained with the variant and wild type major coat protein. By combining the back mutations, it is possible to tailor display to a desired level which is between that obtained with the variant and wild type major coat protein.

5 This process is shown in Example 10.

By a similar process, it is possible to obtain variants which display at a level below the level of the wild type coat protein. For example, mutations may be made in one or more zones and the libraries produced panned for phage which bind only weakly (weaker than phage displaying wild type fusions). The weaker binding phage will be displaced by phage displaying wild type coat 10 protein fusions and can be isolated and sequenced using known methods.

Mutant coat proteins can be obtained which are hypofunctional for incorporation into the viral coat and thus reduce fusion protein display relative to wild type coat protein. In this case, mutations are made in residues which tend to be conserved as wild type in the above described 15 selections for hyperfunctional variants (e.g. Ala10, Ala7, Leu14, Ala18, Ile22, Met28, and Val30 in protein VIII). Conservation of these residues as wild type during the selection for hyperfunctional variants indicates that mutations at these residues are not well tolerated and will tend to produce hypofunctional variants. Variants obtained through mutations at these sites can then be screened 20 for their ability to display a given fusion protein relative to the wild type coat protein display levels. The heterologous peptide portion of the fusion protein may be any polypeptide or protein which can be captured or bound by a binding partner. Suitable fusions may display an epitope tag 25 or other polypeptide which can be bound by an antibody or binding partner. Hypofunctional variants displaying the fusion at the desired reduced levels relative to wild type can then be used for the construction of libraries of the fusion protein for the purposes of phage display. Although the preferred residues for the production of hypofunctional variants are those which were 30 conserved as wild type, any residue of the coat protein can be mutated and the resulting variant tested for its ability to allow display of a fusion protein. In this way, it is possible to select a display level below that afforded by wild type simply by using the appropriate hypofunctional mutant. As with the hyperfunctional variants described above, several hypofunctional mutations can be combined to produce further reductions in display to levels desired. While, the selection of 35 hypofunctional variants requires a screen rather than a selection, the method is relatively simple since most mutations in proteins cause reductions in activity rather increases and suitable screening procedures are known. Thus, most mutations in the coat protein should be deleterious mutations which result in hypofunctional variants.

The libraries of expression vectors are optionally mixed and used to transform suitable 35 host cells which are subsequently cultured under conditions suitable to form phage or phagemid particles. The phage or phagemid particles are contacted with a target molecule capable of binding to the polypeptide portion of the fusion protein displayed on the surface of the phage, so that at least a portion of the phage particles bind to the target molecule. Particles which contain fusion

proteins displayed in greater numbers on the virus particles will be preferentially bound by the target molecule. Separation of particles which bind to the target from those that do not bind enables one to obtain an enriched library of particles containing fusion proteins which display greater numbers of the heterologous protein on the surface of the particles. This panning process  
5 can be repeated multiple times, generally from 2 - 10, preferably 2 - 6, times to obtain further enriched libraries containing clones which contain fusion genes encoding fusion proteins of the heterologous polypeptide linked to the selected variants of the major coat protein, the variants which allow improved incorporation of the fusion protein into the virus coat in the phage display system. This method allows one to select major coat protein variants which are best able to display  
10 the particular heterologous polypeptide and optionally other polypeptides as a fusion protein on the surface of the phage particle.

The clones selected by the process described above will have an improved capacity to display the heterologous protein on the surface of the phage in the phage display system. The method is, therefore, generally useful in displaying heterologous polypeptides which are difficult to  
15 display using fusion proteins based on wild type coat protein amino acid sequence. The improved fusion protein may be used in monovalent and/or polyvalent phage display systems. In polyvalent systems, the improved fusion protein can be used to increase the number of fusion proteins which are expressed on phage particles or to modulate the number of displayed proteins to a desired range. Phage particles displaying a greater number of fusion proteins will have a greater affinity  
20 for target molecules and will be preferentially bound and separated from particles which display fewer heterologous polypeptides as fusion proteins. This is useful in processes for the discovery of weakly binding ligands where the binding affinity of the ligand will be increased by known protein engineering techniques, such as the maturing of antibodies or antibody fragments by humanization, etc. In polyvalent display, the fusion proteins of the invention allow display of only a few to  
25 several hundreds of polypeptides on the phage surface. Generally, about 3 to about 50 polypeptides will be displayed in a moderate display system. However, with the fusion protein and phage display system of the invention it is also possible to display about 50, preferably 100 - 900, and up to about 1000 polypeptides or more by selecting a coat protein variant through phage display which is capable of high display numbers.

30 Vaccination techniques based upon phage expressing antigenic proteins fused to the coat protein have been described (Fanutti, C., et al. (1998) *Biochem. Soc. Trans.*, 26: S8; Jiang, J., et al. (1997) *Infect. Immun.*, 65:4770; Delmastro, P., et al. (1997) *Vaccine*, 15:1276; Galfre, G., et al. (1996) *Methods Enzymol.*, 267:109). This invention can also be used to enhance the effectiveness  
35 of phage vaccinations. The variants of the coat protein which increase expression of protein fusions on the surface of phage increase the antigenicity of phage vaccinations. Furthermore, the method can be used to generate variants of the coat protein which stimulate the immune system as haptens. Alternatively, the invention can be used to ameliorate immune response to the phage carrying the antigenic protein.

Alternatively, in monovalent display systems the method and fusion proteins of the invention can be used to precisely tailor display of a protein to a level which is high enough to allow for detection and enrichment of desired affinities, but is low enough to avoid avidity effects associated with polyvalency. Proteins which display polyvalently as fusions to wild type major coat protein can be displayed monovalently as fusions to an appropriate hypo-functional major coat protein variant. Proteins which do not display at all on wild type major coat protein (i.e., cannot be detected as phage-associated entities) can be displayed monovalently as fusions to an appropriate hyper-functional major coat protein variant.

Having obtained a variant major coat protein which improves/tailors display of the heterologous polypeptide on the surface of phage particles, it is then possible to use conventional phage display technologies to construct libraries of variants of the originally displayed heterologous polypeptide and select for a desired property, e.g., binding, enzymatic activity, etc. The fusion protein of the invention, containing a selected variant of the major coat protein of the phage which provides the desired display characteristics, can be used to replace a fusion protein in conventional phage display systems where the conventional fusion protein contains the wild type amino acid sequence of the major coat protein or coat protein fragment. Replacement of the conventional fusion protein with the variant fusion protein of the invention improves the display of heterologous polypeptide in the phage display system. That is, the coat protein portion has been optimized for the polypeptide which is displayed as a fusion protein.

Further, it is possible to replace the original heterologous polypeptide in the new fusion protein obtained as described above with a second different heterologous polypeptide and maintain the benefits of improved incorporation of the fusion protein into virus particles. See Example 7. In this aspect of the invention, the fusion gene which encodes the original polypeptide/major coat protein variant fusion obtained by phage display panning and selection as discussed above is modified to replace the gene encoding the first polypeptide with a gene encoding a second polypeptide of interest. Conventional phage display libraries can then be constructed in which one or more residues of the second polypeptide are varied and selected by phage display panning and selection to obtain variants of the second polypeptide with the desired (e.g., improved) binding properties. This result is also surprising since the variant coat protein portion of the fusion protein was originally selected for the ability to display a different (e.g., the original) polypeptide. Nevertheless, it has been discovered that a fusion protein containing a variant coat protein portion which has been selected for improved display of a heterologous polypeptide will also generally provide improved display of other unrelated heterologous polypeptides as well, even other polypeptides containing multiple subunits. The fusion protein containing the variant coat protein portion can, therefore, be used in general phage display systems.

The phage display system of the invention can also be used to isolate polypeptides which are produced as therapeutic polypeptides using conventional recombinant DNA technology. In this embodiment, the method described above is used to identify a fusion protein containing a desired

coat protein variant portion for use in phage display. The heterologous polypeptide portion of the fusion protein may be the desired product polypeptide itself or may be a different polypeptide where this phage display step is used to select for the coat protein variant portion providing improved surface display as described above. Using a gene for the selected coat protein variant portion in the fusion gene together with a gene for a heterologous polypeptide, one can then use phage display to optimize and select from a library of different potential product heterologous polypeptide sequences to obtain a product polypeptide sequence. This product polypeptide sequence is then cloned into an expression plasmid containing a transcription regulatory element operably linked to a gene fusion encoding the product polypeptide. Expression of the gene fusion in mammalian or bacterial cells yields the product polypeptide using well known recombinant technology. See Sambrook *et al.*

It is also within the scope of the invention to prepare fusion proteins of a heterologous polypeptide and a portion of a phage coat protein, which is not necessarily the major coat protein of the phage, used to display the polypeptide. In this embodiment, for example, a minor coat protein such as coat protein III of a filamentous phage is mutated to form families and libraries of fusion proteins and phage variants as described above and phage display selection and panning are used to obtain specific phage displaying a fusion protein of a heterologous polypeptide and at least a portion of a coat protein variant. Preferably, the coat protein portion is a mutant having at least one altered residue in the transmembrane domain or in the cytoplasmic domain of the coat protein.

With respect to coat protein III, these altered residues will preferably be in the region of residues 377 to 406 as counted from the amino terminal end of the mature coat protein III (Marvin, D. A., Filamentous phage structure, infection, and assembly, *Current Opinion in Structural Biology*, 1998, 8:150-158). Coat protein III variants may contain a plurality of variant residues as generally described above for major coat proteins.

Suitable gene III vectors for display of polypeptides include fUSE5 (Scott, J. K. and Smith G. P. (1990). Searching for peptide ligands with an epitope library. *Science* 249, 386-390); fAFF1 (Cwirla, S. E., Peters, E. A., Barrett, R. W., and Dower, W. J. (1990). Peptides of phage: A vast display library of peptides for identifying ligands. *Proc. Natl. Acad. Sci. U.S.A.* 87, 6378-6382); fd-CAT1 (McCafferty, J., Griffiths, A., D., Winter, G., and Chiswell, D., J. (1990). Phage antibodies: Filamentous phage displaying antibody variable domains. *Nature (London)* 348, 552-554); m663 (Fowlkes, D., Adams, M., Fowler, V., and Kay, B. (1992). Mutlipurpose vectors for peptide expression on the M13 viral surface. *Biotechniques* 13, 422-427); fdtetDOG, pHEN1 (Hoogenboom, H., Griffiths, A., Johnson, K., Chisswell, D., Hudson, P., and Winter, G. (1991). Multi-subunit proteins on the surfaces of filamentous phage: Methodologies for displaying antibody (Fab) heavy and light chains. *Nucleic Acids Res.* 19:4133-4137); pComb3 (Gram, H., Marconi, L. A., Barbas, C. F., Collet, T. A., Lerner, R. A., and Kang, A. S. (1992) *In vitro* selection and affinity maturation of antibodies from a naive combinatorial immunoglobulin library. *Proc. Natl. Acad. Sci. U.S.A.* 89, 3576-3580); pCANTAB 5E (Pharmacia); and LamdaSurfZap

(Hogrefe, H. H., Amberg, J. R., Hay, B. N., Sorge, J. A., and Shope, B. (1993) Cloning in a bacteriophage lambda vector for the display of binding of binding proteins on filamentous phage. *Gene* 137, 85-91).

Phage display methods for proteins, peptides and mutated variants thereof, including  
5 constructing a family of variant replicable vectors containing a transcription regulatory element  
operably linked to a gene fusion encoding a fusion polypeptide, transforming suitable host cells,  
culturing the transformed cells to form phage particles which display the fusion polypeptide on the  
surface of the phage particle, contacting the recombinant phage particles with a target molecule so  
that at least a portion of the particle bind to the target, separating the particles which bind from  
10 those that do not bind, are known and may be used with the method of the invention. See U.S.  
5,750,373; WO 97/09446; U.S. 5,514,548; U.S. 5,498,538; U.S. 5,516,637; U.S. 5,432,018; WO  
96/22393; U.S. 5,658,727; U.S. 5,627,024; WO 97/29185; O'Boyle et al., 1997, *Virology*,  
236:338-347; Soumillion et al., 1994, *Appl. Biochem. Biotech.*, 47:175-190; O'Neil and Hoess,  
1995, *Curr. Opin. Struct. Biol.*, 5:443-449; Makowski, 1993, *Gene*, 128:5-11; Dunn, 1996, *Curr.*  
15 *Opin. Struct. Biol.*, 7:547-553; Choo and Klug, 1995, *Curr. Opin. Struct. Biol.*, 6:431-436;  
Bradbury and Cattaneo, 1995, *TINS*, 18:242-249; Cortese et al., 1995, *Curr. Opin. Struct. Biol.*,  
6:73-80; Allen et al., 1995, *TIBS*, 20:509-516; Lindquist and Naderi, 1995, *FEMS Micro. Rev.*,  
17:33-39; Clarkson and Wells, 1994, *Tibtech*, 12:173-184; Barbas, 1993, *Curr. Opin. Biol.*, 4:526-  
530; McGregor, 1996, *Mol. Biotech.*, 6:155-162; Cortese et al., 1996, *Curr. Opin. Biol.*, 7:616-621;  
20 McLafferty et al., 1993, *Gene*, 128:29-36.

The heterologous polypeptide portion of the fusion protein may contain as few as 4-10 or  
up to 20-30 amino acid residues and even up to about 50 -80 residues. These smaller peptides are  
useful in determining the antigenic properties of the peptides, in mapping the antigenic sites of  
proteins, etc. The heterologous polypeptide may also contain one or more subunits containing at  
25 least about 100 amino acid residues which may be folded to form a plurality of rigid secondary  
structures displaying a plurality of amino acids capable of interacting with the target. If the  
heterologous polypeptide portion of the fusion protein is mutated to form a library and subjected to  
phage display selection, it is preferred that polypeptide be mutated at codons corresponding to the  
amino acids capable of interacting with the target so that the integrity of the rigid secondary  
30 structures will be preserved. The residues can be determined by alanine scanning mutagenesis, for  
example. U.S. 5,580,723 and U.S. 5,766,854.

The heterologous polypeptide portion may also be a protein, preferably a mammalian  
protein, such as a cytokine, and the protein may be selected from human growth hormone(hGH),  
N-methionyl human growth hormone, bovine growth hormone, parathyroid hormone, thyroxine,  
35 insulin A-chain, insulin B-chain, proinsulin, relaxin A-chain, relaxin B-chain, prorelaxin,  
glycoprotein hormones such as follicle stimulating hormone(FSH), thyroid stimulating  
hormone(TSH), leutinizing hormone(LH), glycoprotein hormone receptors, calcitonin, glucagon,  
factor VIII, an antibody, lung surfactant, urokinase, streptokinase, human tissue-type plasminogen

activator (t-PA), bombesin, coagulation cascade factors including factor VII, factor IX, and factor X, thrombin, hemopoietic growth factor, tumor necrosis factor-alpha and -beta, enkephalinase, human serum albumin, mullerian-inhibiting substance, mouse gonadotropin-associated peptide, a microbial protein, such as betalactamase, tissue factor protein, inhibin, activin, vascular endothelial growth factor (VEGF), receptors for hormones or growth factors; integrin, thrombopoietin (TPO), protein A or D, rheumatoid factors, nerve growth factors such as NGF- alpha, platelet-growth factor, transforming growth factors (TGF) such as TGF-alpha and TGF-beta, insulin-like growth factor-I and -II, insulin-like growth factor binding proteins, CD-4, DNase, latency associated peptide, erythropoietin (EPO), osteoinductive factors, interferons such as interferon-alpha, -alphacon-1, -beta, and -gamma, colony stimulating factors (CSFs) such as M-CSF, GM-CSF, and G-CSF, interleukins (ILs) such as IL-1, IL-2, IL-3, IL-4, IL-6, IL-8, IL-10, IL-12, superoxide dismutase; decay accelerating factor, viral antigen, HIV envelope proteins such as GP120, GP140, atrial natriuretic peptides A, B or C, Apo2L, novel erythropoiesis stimulating protein (NESP), anestim, keratinocyte growth factor (KGF), brain-derived neurotrophic factor (BDNF), glial cell line-derived neurotrophic factor (GDNF), leptin, IL-1 receptor antagonist (IL-1ra), soluble tumor necrosis factor-a receptor type I ( sTNF-RI), immunoglobulins, as well as variants and fragments of any of the above-listed proteins

The heterologous polypeptide portion may also include a molecular tag, also known as an epitope tag, for identifying and/or capturing and purifying the fusion protein. For example, the tag may be Herpes simplex virus glycoprotein D (Paborsky et al. 1990, *Protein Engineering*, 3:547-553) which can be used to affinity purify the fusion protein through binding to an anti-gD antibody, protein A or a fragment thereof (Li et al. (1998) *Mol Biotech.*, 9:187), a polyhistidine tag, e.g., (his)<sub>6</sub> (Sporeno et al., 1994, *J. Biol. Chem.*, 269:10991-10995; Stuber et al., 1990, *Immunol. Methods*, 4:121-152, Waeber et al., 1993, *FEBS Letters*, 324:109-112), etc., which can be used to identify and/or purify the fusion protein through binding to a metal ion (Ni) column (QIAEXPRESS Ni-NTA protein Purification System, Quiagen, Inc.). Other affinity tags known in the art may be used.

In a particularly preferred embodiment, the heterologous polypeptide portion of the fusion protein is the light chain or the heavy chain of an antibody or fragments thereof, such Fab, F(ab')<sub>2</sub>, 30 Fv, diabodies, linear antibodies, etc. The polypeptide may also be a single chain antibody (scFv). The preparation of libraries of antibodies or fragments thereof is well known in the art and any of the known methods may be used to construct a family of transformation vectors which may be transformed into host cells using the method and fusion protein of the invention. Libraries of antibody light and heavy chains in phage (Huse et al., 1989, *Science*, 246:1275) and as fusion 35 proteins in phage or phagemid are well known and can be prepared according to known procedures. See Vaughan et al., Barbas et al., Marks et al., Hoogenboom et al., Griffiths et al., de Kruif et al., noted above, and WO 98/05344; WO 98/15833; WO 97/47314; WO 97/44491; WO 97/35196; WO 95/34648; U.S. 5,712,089; U.S. 5,702,892; U.S. 5,427,908; U.S. 5,403,484; U.S.

5,432,018; U.S. 5,270,170; WO 92/06176; U.S. 5,702,892. Reviews have also published. Hoogenboom, 1997, *Tibtech*, 15:62-70 ; Neri et al., 1995, *Cell Biophysics*, 27:47; Winter et al., 1994, *Annu. Rev. Immunol.*, 12:433-455; Soderlind et al., 1992, *Immunol. Rev.*, 130:109-124; Jefferies, 1998, *Parasitology*, 14:202-206.

5 Specific antibodies contemplated as the heterologous polypeptide portion include antibodies which bind to human leukocyte surface markers, cytokines and cytokine receptors, enzymes, etc. Specific leukocyte surface markers include CD1a-c, CD2, CD2R, CD3-CD10, CD11a-c, CDw12, CD13, CD14, CD15, CD15s, CD16, CD16b, CDw17, CD18-C41, CD42a-d, CD43, CD44, CD44R, CD45, CD45A, CD45B, CD45O, CD46-CD48, CD49a-f, CD50-CD51, 10 CD52, CD53-CD59, CDw60, CD61, CD62E, CD62L, CD62P, CD63, CD64, CDw65, CD66a-e, CD68-CD74, CDw75, CDw76, CD77, CDw78, CD79a-b, CD80-CD83, CDw84, CD85-CD89, CDw90, CD91, CDw92, CD93-CD98, CD99, CD99R, CD100, CDw101, CD102-CD106, CD107a-b, CDw108, CDw109, CD115, CDw116, CD117, CD119, CD120a-b, CD121a-b, CD122, CDw124, CD126-CD129, and CD130.

15 Other antibody binding targets include cytokines and cytokine superfamily receptors, hematopoietic growth factor superfamily receptors and preferably the extracellular domains thereof, which are a group of closely related glycoprotein cell surface receptors that share considerable homology including frequently a WSXWS domain and are generally classified as members of the cytokine receptor superfamily (see e.g. Nicola et al., *Cell*, 67:1-4 (1991) and Skoda, R.C. et al. *EMBO J.* 12:2645-2653 (1993)). Generally, these targets are receptors for interleukins (IL) or colony-stimulating factors (CSF). Members of the superfamily include, but are not limited to, receptors for: IL-2 (b and g chains) (Hatakeyama et al., *Science*, 244:551-556 (1989); Takeshita et al., *Science*, 257:379-382 (1991)), IL-3 (Itoh et al., *Science*, 247:324-328 (1990); Gorman et al., *Proc. Natl. Acad. Sci. USA*, 87:5459-5463 (1990); Kitamura et al., *Cell*, 66:1165-1174 (1991a); Kitamura et al., *Proc. Natl. Acad. Sci. USA*, 88:5082-5086 (1991b)), IL-4 (Mosley et al., *Cell*, 59:335-348 (1989), IL-5 (Takaki et al., *EMBO J.*, 9:4367-4374 (1990); Tavernier et al., *Cell*, 66:1175-1184 (1991)), IL-6 (Yamasaki et al., *Science*, 241:825-828 (1988); Hibi et al., *Cell*, 63:1149-1157 (1990)), IL-7 (Goodwin et al., *Cell*, 60:941-951 (1990)), IL-9 (Renault et al., *Proc. Natl. Acad. Sci. USA*, 89:5690-5694 (1992)), granulocyte-macrophage 20 colony-stimulating factor (GM-CSF) (Gearing et al., *EMBO J.*, 8:3667-3676 (1991); Hayashida et al., *Proc. Natl. Acad. Sci. USA*, 244:9655-9659 (1990)), granulocyte colony-stimulating factor (G-CSF) (Fukunaga et al., *Cell*, 61:341-350 (1990a); Fukunaga et al., *Proc. Natl. Acad. Sci. USA*, 87:8702-8706 (1990b); Larsen et al., *J. Exp. Med.*, 172:1559-1570 (1990)), EPO (D'Andrea et al., *Cell*, 57:277-285 (1989); Jones et al., *Blood*, 76:31-35 (1990)), Leukemia inhibitory factor (LIF) 25 (Gearing et al., *EMBO J.*, 10:2839-2848 (1991)), oncostatin M (OSM) (Rose et al., *Proc. Natl. Acad. Sci. USA*, 88:8641-8645 (1991)) and also receptors for prolactin (Boutin et al., *Proc. Natl. Acad. Sci. USA*, 88:7744-7748 (1988); Edery et al., *Proc. Natl. Acad. Sci. USA*, 86:2112-2116

(1989)), growth hormone (GH) (Leung *et al.*, *Nature*, 330:537-543 (1987)), ciliary neurotrophic factor (CNTF) (Davis *et al.*, *Science*, 253:59-63 (1991) and c-Mpl (M. Souyri *et al.*, *Cell* 63:1137 (1990); I. Vigon *et al.*, *Proc. Natl. Acad. Sci.* 89:5640 (1992)). Still other targets for antibodies made by the invention are erb2, erb3, erb4, IL-10, IL-12, IL-13, IL-15, tumor necrosis factor alpha, thrombin, etc. The variant coat protein fusions and the variant heterologous polypeptides and libraries containing the same can be prepared using conventional mutagenesis techniques. These methods include but are not limited to oligonucleotide-mediated mutagenesis and cassette mutagenesis.

The heterologous polypeptide may be linked to the coat protein or portion thereof through a peptide linker. A linker peptide segment will generally vary in length from about 3 to about 50 amino acid residues, preferably from 5 to 30 residues, more preferably from 10 to 25 residues. Further, the net charge on the linker segment is preferably positive. The identity of and order of the amino acid residues is optional, although one or more specific sequences of the linker peptide segment will generally provide better display of the heterologous polypeptide. The method of this invention can also be used to modulate display levels of a fusion protein by mutating the linker between the fused protein and the coat protein and selecting linkers which afford the desired level of display. In this embodiment, a library of linker segment variants is made by mutating a linker sequence template and the linker sequences which give the best display on phage are selected using phage display selection, for example, an affinity selection for binding to the displayed heterologous polypeptide. Linkers which allow for greater numbers of displayed polypeptides will be selected based on increased affinity for the affinity matrix.

To date, researchers have used specific linkers designed to provide desired attributes. Linkers have been designed to provide flexibility (Wung *et al.* (1997) *J. Immunol. Methods* 204:33-41), such as the Gly-Ala<sub>3</sub> (Holmes *et al.* (1996) *Protein Pept. Lett.* 3:415-422) or Gly<sub>4</sub>Ser<sub>3</sub> linkers (Micheal *et al.* (1996) *Immunotechnology* 2:47-57) and to incorporate sites for specific proteolysis (Lucic, *et al.* (1998) *Australia. J. Biotechnol.* 61:95-108; Matthews, D.J. and Wells, J.A. (1993) *Science*, 26:1113-1117). Considerations for linker optimization include, among other factors, resistance to proteolysis, distance from the phage particle to the fused protein, and conformational effects of the linker upon fusion protein activity. The large number of variables involved makes the selection method of the invention an attractive approach. For example, selection of a linker for increased display of hGH on protein VIII (Fig. 7A) results in increased display relative to a designed Gly/Ser linker (Fig. 8A). A similar selection was also used to select linkers (Fig. 7B) for SAV display (Fig. 8B). In the SAV display, the selection was performed with SAV fused to a protein VIII variant (protein VIII(1e)) which had been previously selected for increased display of SAV (Example 4). This example demonstrates that optimized linkers can be combined with optimized coat protein variants, for example protein VIII variants, to obtain a desired display level, in a manner similar to the combination of different protein VIII variants described above.

The methods described above with reference to obtaining a gene encoding a heterologous polypeptide, variant polypeptide or a fusion protein containing at least a portion of a phage coat protein and a heterologous peptide or variant and isolating the same, oligonucleotide-mediated and cassette mutagenesis, cleaving DNA using restriction enzymes, ligation, separation and selection of 5 DNA using electrophoresis, purification and transformation (e.g., electroporation) procedures, library construction, suitable host or recipient cells and cell concentrations, etc. and the prior art methods noted above may be used in this embodiment of the invention and the description thereof is incorporated here specifically with respect to this embodiment.

10 C. Carboxyl-terminal display and more new phage coat proteins and fusions thereof

Another aspect of the invention is the carboxyl-terminal (C-terminal) display of a heterologous polypeptide on the surface of a filamentous phage using protein fusions with protein III or protein VIII. C-terminal display has been reported on protein VI of M13 (Jespers, L. et al., 1995, Biotechnology 13:378-382). This paper states that protein VI is distinct from proteins III 15 and VIII in its ability to allow for the attachment of polypeptides at the C-terminus. Surprisingly, as a part of this invention, it has been discovered that C-terminal display is also possible with fusions to protein III and VIII. The invention, therefore, allows the C-terminal display of a heterologous polypeptide or library of polypeptides in a manner similar to display at the N-terminus (N-terminal display) of a phage coat protein. In this aspect of the invention, the C-terminal display may be accomplished using a wild type protein III/VIII or a mutant protein 20 III/VIII as described above where the phage display process was applied to the coat protein sequence itself.

Any of the methods of phage or phagemid display, creating coat protein variants and protein fusions thereof with a heterologous polypeptide, libraries of such variants and fusion 25 proteins, expression vectors encoding the variants and protein fusions, libraries of the vectors, a library of host cells containing the vectors, methods for preparing and panning the same to obtain binding polypeptides, etc. described above with reference to N-terminal display may also be used in this aspect of the invention for C-terminal display and the descriptions above are hereby incorporated here and should be considered as part of the description of C-terminal display of the 30 invention.

The invention allows one to evolve new virus particles containing non-wild type coat proteins and coat protein fusions.

The variant protein III/VIII fusion proteins will contain one or more alterations including substitutions, additions or deletions relative to the wild type coat protein sequence. Again, it is 35 surprisingly, that a large number of alterations are possible and are tolerated by the phage while retaining the ability to display polypeptides on the phage surface, in this case as C-terminal fusions. The chemical nature of the residue may be changed, i.e. a hydrophobic residue may be altered to a hydrophilic residue or vice versa. Variants containing 2 - 50, preferably 5 - 40, more preferably 7 -

20, altered residues are possible. Fusion proteins containing any mature coat protein sequence or portion thereof which varies from the wild type sequence of the coat protein or portion thereof is within the scope of the invention. Major coat protein variants containing 2, 3, 4, 5, 6, 7, 8, 9, 10, 5 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49 or 50 variant residues are possible. This aspect of the invention allows one to design a coat protein which is any coat protein other than the wild type coat protein and select for C-terminal fusion proteins which display on the surface of phage. Variants containing substitutions are preferred since these variants will have about the same length as the wild type coat protein sequence. However, deletions of residues to prepare shorter coat 10 proteins and protein fusions thereof are within the scope of the invention. Preferably, the first few residues will be deleted, more preferably N-terminal or C-terminal residues 1 to about 5 can be deleted. Variants which do not enable surface display of the heterologous polypeptide are selected against during the phage display, panning and selection process.

As with N-terminal display described above, it is also possible to produce libraries in 15 which amino acids residues within desired segments of the coat protein are varied to obtain a library of coat protein variants having amino acid additions, substitutions or deletions within defined regions of the coat protein. As an example, the coat protein may be divided into an arbitrary number of zones, generally 2-10 zones, and a library constructed of variants within one or more of the zones. The mature coat proteins of M13, f1 and fd phage, for example, contain 50 20 amino acids and might be divided into 10 zones of 5 amino acid residues each or into zones with unequal numbers of residues in each zone, e.g. zones containing 15, 10, 9, and 8 residues. Zones corresponding to the cytoplasmic, transmembrane and periplasmic regions of the coat protein may be used. A separate library may be constructed for each of the zones in which amino acid alterations are desired. If fusion proteins are desired in which the coat protein variant has an amino 25 acid alteration in zone 1, for example, a single library may be constructed in which one or more of the amino acid residues within zone 1 is varied. Alternatively, one may wish to produce fusion proteins in which 2 zones contain amino acid alterations. Two libraries, each library containing alterations within one of the 2 zones, can be prepared.

Preferably, the heterologous polypeptide is attached to the coat protein or variant thereof 30 through a linker peptide. The linker may contain any number of residues which allow C-terminal display, and will generally contain about 4 to about 30, preferably about 8 to about 20, amino acid residues. The linker may contain any of the naturally occurring residues, although linkers containing predominantly (greater than 50%) glycine and/or serine are preferred. The optimum linker composition and length for display of a particular polypeptide may be selected using phage 35 display as described above and demonstrated in the examples. For example, phage libraries each containing a different linker length may be constructed and phage selection and panning used to isolate the amino acid composition of the linker of any length which optimizes expression and display of the heterologous polypeptide.

As with N-terminal display described above, if a variant coat protein which improves display of a heterologous polypeptide on the surface of phage particles contains multiple mutations relative to wild type, it is also possible to obtain variants which display the heterologous polypeptide at levels intermediate between the levels obtained with the new variant and wild type coat protein. This can be accomplished by separately back mutating each mutated amino acid of the variant back to the wild type sequence or to another altered residue. These back mutations will generally reduce display levels of the heterologous polypeptide to levels varying between display levels obtained with the variant and wild type coat protein. By combining the back mutations, it is possible to tailor display to a desired level which is between that obtained with the variant and wild type coat protein.

By a similar process, it is possible to obtain variants which display at a level below the level of the wild type coat protein. For example, mutations may be made in one or more zones and the libraries produced panned for phage which bind only weakly (weaker than phage displaying wild type fusions). The weaker binding phage will be displaced by phage displaying wild type coat protein fusions and can be isolated and sequenced using known methods.

Mutant coat proteins can also be obtained which are hypofunctional for incorporation into the viral coat and thus reduce fusion protein display relative to wild type coat protein. In this case, mutations are made in residues which tend to be conserved as wild type in the above described selections for hyperfunctional variants. Conservation of these residues as wild type during the selection for hyperfunctional variants indicates that mutations at these residues are not well tolerated and will tend to produce hypofunctional variants. Variants obtained through mutations at these sites can then be screened for their ability to display a given fusion protein relative to the wild type coat protein display levels. Hypofunctional variants displaying the fusion at the desired reduced levels relative to wild type can then be used for the construction of libraries of the fusion protein for the purposes of phage display. Although the preferred residues for the production of hypofunctional variants are those which were conserved as wild type, any residue of the coat protein can be mutated and the resulting variant tested for its ability to allow display of a fusion protein. In this way, it is possible to select a display level below that afforded by wild type simply by using the appropriate hypofunctional mutant. As with the hyperfunctional variants described above, several hypofunctional mutations can be combined to produce further reductions in display to levels desired. While, the selection of hypofunctional variants requires a screen rather than a selection, the method is relatively simple since most mutations in proteins cause reductions in activity rather increases and suitable screening procedures are known. Thus, most mutations in the coat protein should be deleterious mutations which result in hypofunctional variants.

C-terminal display is useful to display cDNA libraries on the surface of phage particles. mRNA can be purified from a tissue source of choice and double stranded cDNAs synthesized using standard techniques (Sambrook et al., 1989, Molecular Cloning: A Laboratory Manual, 2nd Ed. Cold Spring Harbor, New York). A phagemid or phage vector (or a plurality thereof)

containing an open reading frame is then constructed using well established techniques disclosed in Sambrook et al. and the phage and phagemid display references described above and the cDNAs are ligated into the vectors at the 3' end of the coat protein gene. Host cells are then transformed, preferably by electroporation, with the library of vectors and phage particles displaying heterologous polypeptides corresponding to the cDNA library members are obtained (with superinfection of helper phage for phagemid vectors). The C-terminal phage display library obtained may be panned and analyzed using conventional phage display techniques.

The C-terminal display of the invention is also useful to display intracellular, preferably mammalian intracellular, proteins or fragments thereof and polypeptides which are difficult to display using N-terminal display. C-terminal display is, therefore, a complementary display technique to N-terminal display. Intracellular proteins may be difficult to display in a correctly folded form using N-terminal display due to the difference in redox environment in which intracellular proteins normally exist relative to the environment in which secreted proteins fold and form disulfide bonds. The cytoplasm is a reducing environment whereas the periplasm is an oxidizing environment. C-terminal heterologous fusion proteins migrate to the periplasm as in normal phage particle assembly. However, since the heterologous polypeptide remains on the intracellular side of the periplasmic membrane, an intracellular polypeptide may correctly fold prior to incorporation into a phage particle. During assembly of the phage or phagemid particle, the C-terminal fusion protein is incorporated into the particle and displays the heterologous polypeptide on the surface thereof.

C-terminal display bypasses secretion problems encountered with N-terminal display systems. With N-terminal display, it is generally thought that the heterologous polypeptide on the N-terminus must pass through a pore-like structure in the periplasmic membrane in order to enter the periplasmic space with the C-terminus remaining as an anchor in the membrane. The fusion protein is then assembled into a phage particle from the membrane. Using C-terminal display, it is not necessary to have the fusion protein secrete into the host cell periplasm in order to assemble phage particles. C-terminal display is, therefore, useful to display any heterologous polypeptide and is particularly useful to display polypeptides which are difficult to display using N-terminal phage display techniques.

C-terminal display can also be used to display a foreign polypeptide which is secreted into the periplasm during virus particle assembly. For example, by constructing a library of potential membrane proteins and selecting members of the library capable of functioning as coat proteins, it is possible to apply selective pressure to the library and evolve coat proteins which have a foreign polypeptide as a C-terminal fusion and which orient in the cell membrane with the foreign polypeptide in the periplasm and the N-terminus of the fusion protein in the cytoplasm. Such fusion proteins preferably have a positively charged N-terminal portion as a cytoplasmic region and a hydrophobic core portion as a transmembrane region. Such a structure resembles a bacterial secretion signal. Some library members will function as secretion signals and insert into the

bacterial membrane with the N-terminus in the cytoplasm and the C-terminus in the periplasm (inverse coat proteins). Some of the fusions which can insert into the membrane will incorporate into assembling virus particles by virtue of favorable interactions with the phage or phagemid coat. Suitable libraries may be designed in multiple stages. For example, inverse coat proteins may be selected from a library (or libraries) of potential coat proteins by using an epitope tag fused to the C-terminus of the library of coat proteins. After phage particle assembly, antibody binding to the epitope tag is used to isolate members of the virus particle library which display the tag on the surface of the particle. The particles which bind can be isolated/selected and cloned using conventional phage display techniques. In a second step, one of the selectants can be further evolved by phage display to select for improved incorporation into a particle coat. Again, one or more libraries can be constructed to vary different regions of the coat protein to select for those proteins which best display the epitope tag or other protein on the surface of the particle. Coat protein fusions and virus particles prepared according to the invention provide a diversity of tools which are useful to evaluate virus structure and assembly processes, to map the antibody binding epitopes on proteins, to affinity mature binding proteins such as antibodies and fragments thereof to provide binding proteins with higher binding affinities, to produce polypeptides which bind to active and allosteric sites on enzymes, etc. including all of the uses for which phage display is currently employed.

All patent and literature references cited above are incorporated herein by reference in their entirety.

### EXAMPLES

#### Example 1 - Construction of *E. coli* SS320

The new cell line SS320 was prepared by bacterial mating in which the F' episome was transferred from XL1-BLUE cells to MC1061 cells according to known protocols (J. H. Miller, 1972, *Experiments in Molecular Biology*, p190). More specifically, the SS320 cells can be obtained using the following steps:

-Grow 1.0 mL cultures of MC1061 and XL1-BLUE in LB broth to OD<sub>600</sub> = 0.5 (single colonies from freshly streaked plates. MC1061 was streaked on LB plates. XL1-BLUE was streaked on LB/tetracycline (10µg/mL)).

-Mix 0.5 mL of each culture and grow 1 hour at 37°C with slow shaking (50 rpm on a rotary shaker). After mating for 1 hour, agitate at 250 rpm to disrupt the mating.

-Plate dilutions on LB/tetracycline(10µg/mL)/streptomycin(10µg/mL).

-MC1061 carries a streptomycin resistance chromosomal marker while the F' plasmid of XL1-BLUE confers tetracycline resistance. Thus, only the mating progeny (MC1061 harboring the XL1-BLUE F' episome will be resistant to both antibiotics. The unmixed cultures of MC1061

and XL1-BLUE can be plated on the selective media as controls, since neither parent is doubly resistant.

-The resulting strain (SS320) can be used for electroporation and phage production.

The genotypes of the starting MC1061 cells ( available from Bio-Rad Laboratories, Inc.)  
5 and XL1-BLUE episome (available from Stratagene, Inc. in XL1-BLUE cells) and the resulting SS320 cells are as follows:

XL1-BLUE F' episome

F'::Tn10 proA<sup>+</sup>B<sup>+</sup>lacIqD(lacZ)M15

10 MC1061

F-araD139D(ara-leu)7696galE15galK16D(lac)X74rpsL(Str<sup>r</sup>)hsdR2(r<sub>k</sub><sup>-</sup>m<sub>k</sub><sup>+</sup>)mcrAmcrB1

SS320

F'::Tn10 proA<sup>+</sup>B<sup>+</sup>lacIqD(lacZ)M15/

15 F-araD139D(ara-leu)7696galE15galK16D(lac)X74rpsL(Str<sup>r</sup>)hsdR2(r<sub>k</sub><sup>-</sup>m<sub>k</sub><sup>+</sup>)mcrAmcrB1

Various *E. coli* strains were evaluated for cell survival and viability after standard washing steps were performed to prepare the cells for electroporation. *E. coli* were grown in 250 mL cultures and prepared for electroporation as previously described. The total number of colony forming units were titered before and after the wash procedure and the results are shown below.

Strain	Before wash (cfu)	After wash (cfu)	Survival (After/Before)
SS320	4.8 x 10 <sup>12</sup>	4.6 x 10 <sup>12</sup>	0.96
TB1	1.7 x 10 <sup>11</sup>	1.9 x 10 <sup>11</sup>	1.1
JM101	4.5 x 10 <sup>11</sup>	3.6 x 10 <sup>10</sup>	0.08
JM107	2.3 x 10 <sup>11</sup>	1.0 x 10 <sup>10</sup>	0.045
JM109	1.5 x 10 <sup>11</sup>	1.2 x 10 <sup>10</sup>	0.08

The transformation yield achieved with different *E. coli* strains at a fixed concentration of DNA is dependent on the concentration of viable *E. coli* cells in the electroporation reaction. It has now been discovered that the maximum concentration of viable cells which can be achieved with a given strain is dependent upon the resistance of that strain to the washing steps involved in the preparation of electrocompetent cells. The suitability of a particular bacterial (e.g., *E. coli*) strain for electroporation can be easily determined using the following procedure.

Grow a 250 mL culture of bacteria to OD<sub>600</sub> = 0.6 in a 1-L baffled flask. Remove a small aliquot and plate dilutions on appropriate media to determine the total number of viable cells; this

number is the input of cells (input, I). Follow the standard procedures for production of electrocompetent cells as described in Example 2 (scaled down appropriately for the volume of culture used). Plate dilutions of the final preparation of electrocompetent cells on appropriate media to determine the total number of viable cells; this is the number of cells surviving the 5 electrocompetent cell preparation procedure (survivors, S). Divide S by I to determine the ratio of survivors to input (S/I). For a strain ideally suited for electroporation (i.e. a strain which gives the highest transformation yield in comparison with other strains at a fixed DNA concentration), the ratio S/I should be equal to one. This indicates that all the input cells survived the electrocompetent 10 cell preparation procedure. A reduction in the ratio S/I corresponds to a reduction in the concentration of viable cells in the electrocompetent cell preparation; this in turn results in a reduction in the transformation yield. Thus, for the highest transformation yields at a given DNA concentration, a strain with the highest S/I value should be used.

Example 2 – Preparation of *E. coli* for electroporation

15        Electroporation competent cells were prepared as described below:

1. Inoculate 1 mL 2xYT media(5 mg/mL tetracycline) with SS-320 from a fresh LB/tet plate. Grow about 6 hours and inoculate 50 mL 2xYT/tetracycline in a 500-mL flask; grow overnight.

20        2. Inoculate 6 x 900 mL Superbroth (5 mg/mL tetracycline) in 2-L baffled flasks with 5 mL from above culture and grow cells to OD<sub>600</sub> = 0.6-0.8 at 37°C, 200 rpm.

3. Chill three flask on ice (shake periodically). Further steps were performed in a cold room, on ice, with prechilled solutions and equipment.

4. Centrifuge 5.5K/5 min in a SORVALL GS3 ROTOR and decant all supernatant. Add culture from remaining three flasks to same tubes; respin and decant.

25        5. Resuspend in equal volume of 1 mM HEPES, pH7.4 by swirling or stirring. Centrifuge 5.5K/10 min and decant supernatant.

6. Resuspend in equal volume of 1 mM HEPES as in (5) above. Centrifuge 5.5K/10 min and decant supernatant. Resuspend each pellet in 100 mL of 10% (v/v) glycerol (filter sterilized; ultrapure glycerol (Gibco BRL #15514-011)).

30        7. Centrifuge 5.5K/15 min and decant all supernatant. Resuspend in minimum volume of 10% glycerol. Using about 3 mL of 10% glycerol for 5 L of starting culture produces about 12 mL of concentrated cells with about 3-4 x 10<sup>11</sup> cfu/mL.

Example 3 – Mutagenesis Fill-in

35        The mutagenesis reaction was conducted using the procedure described in U.S. 5,750,373 with the changes shown below:

1)        Kinase oligo

62

4  $\mu$ L oligo (330 ng/mL stock; i.e., A<sub>260</sub> = 10)  
4  $\mu$ L 10X TM buffer (0.5M tris pH7.5, 0.1M MgCl<sub>2</sub>)  
4  $\mu$ L 10mM ATP  
2  $\mu$ L 100mM DTT  
5 24  $\mu$ L H<sub>2</sub>O  
2  $\mu$ L kinase (NEB, 10 U/ $\mu$ L)  
40  $\mu$ L

-incubate at 37°C for 0.5 hour.

10 2) Anneal oligo/template  
40  $\mu$ g kunkel template  
1.2  $\mu$ g kinased oligo (i.e. 40  $\mu$ L from above kinase reaction; oligo/template = 3)  
25  $\mu$ L 10X TM buffer  
add H<sub>2</sub>O to 250  $\mu$ L final volume  
15 -incubate at 90°C for 2 minutes, 50°C for 3 minutes.

3) Fill-in

-add:

1  $\mu$ L 100mM ATP  
20 10  $\mu$ L 25mM dNTPs (25mM each dATP, dCTP, dGTP, dTTP)  
15  $\mu$ L 100mM DTT  
6  $\mu$ L T4 ligase (NEB, 400 U/ $\mu$ L)  
3  $\mu$ L T7 polymerase (NEB, 10 U/ $\mu$ L)

-incubate at 20°C for 3 hours.

25

#### Example 4 – *E. coli* Electroporation

Electroporation was conducted as described below:

1. Extract fill-in reaction with an equal volume of phenol/CHCl<sub>3</sub>. Extract with an equal volume of CHCl<sub>3</sub>. Purify and desalt DNA (60 micrograms) using QIAquick gel extraction kit (QIAGEN). Use two columns for each reaction. Follow wash and elution procedures as outlined by QIAGEN; elute each column with 30  $\mu$ L of H<sub>2</sub>O to provide a final theoretical yield of 80  $\mu$ g fill-in product (40  $\mu$ g single strand DNA converted to double strand) in 60  $\mu$ L of H<sub>2</sub>O.
- 30 2. Electroporate DNA (60  $\mu$ L) into 350  $\mu$ L of competent *E. coli* SS320. Use 0.2 cm gaps cells with following settings: 2.5 kV, 200 ohms, 25  $\mu$ F. Use two cells for each reaction (i.e. 200  $\mu$ L for each cell). After the shock, transfer cells to 25 mL SOC media and culture for phenotype expression. After phenotype expression, remove a small aliquot for titre on selective and non-selective media. Transfer cells to 500 mL 2xYT (in a 2-L baffled flask) containing appropriate

antibiotic for phagemid selection and VCS helper phage (m.o.i. = 10). Grow overnight and harvest phage in the morning.

Example 5 - Large library construction with ultrahigh DNA and *E. coli* concentrations

5 The fill-in protocol of Example 3 was followed with two different single stranded templates (a and b) and a mismatch oligonucleotide. Three different input template quantities were used: 1) 20 µg, 2) 30 µg, or 3) 40 µg.

After the fill-in and purification the following double stranded DNA quantities were obtained in 60 µL of water:

10

Reaction	OD260	[DNA], µg/mL	DNA total, µg
a1	9.04	452	27
a2	12.12	606	36
a3	13.92	696	42
b1	7.48	374	22
b2	10.4	520	31
b3	13.12	656	39

Each reaction was used to electroporate 340 µL of SS320 ( $3 \times 10^{11}$  cfu/mL). This gives a total volume of 400 µL with  $1 \times 10^{11}$  cells. Each reaction was electroporated in two 200 microliter aliquots.

15

Reaction	[DNA], µg/mL	Time constants, ms*
a1	68	4.1, 4.1
a2	90	4.2, 4.3
a3	105	4.2, 4.3
b1	55	4.2, 4.2
b2	78	4.3, 4.3
b3	98	4.2, 4.2

\*microseconds

These results indicate that the time constant for electroporations with high DNA concentrations are well above 3.0 ms and that electroporation is easily performed with high DNA concentrations.

The number of transformants and the survival of the cells during transformation was evaluated and is shown in the table below.

(64)

TITER OF LIBRARY SIZE AND SURVIVORS:

Reaction	survival	transform	S/I*	T/S**	T/I***
a1	$5 \times 10^{10}$	$2.3 \times 10^{10}$	0.50	0.46	0.23
a2	$5 \times 10^{10}$	$3.0 \times 10^{10}$	0.50	0.60	0.30
a3	$4.5 \times 10^{10}$	$3.0 \times 10^{10}$	0.45	0.67	0.30
b1	$4 \times 10^{10}$	$2.3 \times 10^{10}$	0.40	0.58	0.23
b2	$4 \times 10^{10}$	$2.3 \times 10^{10}$	0.40	0.58	0.23
b3	$4 \times 10^{10}$	$2.3 \times 10^{10}$	0.40	0.58	0.23

\* survivors/input is the fraction that survive electroporation

\*\* transformants/survivors is fraction of survivors with phagemid

\*\*\*transformants/input is fraction that both survive and transform.

Example 6 – High concentration DNA electroporation

The standard fill-in protocol was followed with a single stranded template and a mismatch oligonucleotide. Seven identical reactions were purified and pooled to produce 400  $\mu$ L of DNA at 750  $\mu$ g/mL (OD<sub>260</sub> = 15.0)

5 Various amounts of DNA were electroporated into *E. coli* SS320 in a final volume of 200  $\mu$ L with a fixed *E. coli* concentration of  $1.5 \times 10^{11}$  cells/mL. The following conditions were used: 0.2 cm cuvettes @ 2.5 kV/cm, 200 ohms, 25  $\mu$ F. After electroporation, the reaction was grown in 10 mL SOC media for 30 minutes and then titered on both LB (survival) and LB/carbenicillin (50  $\mu$ g/mL) (transformation).

10

	[DNA] ( $\mu$ g/mL)	T.C. (ms)	LB (cfu)	carb (cfu)	S/I*	T/S**	T/I***
1	375	3.6	$1.4 \times 10^{10}$	$6.0 \times 10^9$	.47	.43	.20
2	281	3.8	$1.4 \times 10^{10}$	$7.0 \times 10^9$	.47	.50	.23
3	188	4.1	$1.5 \times 10^{10}$	$6.2 \times 10^9$	.50	.41	.21
4	150	4.1	$1.4 \times 10^{10}$	$6.0 \times 10^9$	.47	.43	.20
5	113	4.2	$1.4 \times 10^{10}$	$5.7 \times 10^9$	.47	.41	.19
6	75	4.3	$1.5 \times 10^{10}$	$5.9 \times 10^9$	.50	.42	.20
7	38	4.4	$1.6 \times 10^{10}$	$6.8 \times 10^9$	.53	.43	.23
8	19	4.4	$1.6 \times 10^{10}$	$7.0 \times 10^9$	.53	.44	.23
9	7.5	4.5	$1.4 \times 10^{10}$	$5.0 \times 10^9$	.47	.36	.17
10	3.8	4.5	$1.5 \times 10^{10}$	$2.4 \times 10^9$	.50	.16	.08
11	0	4.5	$1.5 \times 10^{10}$	0	.50	0	0

\* survivors/input is the fraction that survive electroporation

\*\* transformants/survivors is fraction of survivors with phagemid

\*\*\*transformants/input is fraction that both survive and transform.

15 Example 7 - Construction of an extremely large library using multiple electroporations with ultrahigh DNA and *E. coli* concentrations

The fill-in protocol of Example 3 was followed with a single stranded template and a mismatch oligonucleotide. The quantity of input template was 40 micrograms, and 35 identical reactions were performed.

20 After the fill-in, purification was conducted as described in Example 4 except that the extractions with phenol/CHCl<sub>3</sub> and CHCl<sub>3</sub> were omitted, and each column was eluted with 50

66

microL of H<sub>2</sub>O. Two columns were used for each reaction, and thus, the final theoretical yield for each reaction was 80 micrograms of fill-in product in 100 microL of H<sub>2</sub>O.

Each reaction was used to electroporate 700 microL of SS320 ( $3 \times 10^{11}$  cfu/mL). This gives a total volume of 800 microL with  $2 \times 10^{11}$  cells. Each reaction was electroporated in two 5 400 microL aliquotes as described in Example 4, except that the cells were transferred to 50 mL of SOC media after the shock. After phenotype expression, the cells were titred on selective media. When combined together, the 35 independent reactions provided a library size of  $1.79 \times 10^{12}$  different members. The results for the 35 independent reactions are presented below:

Reaction	transformants
1	$5.0 \times 10^{10}$
2	$4.6 \times 10^{10}$
3	$4.6 \times 10^{10}$
4	$5.4 \times 10^{10}$
5	$5.2 \times 10^{10}$
6	$5.8 \times 10^{10}$
7	$4.6 \times 10^{10}$
8	$5.0 \times 10^{10}$
9	$5.0 \times 10^{10}$
10	$4.6 \times 10^{10}$
11	$5.2 \times 10^{10}$
12	$5.6 \times 10^{10}$
13	$5.6 \times 10^{10}$
14	$5.0 \times 10^{10}$
15	$4.6 \times 10^{10}$
16	$4.6 \times 10^{10}$
17	$5.8 \times 10^{10}$
18	$5.6 \times 10^{10}$
19	$5.0 \times 10^{10}$
20	$5.0 \times 10^{10}$
21	$4.8 \times 10^{10}$
22	$4.8 \times 10^{10}$
23	$5.0 \times 10^{10}$

24	5.2 x 10 <sup>10</sup>
25	5.6 x 10 <sup>10</sup>
26	4.6 x 10 <sup>10</sup>
27	5.4 x 10 <sup>10</sup>
28	5.4 x 10 <sup>10</sup>
29	5.8 x 10 <sup>10</sup>
30	4.6 x 10 <sup>10</sup>
31	5.0 x 10 <sup>10</sup>
32	5.4 x 10 <sup>10</sup>
33	5.8 x 10 <sup>10</sup>
34	5.0 x 10 <sup>10</sup>
35	4.8 x 10 <sup>10</sup>

#### Materials for further Examples

Reagents for dideoxynucleotide sequencing were from United States Biochemicals. Enzymes and plasmid pMal-p2 were from New England Biolabs. Maxisorp immunoplates were 5 from NUNC (Roskilde, Denmark). *E. coli* XL1-Blue was from Stratagene; the construction of *E. coli* SS-320 is described above. Bovine serum albumin (BSA), Tween 20, and *o*-phenylenediamine dihydrochloride were from Sigma. HRP/anti-M13 conjugate was from Pharmacia Biotech. *Streptomyces avidinii* was from ATCC (accession no. 27419). Goat anti-streptavidin polyclonal antibody was from Zymed Laboratories (South San Francisco, USA).

10

#### Oligonucleotides for Examples 8-21

DNA degeneracies are represented in the IUB code (K = G/T, N = A/C/G/T, R = A/G, S = G/C, W = A/T, Y = C/T).

IPTG-1: AAAAGAATTCCCCGACACCATCGAATGGTGC (SEQ ID NO. 9)

15 IPTG-2: ACCAGATGCATAAGCCGAGGCGGAAACATCATCG (SEQ ID NO. 10)

IPTG-3: TTTTCTAGACAGGCCCTCCCACCAAGATGCATAAGCCGAGGCGGAAAA  
CATCATCGTC (SEQ ID NO. 11)

SAV-1: GGCTATCGGAATGCATCGGGCATCACCGGCACCTG (SEQ ID NO. 12)

SAV-2: GAGTCATAGTCGTCAAGGCCTCCTCCGGATCCTCCACCCACCTT

20 GGTGAAGGTGTCGTGG (SEQ ID NO. 13)

hGH-1: GGGTATCTAGAGGTTGAG (SEQ ID NO. 14)

hGH-2: TGGAGCTCCCGGATCCTCCACCGCTCTGGAAGGCCACAGCTGCCCTC  
(SEQ ID NO. 15)

g8stop1: GGATCCGGGAGCTCCAGCTGATGAGGTGACGATCCCGCAAAA (SEQ ID NO. 16)

g8stop2: GATCCCGCAAAAGCGGCCTGATGATCCCTGCAAGCCTCAGCG (SEQ ID NO. 17)

5   g8stop3: CAAGCCTCAGCGACCGAATGATGAGGTTATGCGTGGCGATG (SEQ ID NO. 18)

g8stop4: GCGTGGCGATGGTTGTTGATGAGTCGGCGCAACTATCGGT (SEQ ID NO. 19)

g8stop5: GCAACTATCGGTATCAAGTGATGAAAGAAATTCACCTCGAAA (SEQ ID NO. 10 20)

g8V1: GGATCCGGGAGCTCCAGCRNTNASRNTNASNASNYCRNTRNARNT RNTTTAACCTCCCTGCAAGCC (SEQ ID NO. 21)

g8V2: GATCCCGCAAAAGCGGCCNWTNASRNTNYTNASRNTRNTRNTRNT ASTATATCGGTTATGCGTGG (SEQ ID NO. 22)

15   g8V3: CAAGCCTCAGCGACCGAANWCNCNKTNWCNCNYYTNKGNYTNKGN WTNWTGTCATTGTCGGCGCAACTATC (SEQ ID NO. 23)

g8V4: GCGTGGCGATGGTTGTTNWTNWCNCNWTNKTNYTNNTNNNTNNT AAGCTTTAACGAAATTCAACC (SEQ ID NO. 24)

g8V5: GCAACTATCGGTATCAAGNNNSAAGAAANNSNNNGAAANN 20   GNNGTGATAAACCGATAACAATTAAAGGC (SEQ ID NO. 25)

g8(1a): GATCCCGCAAAAGCGGCCTATGAGGCTTGTGAGGATATTGCTAC TAACTATATCGGTTATGCGTGG (SEQ ID NO. 26)

R64A: CCGACACCCCTCAATGCTGAGGAAACACAACAGAAA (SEQ ID NO. 27)

D171A: TTCAGGAAGGACATGGCTAAGGTCGAGACATTCTG (SEQ ID NO. 28)

25   Y164A/R178A: AACTACGGCTGCTCGCTTCAAGGAAGGACATGGACAAGG TCGAGACATTCTGGCTATCGTCAGTGCCGC (SEQ ID NO. 29)

K172A/R178A: TTCAGGAAGGACATGGACGCTGTCGAGACATTCTG GCTATCGTCCAGTGCCGCTCT (SEQ ID NO. 30)

Lstop: GGTGGAGGATCCGGGAGCTGATGAGCCGAGGGTGACGATCCC (SEQ ID NO. 31)

30   Lstop2: CACCAAGGTGGTCTAGAGCTAATAATAAGCCGAGGGTGACGA TCCC (SEQ ID NO. 32)

LV: GAGGGCAGCTGTGGCTTCGGTGGCGGTVVCVVCVVCVVCV (SEQ ID NO. 33) VCVVCVVCVVCVVCVVCVVCVVCVVCV (SEQ ID NO. 34)

35   LV5: CACCAAGGTGGTCTAGAGCVVCVVCVVCVVCVCGCCGAGGGTGA CGATCCC (SEQ ID NO. 35)

LV10: CACCAAGGTGGTCTAGAGCVVCVVCVVCVVCVVCV (SEQ ID NO. 36)

LV15: CAC CAAGGTGGTCTAGAGCVVCVVCVVCVVCVVCVVCVVCV  
 CVVCVVCVVCVVCVVCVVCVVCGCCGAGGGTGACGATCCC (SEQ ID NO. 37)

LV20: CACCAAGGTGGTCTAGAGCVVCVVCVVCVVCVVCVVCVVCV  
 CVVCVVCVVCVVCVVCVVCVVCVVCVVCVVCGCCGAGGGTGACGATCCC  
 (SEQ ID NO. 38)

LV25: CACCAAGGTGGTCTAGAGCVVCVVCVVCVVCVVCVVCV  
 CVVCVVCVVCVVCVVCVVCVVCVVCVVCVVCVVCVVCVVCV  
 CVVCVVCGCCGAGGGTGACGATCCC (SEQ ID NO. 39)

g8V2c: AAGTCGCTAGAGATGCTTATGAGGCTTGTAGGATATTGCTAC  
 TAACTATATCGTTATGCGTGG (SEQ ID NO. 40)

g8V3c: GAGGATATTGCTACTAACCTTTCTTCTCCTGGACTGTGC  
 ATCTTGTCAATTGTCGGCGCAACT (SEQ ID NO. 41)

g8V2-E12N: GCAAAAGCGGCCTATAACGCTCTGAGGATATT (SEQ ID NO. 42)

g8V2-D16A: TATGAGGCTTGTAGGCCATTGCTACTAACTAT (SEQ ID NO. 43)

g8V2-I17S: GAGGCTTGTAGGATTCTAGCTACTAACTATATC (SEQ ID NO. 44)

g8V2b: GATCCCGAAAAGCGGCCTATGAGGCTTGTAGGATATTGCTA  
 CTAACATATCGTTATGCGTGG (SEQ ID NO. 45)

L-wt: GAGGGCAGCTGTGGCTTCCAGAGCGGTGGAGGATCCGGGAG  
 CTCCAGCGCCGAGGGTGACGATCCC (SEQ ID NO. 46)

S13A/S17I: CCCGCAAAAGCGGCCTTAACGCTTGCAAGCCATTGCGACC  
 GAATATATCGTTATGCG (SEQ ID NO. 47)

g8V3b: CAAGCCTAGCGACCGAACTTTCTTCTCCTGGACTGTGCATC  
 TTGTCATTGTCGGCGCAACT (SEQ ID NO. 48)

D1A: TCCGGGAGCTCCAGCGCAAGAGTGAGAAGTTC (SEQ ID NO. 49)

K2E: GGGAGCTCCAGCGATGAGAGTGAGAAGTTCGCT (SEQ ID NO. 50)

S3G: AGCTCCAGCGATAAGGGTGAGAAGTTCGCTAGA (SEQ ID NO. 51)

E4D: TCCAGCGATAAGAGTGACAAGTTCGCTAGAGAT (SEQ ID NO. 52)

K5D: AGCGATAAGAGTGAGGATTTCGCTAGAGATGCT (SEQ ID NO. 53)

F6P: GATAAGAGTGAGAAGCCGCTAGAGATGCTTT (SEQ ID NO. 54)

R8K: AGTGAGAAGTCGCTAAAGATGCTTTAACTCC (SEQ ID NO. 55)

D9A: GAGAAGTCGCTAGAGCGGCTTTAACTCCCTG (SEQ ID NO. 56)

Y11F: CCCGCAAAAGCGGCCTTGAGGCTTGTAGGAT (SEQ ID NO. 57)

E12N: GCAAAAGCGGCCTATAACGCTTGTAGGATATT (SEQ ID NO. 58)

A13S: AAAGCGGCCTATGAGTCCTGTAGGATATTGCT (SEQ ID NO. 59)

E15Q: GCCTATGAGGCTTCAAGATATTGCTACTAAC (SEQ ID NO. 60)

D16A: TATGAGGCTTGTAGGCCATTGCTACTAACTAT (SEQ ID NO. 61)

I17S: GAGGCTTGTAGGATTCTAGCTACTAACTATATC (SEQ ID NO. 62)

N20E: GAGGATATTGCTACTGAATATATCGTTATGCG (SEQ ID NO. 63)

*L21Y*: GCCTCAGCGACCGAATATTCTTCTCCTGGG (SEQ ID NO. 64)  
*F22I*: TCAGCGACCGAACTTATCTTCTCCTGGGACT (SEQ ID NO. 65)  
*F23G*: GCGACCGAACCTTCGGTCTCCTGGGACTGTG (SEQ ID NO. 66)  
*L24Y*: ACCGAACCTTTCTTTATCTTGGGACTGTGCAT (SEQ ID NO. 67)  
5   *L25A*: GAACTTTCTTCTCGGGGGACTGTGCATCTT (SEQ ID NO. 68)  
*G26W*: CTTTTCTTCTCCTTGGACTGTGCATCTTGTC (SEQ ID NO. 69)  
*T27A*: TTCTTCTCCTGGGGCGGTGCATCTTGTCAATT (SEQ ID NO. 70)  
*V28M*: TTTCTCCTGGGACTATGCATCTTGTCAATTGTC (SEQ ID NO. 71)  
*H29V*: CTCCTTGGGACTGTGGTCTTGTCAATTGTCGGC (SEQ ID NO. 72)  
10   *L30V*: CTTGGGACTGTGCATGTTGTCAATTGTCGGCGCA (SEQ ID NO. 73)  
*E12N/A13S*: GCAAAAGCGGCCTATAACTCCCTGAGGATATTGCT (SEQ ID NO. 74)  
*E12N/I17S*: GCAAAAGCGGCCTATAACGCTCTGAGGATTCAAGCTACT  
AACTATATC (SEQ ID NO. 75)  
*A13S/I17S*: CCCGCAAAAGCGGCCTATGAGTCCCTGAGGATTCAAGCTACT  
15   AACTATATCGGTTATGCG (SEQ ID NO. 76)  
*E12N/A13S/I17S*: GCAAAAGCGGCCTATAACTCCCTGAGGATTCAAGCT  
ACTAACTATATC (SEQ ID NO. 77)

Example 8 - pS349: A phagemid for phage display of hGH on Protein VIII.

20       A DNA fragment containing the gene for hGH was amplified using the PCR (with a derivative of plasmid pB0475 (Cunningham, B. C., Jhurani, P., Ng, P., and Wells, J. A. (1989) *Science* 243:1330-1336) as template and oligonucleotides *hGH-1* and *hGH-2* as primers). The DNA fragment was digested with *Nsi*I and cloned into a protein VIII display phagemid (Lowman, H. B., Chen Y. M., Skelton, N. J., Mortensen, D. L., Tomlinson, E. E., Sadick, M. D., Robinson, I. 25   C. A. F., and Clark, R. G. (1998) *Biochemistry* 37:8870-8878) which had been first digested with *Kas*I and treated with T4 DNA polymerase to produce blunt ends and subsequently digested with *Nsi*I. The resulting phagemid was designated pS135a.

30       The PCR was used with primers *IPTG-1* and *IPTG-2* to amplify a 1.6 kbp fragment of pMal-p2 (New England Biolabs Product Catalog (1996-97) p212) containing the *lacIq* gene and a gene fragment encoding the signal peptide from maltose binding protein under the control of the *P<sub>tac</sub>* promoter. The DNA fragment was digested with *Eco*RI and *Nsi*I and ligated with the large fragment resulting from a similar digestion of pS135a. The resulting phagemid (designated pS349) contains a gene encoding a fusion product (the maltose binding protein signal peptide, followed by hGH, followed by a Gly/Ser-rich linker peptide (QSGGGSGSSS) (SEQ ID NO. 78), and protein 35   VIII of *E. coli* bacteriophage M13 under the control of the IPTG-inducible *P<sub>tac</sub>* promoter (New England Biolabs). In addition, pS349 also contains the *lacIq* gene for effective transcription repression in the absence of IPTG.

Example 9 - pW277e: A phagemid for phage display of SAV on protein VIII.

A derivative of pS349 was constructed and designated pS657a. pS657a differs from pS349 in two respects. Firstly, the gene encoding hGH has been replaced by sequence encoding a pentapeptide (GGRPV) (SEQ ID NO. 79). Secondly, the introduction of an *Xba*I site in the linker preceding protein VIII has changed the codon encoding glutamine to an amber (TAG) stop codon. Digestion with *Nsi*I and *Xba*I excises the pentapeptide-encoding sequence and allows for the directional cloning of appropriately digested DNA fragments into a position analogous to that of the hGH gene in pS349.

A PCR was performed with *Streptomyces avidinii* genomic DNA as template and oligonucleotides *SAV-1* and *SAV-2* as primers. The amplified DNA fragment contained codons 16 to 133 of the streptavidin (SAV) gene open reading frame flanked by an *Nsi*I site at the 5' end and an *Xba*I site at the 3' end. The fragment was digested with *Nsi*I and *Xba*I and cloned into similarly digested phagemid pS657a. The resulting phagemid (pW277e) encodes a fusion product similar to that encoded by pS349 except that hGH has been replaced by SAV. Also, an amber codon has been positioned between the segments encoding SAV and protein VIII.

Example 10 - Construction of mutant protein VIII libraries.

For library construction, protein VIII was divided into five zones encompassing approximately 10 contiguous residues each (zone 1, residues 1 to 10; zone 2, residues 11 to 20; zone 3, residues 21 to 30; zone 4, residues 31 to 39; zone 5, residues 40 to 50). Libraries were constructed using a modified version (SS320 described above) of a previously described method (Lowman, H. B. (1998) Phage Display of Peptide Libraries on Protein Scaffolds. From: *Methods in Molecular Biology*, vol. 87: *Combinatorial Peptide Library Protocols*. Edited by: S. Cabilly. Publisher: Humana Press Inc., Totowa, NJ). Briefly for each zone, an oligonucleotide (*g8stopn*, where "n" is the zone number) was used with either pS349 (for hGH display) or pW277e (for SAV display) as template to introduce two consecutive TGA stop codons within the zone, using the method of Kunkel (Kunkel, T. A. (1985) *Proc. Natl. Acad. Sci. USA* 82:488-492). The resulting phagemid was used as template in a second round of the Kunkel method with a degenerate oligonucleotide (*g8Vn*, where "n" is the zone number) designed to introduce mutations at the desired sites.

Libraries were constructed for each zone of the protein VIII moiety within the hGH-protein VIII fusion product of pS349. The diversities of these libraries were as follows: zone-1,  $2.5 \times 10^{10}$ ; zone-2,  $2.5 \times 10^{10}$ ; zone-3,  $2.5 \times 10^{10}$ ; zone-4,  $1.3 \times 10^{10}$ ; and zone-5,  $5.0 \times 10^9$ . Libraries were constructed for zone-1, zone-2, and zone-3 of the protein VIII moiety within the SAV-protein VIII fusion product of pW277e. The diversities of these libraries were as follows: zone-1,  $3.0 \times 10^9$ ; zone-2,  $6.8 \times 10^9$ ; and zone-3,  $8.6 \times 10^9$ .

Libraries were also constructed to vary the linker between the fused protein and protein VIII. For hGH display, the oligonucleotide *Lstop* was used to introduce two consecutive TGA stop

codons within the linker between hGH and protein VIII. The resulting phagemid was used as template in a second round of the Kunkel method with a degenerate oligonucleotide (*LV*) designed to introduce a linker of the form (Gly)<sub>3</sub>(Xaa)<sub>14</sub>(Gly)<sub>2</sub> (where Xaa is a variable position) in place of the Gly/Ser-rich linker encoded by pS349. For SAV display, the linker was varied between 5 SAV and variant protein VIII (1e) (see Figure 2, for the sequence of protein VIII (1e)). The oligonucleotide *Lstop2* was used to introduce three consecutive TAA stop codons within the linker between SAV and protein VIII (1e). The resulting phagemid was used as template for the production of libraries with linkers of variable length and sequence. The oligonucleotides *LV5*, *LV10*, *LV15*, *LV20*, and *LV25* were used to construct libraries with linkers containing 5, 10, 15, 20, 10 or 25 variable residues, respectively.

The diversities of the linker libraries were as follows: hGH-LV- protein VIII,  $1.8 \times 10^{10}$ ; SAV-LV5- protein VIII,  $1.4 \times 10^{10}$ ; SAV-LV10- protein VIII,  $9.8 \times 10^9$ ; SAV-LV15- protein VIII,  $1.2 \times 10^{10}$ ; SAV-LV20- protein VIII,  $1.1 \times 10^{10}$ ; SAV-LV25- protein VIII,  $6.0 \times 10^9$ .

15 Example 11 - Selection of protein VIII variants which increase fusion protein display.

Phage from the hGH- protein VIII libraries described above were cycled through rounds of binding selection with hGHbp (Fuh, G. *et al.* (1990) *J. Biol. Chem.* 265:3111; Cunningham, B. C., Ultsch, M., De Vos, A. M., Mulkerrin, M. G., Clauser, K. R., and Wells, J. A. (1991) *Science* 254:821-825) coated on 96-well Maxisorp immunoplates as a target. All libraries were sorted 20 separately. Phage were propagated in *E. coli* SS320 cells with M13-VCS helper phage (Stratagene). After five rounds of binding selection, individual phage were isolated and analyzed for hGH display using a phage ELISA with hGHbp as target (see below). Phage exhibiting strong signals in the phage ELISA were sequenced (Sanger, F. *et al.* (1979) *Proc. Natl. Acad. Sci. USA*, 74:5463-5467).

25 The SAV- protein VIII libraries were pooled and binding selection was performed as described above for the hGH- protein VIII libraries, except that the binding target was an anti-SAV polyclonal antibody. Phage were propagated in the *SupE E. coli* strain XL1-Blue in which the amber stop codon is suppressed as glutamine (Bullock, W. O., Fernandez, J. M., and Short, J. M. (1987) *Biotechniques* 5:376-379).

30

Example 12 - Site-directed mutagenesis.

Mutageneses were performed using the method of Kunkel (Kunkel, *et al.* (1987) *Meth. Enzymol.* 154:367-382). Template DNA was prepared by growing an appropriate plasmid (e.g., containing the hGH gene fused to the carboxy-terminal half of M13 gene III) in host cells with 35 M13-K07 phage added as helper phage. Single-stranded, uracil-containing DNA was prepared for mutagenesis to introduce the desired mutation into the hGH-protein VIII gene fusion. Oligonucleotide-directed mutagenesis was carried out using T7 DNA polymerase and the

appropriate oligodeoxy-nucleotides. Clones from the mutagenesis were confirmed by dideoxy DNA sequencing.

The mutagenic oligonucleotide *g8(1a)* was used to introduce the protein VIII mutations of selectant hGH- protein VIII (1a) into phagemid pW277e. Mutant hGH genes were constructed 5 using the appropriately named oligonucleotide (e.g., oligonucleotide *R64A* encodes the mutation of Arg64 to Ala).

The mutagenic oligonucleotide *g8V2c* was used to introduce the mutations of protein VIII(2a) into the gene encoding protein VIII(1a). The mutagenic oligonucleotide *g8V3c* was used to introduce the mutations of protein VIII(3a) into the gene encoding protein VIII(2a). The 10 mutation E12N, D16A, or I17S was introduced into the gene encoding protein VIII(2a) using the mutagenic oligonucleotide *g8V2-E12N*, *g8V2-D16A*, or *g8V2-I17S*.

Example 13 - Phage ELISAs for determining relative levels of fusion protein display on protein VIII and protein VIII variants thereof.

15 Cultures of *E. coli* XL1-Blue (Bullock, W. O., Fernandez, J. M., and Short, J. M. (1987) *Biotechniques* 5:376-379) harboring phagemids were grown for 8 hours at 37°C in 1 mL of 2YT, 50 µg/mL carbenicillin, 10 µg/mL tetracycline. The cultures were transferred to 30 mL of the same media (supplemented with M13-VCS helper phage ( $10^{10}$  phage/mL) and IPTG at the appropriate concentration) for overnight growth at 37°C. Phage were harvested from the culture 20 supernatant by precipitation twice with PEG/NaCl (Lowman, H. B., (1998) *Phage Display of Peptide Libraries on Protein Scaffolds*. From: *Methods in Molecular Biology*, vol. 87: *Combinatorial Peptide Library Protocols*. Edited by: S. Cabilly. Publisher: Humana Press Inc., Totowa, NJ) and resuspended in 1 mL of PBS, 0.2% BSA, 0.1% Tween (BSA blocking buffer). Phage concentrations were determined spectrophotometrically ( $\epsilon_{268} = 1.2 \times 10^8 \text{ M}^{-1}\text{cm}^{-1}$ ).

25 Maxisorp immunoplates (96-well) were coated with target protein for 2 hours at room temperature (100 µL at 5 µg/mL in 50 mM carbonate buffer, pH 9.6). The plates were then blocked for 1 h with 0.2% BSA in phosphate-buffered saline (PBS) and washed (8X) with PBS, 0.05% Tween 20. Phage particles were diluted serially using PBS, 0.2% BSA, 0.1% Tween (BSA 30 blocking buffer) and then transferred (100 µL) to coated wells. After 1 h, plates were washed (8X) with PBS, 0.05% Tween 20, incubated with 100 µL of 1:3000 HRP/anti-M13 conjugate in BSA blocking buffer for 30 min, and then washed with PBS, 0.05% Tween 20 (8X) and PBS (2X). Plates were developed using an *o*-phenylenediamine dihydrochloride/H<sub>2</sub>O<sub>2</sub> solution (100 µL), stopped with 2.5 M H<sub>2</sub>SO<sub>4</sub> (50 µL), and read spectrophotometrically at 492 nm. Li, B. et al., (1995) *Science* 270:165-1660.

Example 14 - display of SAV on a protein VIII variant selected for increased display of hGH.

The method of Kunkel (Example 12) was used with the mutagenic oligonucleotide *g8V2b* to introduce the protein VIII mutations of selectant hGH-protein VIII(2a) into phagemid pW277e. The resulting phagemid encoded a fusion protein identical to that encoded by pW277e except that the protein VIII within the fusion moiety contained the mutations of variant protein VIII(2a). SAV display was measured by phage ELISAs (Example 13) with either anti-SAV polyclonal antibody (Fig. 4a) or biotinylated BSA (Fig. 4b) as target.

Example 15 - display and detection of hGH variants with attenuated binding affinities.

hGH mutants with reduced site 1 binding affinity for hGHbp (Pierce et al., above) were displayed as fusions to either wild type protein VIII or variant protein VIII(1a). Mutant hGH genes were constructed using the method of Kunkel (Example 12) with the following mutagenic oligonucleotides: hGH(R64A), oligonucleotide *R64A*; hGH(D171A), oligonucleotide *D171A*; hGH(Y164A/R178A), oligonucleotide *Y164A/R178A*; hGH(K172A/R178A), oligonucleotide *K172A/R178A*. For display of hGH fused with wild type protein VIII, the mutagenesis template was pS349. For display of hGH fused with variant protein VIII(1a), the template was a derivative of pS349 encoding a fusion protein consisting of hGH fused to protein VIII(1a). hGH display was measured by phage ELISA (Example 13) with the hGHbp as target (Fig. 3).

Example 16 - display of hGH with protein VIII variants combining mutations in different zones.

The method of Kunkel (Example 12) was used to combine mutations from protein VIII variants independently selected for increased hGH display. The oligonucleotide *g8V2c* was used to introduce the mutations of protein VIII(2a) into the gene encoding protein VIII(1a). The oligonucleotide *g8V3c* was used to introduce the mutations of protein VIII(3a) into the gene encoding protein VIII(2a). hGH display was measured by phage ELISA (Example 13) with an anti-hGH monoclonal antibody as target (Fig. 5).

Example 17 - display of hGH with protein VIII variants derived from protein VIII(2a) through back mutations to the wild type sequence.

The method of Kunkel (Example 12) was used to introduce the mutation E12N, D16A, or I17S into the gene encoding protein VIII(2a) using the mutagenic oligonucleotide *g8V2-E12N*, *g8V2-D16A*, or *g8V2-I17S*, respectively. hGH display was measured by phage ELISA (Example 13) with an anti-hGH monoclonal antibody as target (Fig. 6).

Example 18 - display of hGH with phagemid pS1607.

Further sequence analysis revealed that the fusion-protein VIII gene contained within the pS349 clone used in Figures 2, 3, 5, and 8 had a deletion of five base pairs consisting of the final base pair encoding the linker between hGH and protein VIII and the first four base pairs encoding

protein VIII. This deletion introduced a frameshift which reduced hGH display. The method of Kunkel (Example 12) was used with the mutagenic oligonucleotide *L-wt* to correct the frameshift in pS349. The resulting phagemid was designated pS1607. Phagemid pS1607 differs from pS349 only in the addition of five base pairs to correct this frameshift. In pS349, the sequence following 5 the hGH gene is as follows: CAGAGCGGTGGAGGATCCGGGAGCTCCAGGGGT (the underlined bases are part of the beginning of the protein VIII gene) (SEQ ID NO. 80). In pS1607, the corresponding sequence is as follows:

CAGAGCGGTGGAGGATCCGGGAGCTCCAggccGAGGGGT (lower case indicates the bases inserted through mutagenesis with oligonucleotide L-wt) (SEQ ID NO. 81). hGH display was 10 measured by phage ELISA (Example 13) with the hGHbp as target (Fig. 9).

Example 19 - Fab display with a protein VIII variant.

Phagemid pS1705a directs secretion of a free Fab light-chain and a Fab heavy-chain fused to protein VIII. The Fab heavy-chain also contains a peptide flag (MADPNRFRGKDL) (SEQ ID 15 NO. 82) fused to its N-terminus which can be detected with a specific monoclonal antibody. The method of Kunkel (Example 12) was used with the mutagenic oligonucleotide *S13A/S17I* and the template pS1705a, the resulting phagemid was designated pS1709b. Phagemid pS1709b is identical to pS1705a except that the protein VIII gene linked to the Fab heavy-chain contains the mutations S13A/S17I which were observed in protein VIII variants selected for increased display 20 of hGH (Fig. 1B). Fab display was measured by phage ELISA (Example 13) with a peptide flag-specific monoclonal antibody as target. Fab display with pS1709b was greater than Fab display with pS1705a (Fig. 10). Thus protein VIII mutations which were selected for increased display of hGH also increased Fab display.

25 Example 20 - display of hGH with protein VIII variants combining mutations in different zones.

The method of Kunkel (Example 12) was used to combine mutations from protein VIII variants independently selected for increased hGH display. The oligonucleotide *g8V2c* was used to introduce the mutations of protein VIII(2a) into the gene encoding protein VIII(1a). The oligonucleotide *g8V3c* was used to introduce the mutations of protein VIII(3a) into the gene 30 encoding protein VIII(2a). The oligonucleotide *g8V3b* was used to introduce the mutations of protein VIII(3a) into the gene encoding protein VIII(1a). The oligonucleotide *g8V3c* was used to introduce the mutations of protein VIII(3a) into the gene encoding protein VIII containing the mutations of protein VIII(1a) and protein VIII(2a). hGH display was measured by phage ELISA 35 (Example 13) with an anti-hGH monoclonal antibody as target. All protein VIII variants increased hGH display in comparison with wild-type protein VIII (Fig. 11).

Example 21 - modulated display of hGH with protein VIII variants derived from protein VIII selectants through back mutations to the wild-type sequence.

Back mutation scanning is the independent conversion of each mutation within a coat protein, such as protein VIII, variant back to the wild-type sequence. A protein VIII selectant with 5 mutations in either zone 1, 2, or 3 was subjected to back mutation scanning analysis. The following selectants were analyzed: protein VIII(1a), protein VIII(2a), and protein VIII(3a) (Fig. 1). The method of Kunkel (Example 12) was used to mutate each mutation in a given variant back to the wild-type sequence. Appropriately designed and named oligonucleotides were used (e.g. the oligonucleotide *D1A* mutates Asp1 in protein VIII(1a) to Ala). In addition, double and triple back 10 mutations were introduced into protein VIII(2a), again using appropriately designed and named oligonucleotides (e.g., the oligonucleotide *A13S/I17S* simultaneously mutates A13 and I17 to Ser.).

hGH display was measured by phage ELISA (Example 13) with an anti-hGH monoclonal antibody as target. Some of the back mutations reduced hGH display, allowing for the modulation of hGH display (Fig. 12).

15

Oligonucleotides for Examples 22-25

*Add-NX:* GATGGTGAAGCTGCGGCTGATGCATCTGGTAGCGTCTAGAGC  
CACCATCACCATCACCAT (SEQ ID NO: 83)

*add-P12-7:* GCTGTCGGTATTATTTACATGCTCCTCGTGGAGGCGTCGCC  
20 TGGGCTGCTAACGGCGCCA (SEQ ID NO: 84)

*G-0:* ACCTCGAAAGCAAGCCATCACCATCACCATGCG (SEQ ID NO: 85)

*G-1:* ACCTCGAAAGCAAGCGGCCATCACCATCACCATGCG (SEQ ID NO: 86)

*G-2:* ACCTCGAAAGCAAGCGGTGGCCATCACCATCACCATGCG (SEQ ID NO: 87)

*G-3:* ACCTCGAAAGCAAGCGGTGGTGGCCATCACCATCACCATGCG (SEQ ID NO: 88)

25 *G-4:* ACCTCGAAAGCAAGCGGCGGTGGTGGCCATCACCATCACCATGCG (SEQ ID NO: 89)

*G-6:* ACCTCGAAAGCAAGCGGTGGTGGCGGTGGTGGCCATCAC  
CATCACCATGCG (SEQ ID NO: 90)

*G-7:* ACCTCGAAAGCAAGCGGCCGTGGTGGCGGTGGTGGCCATCAC  
30 *G-8:* ACCTCGAAAGCAAGCGGTGGCGGTGGTGGCGGTGGTGGCCATCACCATCAC  
GCG (SEQ ID NO: 92)

*G-9:* ACCTCGAAAGCAAGCGGCCGTGGCGGTGGTGGCGGTGGTGGCCATCAC  
CATCACCATGCG (SEQ ID NO: 93)

35 *G-10:* ACCTCGAAAGCAAGCGGTGGCGGTGGCGGTGGTGGCGGTGGTGGC  
CATCACCATCACCATGCG (SEQ ID NO: 94)

*G-12:* ACCTCGAAAGCAAGCGGTGGCGGTGGCGGTGGCGGTGGTGGCGGT  
GGTGGCCATCACCATCACCATGCG (SEQ ID NO: 95)

G-14: ACCTCGAAAGCAAGCGGTGGTGGCGGTGGCGGTGGCGGTGGCGGT  
 GGTGGCGGTGGTGGCCATCACCATCACCATGCG (SEQ ID NO: 96)  
 G-16: ACCTCGAAAGCAAGCGGCAGCGGTGGTGGCGGTGGCGGTGGCGGTGGC  
 GGTGGTGGCGGTGGTGGCCATCACCATCACCATGCG (SEQ ID NO: 97)  
 5 G-18: ACCTCGAAAGCAAGCGGCAGCGGTGGCGGTGGCGGTGGCGGTGGC  
 GGTGGCGGTGGCGGTGGCGGTGGCCATCACCATCACCATGCG (SEQ ID NO: 98)  
 G-20: ACCTCGAAAGCAAGCGGTGGCGGTGGCGGTGGCGGTGGCGGTGGC  
 GGTGGCGGTGGCGGTGGCGGTGGCGGTGGCGGTGGCGGTGGCGGTGGC  
 99)  
 10 Lib-zone1: CAAGGACCATAGATTATGNNNSNNNSNNNSNNNSNSAAGTT  
 TCTGAAAGTTTTGTTTT (SEQ ID NO: 100)  
 Lib-zone2: ATTATGAGCAAGAGCACTNNNSNNNSNNNSNNNSNNSGTT  
 TTTGTTTTCTGTTGAT (SEQ ID NO: 101)  
 Lib-zone3: TTCAAAAAGTTCTGAAANNSNNNSNNNSNNNSNNNSNNNS  
 15 NNSNSNSAATTGGATTGGCTGTCGGT (SEQ ID NO: 102)  
 Lib-zone4: GTTTTTCTGTTGATGTTGATNNNSNNNSNNNSNNNSNNNS  
 NNSNNNSNNSGCGGCTGATGCATTCCA (SEQ ID NO: 103)  
 Lib-zone5: TGGGCTGTCGGTATTATTNNNSNNNSNNNSNNNSNNNSNNNS  
 NNSNNSGCTGCTAAGGCGCCAGACGATGGT (SEQ ID NO: 104)  
 20 Lib-zone6: AGCGCTCAGCTGAGCAACTCNSNNNSNNNSNNNSNNNSNNNS  
 NNSNSNSNSGCGGCTGATGCATTCCA (SEQ ID NO: 105)  
 Lib-linker: GATGGTGAAGCTGCGGCTVVCVVCVVCVVCVVCVVC  
 VVCVVCVVCVVCVVCVFCATGCATTCCAACATACCA (SEQ ID NO: 106)  
 Pep-ins: ACTTTCAAAAAGTTCTGAAANWTNKTNWTNYTNYTNKT  
 25 NWTNWTNWTNWTNWTNKGNYTNKGNYTNWCNKTNWTGAGACTGCTAGCGCTC  
 AG (SEQ ID NO: 107)

Example 22 - Determination of optimal linker length for the display of a peptide fused to the C-terminus of protein VIII.

30 Standard molecular biology techniques were used to construct a phagemid designated pS1290a. pS1290a is identical to phagemid pS349 (see Example 8) except that the open reading frame (ORF) under the control of the IPTG-inducible Ptac promoter (New England Biolabs) has been deleted and replaced by a new ORF. The new ORF encodes a fusion product consisting of the maltose binding protein signal peptide, followed by a Ser residue, followed by residues 2-50 of  
 35 mature protein VIII of *E. coli* bacteriophage M13. The ORF is followed by two TAA stop codons, followed by sequence (CACCATCACCATCACCATGCG) (SEQ ID NO: 108) encoding a heptapeptide (HHHHHHA, hexaHis) flag or epitope tag, followed by two stop codons (TGATAA).

pS1290a was mutated using the method of Kunkel (Example 12). The two TAA stop codons and the first His codon following the protein VIII C-terminus were replaced by various numbers of Gly codons. Appropriately designed and named mutagenic oligonucleotides were used (e.g., oligonucleotide G-6 inserts six Gly codons). This resulted in the construction of a series of 5 phagemids encoding ORFs designed to secrete protein VIII molecules with C-terminal fusions consisting of linkers containing varying numbers of Gly residues followed by a pentaHis flag (HHHHHHA). The number of Gly residues was varied from zero (*i.e.*, the polyHis flag was fused directly to the protein VIII C-terminus) to 20. PentaHis flag display was measured by phage ELISA (Example 13) with an anti-(His)5 antibody (Qiagen) as the capture target (Fig. 13).

10

Example 23 - Optimization of the linker sequence for display of a peptide fused to the C-terminus of protein VIII.

15

Libraries were constructed to vary the linker between protein VIII and the hexaHis flag encoded by pS1290a. Libraries were constructed using a modified version of a previously described method (see Example 10). Mutagenic oligonucleotides were used to replace the two TAA stop codons between protein VIII and the hexaHis flag with libraries of linkers. The lengths of the linkers were varied and depended on the mutagenic oligonucleotides used: oligonucleotides UH-L4, UH-L5, UH-L6, UH-L8, or UH-L10 introduced linkers containing 4, 5, 6, 8, or 10 residues respectively. The total diversity of the linker libraries was  $5.7 \times 10^{10}$ .

20

Phage from the linker libraries described above were pooled together and cycled through rounds of binding selection with an anti-(His)4 antibody (Qiagen) as the capture target. After two rounds of selection, individual clones were assayed for hexaHis flag display using a phage ELISA with the anti-(His)4 antibody as target. Clones exhibiting the strongest signals were subjected to DNA sequence analysis and the linker sequences were deduced from the DNA sequence and are shown below.

25

	GCC A	TGG W	GAG E	GAG E	AAC N	ATC I	GAC D	AGC S	GCC A	CCC P	(SEQ ID NO. 109) (SEQ ID NO. 110)
30	CAG Q	TAC Y	GGG G	ACG T	CCG P	GAC D	ACC T	GAC D	ACC T	GAC D	(SEQ ID NO. 111) (SEQ ID NO. 112)
35	ACG T	GGG G	TGG W	TTG L	GAG E	GGG G	CCC P	GAC D	ACC T	CCC P	(SEQ ID NO. 113) (SEQ ID NO. 114)
40	CTC L	ATG M	GGC G	CCC P	GGC G	GCG A	GAC D	GGC G			(SEQ ID NO. 115) (SEQ ID NO. 116)
	CAC H	GAC D	TCG S	GTC V	CCG P	AGC S	AAC N	GGC G			(SEQ ID NO. 117) (SEQ ID NO. 118)

Linkers selected for display of a peptide fused to the C-terminus of protein VIII. The sequences shown were inserted between the final residue of protein VIII and a heptapeptide (HHHHHHHA, referred to as a hexaHis flag). For each selectant, the DNA sequence is shown with

the deduced amino acid sequence below. The numerical designation for each sequence is shown to the left.

The level of polyHis flag display achieved with an optimized linker was compared with levels of display achieved with poly-glycine linkers of various length (Example 22) using a phage 5 ELISA with an anti-(His)5 antibody (Qiagen) as the capture target (Fig. 14).

Example 24 – Design and selection of a new phage coat protein (Protein-12, P12) for the display of polypeptides as C-terminal fusions.

This example demonstrates the de novo design of a phage coat protein and the display of a 10 protein of interest on the surface of phage particles containing the fusion protein, illustrating the broad scope of the method of the invention to prepare any variant phage coat protein. The retrotranslation of a peptide is the backward reading of the primary sequence and the resulting peptide is the retro-peptide of the original peptide. For example, the retrotranslation of the peptide Gly-Ala-Leu is the retro-peptide Leu-Ala-Gly.

15 Standard molecular biology techniques were used to construct a phagemid designated pS1207a. pS1207a is identical to phagemid pS349 (Example 8) except that the ORF under the control of the IPTG-inducible Ptac promoter (New England Biolabs) has been deleted and replaced by a new ORF. The DNA sequence of the new ORF is as follows:

ATGAGCAAGAGCACTTTCAAAAAGTTCTGAAAGAGACTGCTAGCGCTCAGCTGAGC  
20 AACCTCGCTGCTAAGGCAGACGATGGTGAAGCTGCGGCTACCACCATCACCA  
ATGCG (SEQ ID NO: 119)

The new ORF encodes the following polypeptide:

MSKSTFKKFLKETASAQLSNAAKAPDDGEAAHHHHHA. (SEQ ID NO: 120).

This ORF was designed as follows. The first two residues were (Met-Ser) chosen to allow 25 good translation initiation. This dipeptide was followed by a retrotranslation of residues 40-48 of mature protein VIII from M13 bacteriophage (KLFKKFTSK retrotranslated to KSTFKKFLK) which was in turn followed by a retrotranslation of protein VII residues 1-20 (AEGDDPAKAAFNLSLQASATE retrotranslated to ETASAQLSNSAAKAPDDGEA). To the C-terminus of this polypeptide was fused a nonapeptide (AAHHHHHHHA) hexaHis flag. Thus, this 30 ORF consists of the dipeptide Met-Ser, followed by a retrotranslation of residues 1-48 of mature protein VIII with the central hydrophobic section (residues 21-30) deleted, followed by a hexaHis flag.

A library of 19-mer peptides was inserted between residues 11 and 12 of the above 35 described ORF, using a modified version of a previously described method (see Example 10) with pS1207a as the template and *Pep-ins* as the mutagenic oligonucleotide. The resulting library encoded ORFs with the following sequences:

MSKSTFKKFLK-(x)19-ETASAQLSNAAKAPDDGEAAHHHHHA (SEQ ID NO: 121)

where "(x)19" indicates a random 19-mer peptide library. The degenerate codons used at each position within the library are shown in Figure 15. The library diversity was  $8.3 \times 10^{10}$ .

Phage from the library were cycled through rounds of binding selection with an anti-(His)4 antibody (Qiagen) as the capture target. After three or four rounds of selection, individual clones 5 were assayed for hexaHis flag display using a phage ELISA with either the anti-(His)4 antibody or bovine serum albumin (BSA) as target. Of 72 clones assayed, six exhibited at least a two-fold greater signal when captured with the anti-(His)4 antibody rather than with BSA (Fig. 16). These clones were subjected to DNA sequence analysis and the protein sequence was deduced from the DNA sequence.

10 These protein sequences represent a new class of phage coat proteins which we designate "Protein-12" (P12). The individual unique clones are designated by an additional numeral (eg. Protein-12-1 or P12-1). As shown in Figure 16, peptides fused to the C-terminus of P12 are displayed on the surface of M13 phage. The phagemid containing the gene encoding P12-1 was named pS1230a.

15

Example 25 – Selection of a second generation P12 for the display of a large protein as a C-terminal fusion.

The method of Kunkel (Example 12) was used with the mutagenic oligonucleotide *add-NX* to insert an *NsiI* restriction site followed by an *XbaI* restriction site into phagemid pS1230a, 20 between the regions encoding P12-1 and the polyHis flag. The resulting sequence was as follows: ...gctgcggctGATGCATCTGGTAGCGTCTAGAGCCaccatcaccatcaccat... (SEQ ID NO: 122) The inserted sequence is shown in upper case text with the *NsiI* and *XbaI* restriction sites. The inserted sequence is preceded by sequence encoding the final residues of P12-1 and followed by sequence encoding the polyHis flag (both shown in lower case text). The new phagemid was 25 designated pS1232a.

Phagemid pS1232a was digested with *NsiI* and *XbaI* and a similarly digested DNA fragment encoding an hGH variant (hGH supermutant, hGHsm) with improved affinity for the hGH binding protein (hGHbp) was inserted. The phagemid was designated pS1239b; it contains an ORF encoding P12-1 followed by a tetrapeptide linker (Ala-Ala-Asp-Ala), followed by hGHsm 30 as shown below. The protein product of the pS1239b ORF is depicted; it consists of P12-1, followed by a tetrapeptide linker (AADA), followed by hGHsm. P12-1 was divided into six zones as indicated, and a library was constructed for each zone. In addition, a linker library was constructed in which random 14-residue peptides were inserted in the middle of the tetrapeptide linker as shown.

M S K S T F K K F L K  
 5 |-----|-----|  
 zone 1 zone 2

V F V F S V D V D N N W I W A V G I I  
 10 |-----|-----|  
 zone 3 zone 4

E T A S A Q L S N F A A K A P D D G E A  
 15 |-----|-----|  
 zone 5 zone 6

A A D A |---hGHsm  
 25 |  
 linker library  
 (insert 14 VVC codons between Ala-Asp) (SEQ ID NO. 123)

30 Phage particles produced from pS1239b did not display hGHsm at levels detectable in a phage ELISA with hGHbp as the capture target.

To obtain a P12 variant capable of displaying hGHsm as a C-terminal fusion, libraries were constructed to vary the sequence of P12-1 encoded by pS1239b. For library construction, a previously described method was used (Example 10). P12-1 was divided into six zones with each 35 zone containing a stretch of contiguous residues (zone 1, residues 2 to 7; zone 2, residues 6 to 11; zone 3, residues 12 to 21; zone 4, residues 21 to 30; zone 5, residues 31 to 40; zone 6, residues 41 to 50). Oligonucleotides were designed to simultaneously replace all codons within the zone with an equal number of degenerate codons (NNN, where N = A, C, G, or T) encoding all twenty natural amino acids. Each oligonucleotide was named according to the zone it mutated (*e.g.*

40 Oligonucleotide *Lib-zone1* mutated zone 1). In addition, an oligonucleotide (*Lib-linker*) was designed to insert 14 degenerate codons (VVC, where V = A, C, or G; encoding Ala, Arg, Asn, Asp, Gly, His, Pro, Ser, or Thr) into the middle of the tetrapeptide linker connecting P12-1 to hGHsm. The diversities of these libraries were as follows: zone 1,  $2.5 \times 10^{10}$ ; zone 2,  $2.5 \times 10^{10}$ ; zone 3,  $2.6 \times 10^{10}$ ; zone 4,  $2.4 \times 10^{10}$ ; zone 5,  $2.4 \times 10^{10}$ ; zone 6,  $2.3 \times 10^{10}$ ; linker library,  $2.8 \times 45 10^{10}$ .

Phage from all the libraries were pooled and cycled through rounds of binding selection with hGHbp (Example 11) coated on 96-well Maxisorp immunoplates as a target. Phage were propagated in *E. coli* SS320 cells with M13-VCS helper phage (Stratagene). After four rounds of binding selection, individual clones were analyzed for hGHsm display. For each of the rounds 2, 50 3, and 4, 24 clones were analyzed. Phage were isolated from each clone and hGHsm display was

detected using a phage ELISA (Example 13). A single clone from round 2 exhibited 10-fold greater binding to plates coated with hGHbp in comparison with plates coated with BSA; all other clones exhibited similar binding to either hGHbp or BSA coated plates. The phagemid corresponding to the positive clone was designated pS1258.

5 The complete DNA sequence of the P12-1 variant encoding ORF of pS1258 was determined and the protein sequence was deduced and shown below. The amino acid numbering is shown to the right.

	ATG	AGC	AAG	AGC	ACT	TTC	AAA	AAG	TTT	CTG
10	M	S	K	S	T	F	K	K	F	L
	AAA	GTT	TTT	GTT	TTT	TCT	GTT	GAT	GTT	GAT
	K	V	F	V	F	S	V	D	V	D
15	AAT	AAT	TGG	ATT	TGG	GCT	GTC	GGT	ATT	ATT
	N	N	W	I	W	A	V	G	I	I
20	TAC	ATG	CTC	CTC	GTG	GAG	GCG	TCG	CCC	TGG
	Y	M	L	L	V	E	A	S	P	W
25	GCT	GCT	AAG	GCG	CCA	GAC	GAT	GGT	GAA	GCT
	A	A	K	A	P	D	D	G	E	A

(SEQ ID NO. 124)

30 The new variant coat protein was named P12-7; its sequence differs from that of P12-1 in zone 5. The fusion of hGHsm to the C-terminus of P12-7 permits the display of hGHsm on the surface of M13 phage, as evidenced by a phage ELISA.

We also wished to demonstrate that P12-7 permits the display of other proteins, for example wild-type hGH. A phagemid analogous to pS1239b (described above) was constructed 35 and designated pS1239a, with the only difference being that pS1239b encodes a fusion protein consisting of P12-1 followed by wild-type hGH (Example 8). Phage particles produced from pS1239a did not display hGH at levels detectable in a phage ELISA. The method of Kunkel (Example 12) was used with a mutagenic oligonucleotide (*add-P12-7*) to convert the pS1239a DNA sequence encoding P12-1 to DNA sequence encoding P12-7. The new phagemid was 40 designated pW930a; it contains an ORF encoding a fusion protein consisting of P12-7 followed by wild-type hGH. Phage particles isolated from *E. coli* cultures harboring pW930a displayed hGH on their surface, as evidenced by a phage ELISA .

Example 26 – Optimization of linker sequences for display of a peptide fused to the C-terminus of the protein III C-terminal domain.

Oligonucleotides for Example 26:

5    *UH-L4*: TTCACCTCGAAAGCAAGCNSNNNSNNSCACCAT  
      CACCATCACCAT (SEQ ID NO: 125)  
      *UH-L5*: TTCACCTCGAAAGCAAGCNSNNNSNNNSNNSCACCAT  
      CACCATCACCAT (SEQ ID NO: 126)  
      *UH-L6*: TTCACCTCGAAAGCAAGCNSNNNSNNNSNNNSNNSCACCAT  
10    CACCATCACCAT (SEQ ID NO: 127)  
      *UH-L8*: TTCACCTCGAAAGCAAGCNSNNNSNNNSNNNSNNSVVCVCCACCAT  
      CACCATCACCAT (SEQ ID NO: 128)  
      *UH-L10*: TTCACCTCGAAAGCAAGCNSNNNSNNNSNNNSNNNSNNSVVCVVC  
      VVCVCCACCATCACCATCACCAT (SEQ ID NO: 129)  
15    *UHg3-L6*: CTGCGTAATAAGGAGTCTNNNSNNNSNNNSNNNS  
      CACCATCACCATCACCATTAATCATGCCAGTTCTTTGG (SEQ ID NO: 130)  
      *UHg3-L8*: CTGCGTAATAAGGAGTCTNNNSNNNSNNNSNNNSNNNS  
      NNSNNSCACCATCACCATCACCATTAATCATGCCAGTTCTTTGG (SEQ ID NO: 131)  
      *UHg3-L10*: CTGCGTAATAAGGAGTCTNNNSNNNSNNNSNNNSNNNS  
20    NNSNNNSNNSCACCATCACCATCACCATTAATCATGCCAGTTCTTTGG  
      (SEQ ID NO: 132)

Standard molecular biology techniques were used to construct a phagemid designated pS1428d. Phagemid pS1428d is similar to pS1290a, except that the ORF under the control of the IPTG-inducible Ptac promoter (New England Biolabs) consists of the maltose binding protein signal peptide followed by the C-terminal domain of M13 protein III (Lowman *et al.*, (1991) *Biochemistry*, 30:10832). The method of Kunkel (Example 12) was used to fuse libraries to the C-terminus of the protein III C-terminal domain encoded by pS1428d. The libraries consisted of random linkers of various lengths followed by a hexaHis flag (HHHHHH). The end result was libraries containing ORFs which encoded the C-terminal domain of protein III, followed by random polypeptide linker sequences, followed by the hexaHis flag. The lengths of the linkers were varied and depended on the mutagenic oligonucleotides used: oligonucleotides *UHg3-L6*, *UHg3-L8*, or *UHg3-L10* introduced linkers containing 6, 8, or 10 residues respectively. The diversities of the libraries were as follows: *UHg3-L6*,  $3.5 \times 10^{10}$ ; *UHg3-L8*,  $1.2 \times 10^{10}$ ; *UHg3-L10*,  $2.8 \times 10^{10}$ .

Phage from the libraries were pooled together and cycled through binding selection with an anti-(His)4 antibody (Qiagen) as the capture target. After two rounds of selection, individual

clones were assayed for hexaHis flag display using a phage ELISA with the anti-(His)4 antibody as target. Three clones exhibiting strong signals were subjected to DNA sequence analysis and the selected linker sequences are shown below.

5	g3-1 (SEQ ID NO. 133)	GGG	CAG	GCC	AGG	ATC	GTC	TAC	CGG	CAG	AAG
		G	Q	A	R	I	V	Y	R	Q	K
10	g3-2 (SEQ ID NO. 135)	AGG	ATC	AGG	GTC	CTG	CAG	AAG	GGC	AAG	GAG
		R	I	R	V	L	Q	K	G	K	E
15	g3-3 (SEQ ID NO. 137)	CGC	GCC	AAG	ATC	GAG	CAG	ATC	TGC	AAG	GAG
		R	A	K	I	E	Q	I	C	K	E
20											
	(SEQ ID NO. 138)										

The sequences shown were inserted between the final residue of the protein III C-terminal domain and a hexaHis flag. For each selectant, the DNA sequence is shown with the deduced amino acid sequence below. A designation for each sequence is shown to the left.

25 The levels of polyHis flag display were compared with levels of display achieved with C-terminal or N-terminal fusions to protein VIII. Interestingly, display with C-terminal fusion to the protein III C-terminal domain was equivalent to display with N-terminal fusion to protein VIII and about 10-fold higher than display with C-terminal fusion to protein VIII (Fig. 18).

30 The foregoing written specification is considered to be sufficient to enable one skilled in the art to practice the invention. The present invention is not to be limited in scope by the cultures deposited, since the deposited embodiments are intended as separate illustrations of certain aspects of the invention and any cultures that are functionally equivalent are within the scope of this invention. The deposit of material herein does not constitute an admission that the written description herein contained is inadequate to enable the practice of any aspect of the invention, 35 including the best mode thereof, nor is it to be construed as limiting the scope of the claims to the specific illustrations that it represents. Indeed, various modifications of the invention in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description and fall within the scope of the appended claims.

40 While the invention has necessarily been described in conjunction with preferred embodiments, one of ordinary skill, after reading the foregoing specification, will be able to effect various changes, substitutions of equivalents, and alterations to the subject matter set forth herein, without departing from the spirit and scope thereof. Hence, the invention can be practiced in ways other than those specifically described herein. It is therefore intended that the protection granted by Letters Patent hereon be limited only by the appended claims and equivalents thereof.

## WHAT IS CLAIMED:

1. A fusion protein comprising a heterologous polypeptide fused to a major coat protein of a virus, wherein the major coat protein is a variant of a wild type major coat protein of the virus.  
5
2. The fusion protein of claim 1, wherein the virus is selected from the group consisting of a filamentous phage, a lambda phage, a Baculovirus, a T4 phage and a T7 phage.
3. The fusion protein of claim 1, wherein the phage is a filamentous phage, the major coat protein is gpVIII and the heterologous polypeptide is fused to the N-terminus or the C-terminus thereof.  
10
4. The fusion protein of claim 1, wherein the major coat protein is a filamentous phage coat protein variant which contains at least one amino acid residue selected from the list below in the position indicated:  
15

	<u>Residue Number</u>	<u>Amino Acid Residue</u>
	1	E, L, V, Q, D, I, N
	2	R, H, F, W, E, K, Y, D
20	3	T, E, L, S, D, I, V, A
	4	D, R, H, E, K
	5	R, H, N, D, K, Q, E
	6	Y, W, S, I, L, F, T, V
	7	T, N, S
25	8	D, H, R, E, K
	9	E, Q, T, D, N, S
	11	W, I, V, Y, L, F
	12	R, H, N, E, D, K, Q
	13	I, L, E, Q, A, V, D, T, N, S
30	14	L, I, V
	15	D, R, N, E, K, H, Q
	16	E, V, L, T, D, I, A, S, G
	17	E, V, L, I, A, T, D
	18	L, V, I
35	19	L, T, Q, E, I, V, S, A, N, D
	20	R, D, H, N, Q, K, E
	21	W, Y, I, L, F, V
	22	W, F, Y

	23	W, Y, I, V, H, K, F, L, R
	24	I, Q, L, N, V
	25	S, L, I, T, V
	26	A, I, V, G, L, M
5	27	N, T, S
	28	I, L, V
	29	K, R, F, W, H, Y
	30	I, V, L.

10 5. A fusion protein comprising a heterologous polypeptide fused to at least a portion of a coat protein of a filamentous phage, wherein the coat protein is a variant of a wild type coat protein of the phage, the variant having an alteration in the transmembrane domain or in the cytoplasmic domain of the coat protein.

15 6. The fusion protein of claim 5, wherein the coat protein is gpIII of a filamentous phage and the heterologous polypeptide is fused to the N-terminus or the C-terminus thereof.

7. The fusion protein of claim 1, wherein the variant has 2 - 50 altered residues relative to the wild type coat protein sequence.

20 8. The fusion protein of claim 1, wherein the heterologous polypeptide is an antibody or a fragment thereof or a cytokine or a cytokine receptor.

9. A replicable expression vector comprising a gene fusion, wherein the gene fusion encodes the fusion protein of claim 1.

25 10. A library comprising a plurality of the replicable expression vectors of claim 9, the expression vectors comprising a plurality of different gene fusions encoding a plurality of fusion proteins.

30 11. Host cells comprising the vector of claim 20.

12. A virus displaying the fusion protein of claim 1 on the surface thereof.

35 13. A library of virus, comprising a plurality of the virus of claim 12 displaying a plurality of different fusion proteins on the surface thereof.

14. A method, comprising:

constructing a library of phage or phagemid particles displaying a plurality of the fusion protein of claim 1;

contacting the phage or phagemid particles with a target molecule so that at least a portion of the particles bind to the target molecule; and

5 separating the particles that bind from those that do not bind.

15. A method of decreasing the detection limit of a phage display system utilizing a phage containing a gene fusion encoding a fusion protein, where the gene fusion comprises a first gene encoding a heterologous polypeptide and a second gene encoding at least a portion of a phage coat 10 protein, the method comprising mutating the second gene to encode a variant of a wild type coat protein of the phage.

16. A method of transforming cells, comprising electroporating cells in the presence of heterologous DNA under conditions suitable to allow the heterologous DNA to enter the cells, 15 wherein the heterologous DNA is purified by affinity purification.

17. The method of claim 16, wherein the heterologous DNA is present at a concentration of about 1 picogram to about 500 micrograms/mL.

20 18. The method of claim 16, obtaining at least  $1 \times 10^{10}$  transformants in one electroporating step.

19. The method of claim 16, wherein the cells are present at a concentration of about  $1 \times 10^{11}$  to about  $4 \times 10^{11}$  cfu/mL.

25

20. The method of claim 19, wherein the cells are F'::Tn10 *proA<sup>+</sup>B<sup>+</sup>lacIqD(lacZ)M15/F-araD139D(ara-leu)7696galE15galK16D(lac)X74rpsL(Str<sup>r</sup>)hsdR2(r<sub>k</sub><sup>-</sup>m<sub>k</sub><sup>+</sup>)mcrAmcrB1 E. coli* cells.

30

21. A method for producing a product polypeptide, comprising the steps of:  
(1) culturing a host cell transformed with a replicable expression vector, the replicable expression vector comprising DNA encoding a product polypeptide operably linked to a control sequence capable of effecting expression of the product polypeptide in the host cell;

35

wherein the DNA encoding the product polypeptide has been obtained by a method comprising the steps of:

5  
(a) constructing a family of variant replicable plasmids comprising a transcription regulatory element operably linked to a gene fusion encoding a fusion protein, wherein the gene fusion comprises a first gene encoding a polypeptide and a second gene encoding at least a portion of a phage coat protein, wherein the variant replicable plasmids comprise variant first genes encoding variant polypeptides;

10  
16; (b) transforming suitable host cells with the plasmids using the method of claim

10  
15  
(c) optionally, when the plasmid is a phagemid which requires a helper phage to produce phage particles, infecting the transformed host cells with an amount of helper phage encoding the phage coat protein sufficient to produce recombinant phagemid particles, preferably wherein no more than a minor amount of the phagemid particles display one or more copies of the fusion protein on the surface of the phagemid particles;

15  
(d) culturing the transformed infected host cells under conditions suitable for forming recombinant phage particles containing at least a portion of the plasmid and capable of transforming the host cells;

20  
(e) contacting the recombinant phage particles with a target molecule so that at least a portion of the phage particles bind to the target molecule;

(f) separating phage particles that bind to the target molecule from those that do not bind;

25  
(g) selecting one of the variant polypeptides encoded by the plasmid in a phage particle which binds or does not bind to the target molecule as the product polypeptide and cloning DNA encoding the product polypeptide into the replicable expression vector; and

(2) recovering the expressed product polypeptide.

25

22. A fusion protein comprising at least a portion of a protein III or protein VIII filamentous phage coat protein having a heterologous polypeptide fused to the carboxyl-terminus thereof.

30

23. A replicable expression vector comprising a gene fusion, wherein the gene fusion encodes the fusion protein of claim 22.

35  
24. A library comprising a plurality of the replicable expression vectors of claim 23, the expression vectors comprising a plurality of different gene fusions encoding a plurality of fusion proteins.

25. Host cells comprising the vector of claim 23.

26. A virus displaying the fusion protein of claim 22 on the surface thereof.

27. A library of virus, comprising a plurality of the virus of claim 26 displaying a plurality of different fusion proteins on the surface thereof.

5 28. A method, comprising:

constructing a library of phage or phagemid particles displaying a plurality of the fusion protein of claim 22 on the surface thereof;

contacting the phage or phagemid particles with a target molecule so that at least a portion of the particles bind to the target molecule; and

10 separating the particles that bind from those that do not bind.

1/17

**Zone 1: codons 1 to 10**

L	1 RNT	2 NAS	3 RNT	4 NAS	5 NAS	6 NYC	7 RNT	8 RNA	9 RNT	10 RNT	(SEQ ID NO. 139)
l	A	D	A	D	D	A	A	A	A	A	
b	D	E	D	E	E	F	D	E	D	D	
r	G	H	G	H	H	I	G	G	G	G	
a	I	K	I	K	K	L	I	I	I	I	
r	N	N	N	N	N	P	N	K	N	N	
y	S	Q	S	Q	Q	S	S	R	S	S	
	T	Y	T	Y	Y	T	T	T	T	T	
	V	V				V	V	V	V	V	
wt	GCC A	GAG E	GGT G	GAC D	GAT D	CCC P	GCA A	AAA K	GCG A	GCC A	(SEQ ID NO. 140) (SEQ ID NO. 141)
1 a	GAT D	AAG K	AGT S	GAG E	AAG K	TTC	GCT	AGA	GAT	GCT	(SEQ ID NO. 142) (SEQ ID NO. 143)
1 b	AAT I	AAG K	GAT D	GAG E	CAG Q	TTC	GCT	AGA	GCT	GCT	(SEQ ID NO. 144) (SEQ ID NO. 145)
1 c	ATT I	TAC Y	ATT I	AAG K	GAG E	ACC	AGT	AAA	AAT	GCT	(SEQ ID NO. 146) (SEQ ID NO. 147)
1 d	AAT N	TAC Y	GTT V	GAC D	CAG Q	GTC	AGT	AAA	AAT	GCT	(SEQ ID NO. 148) (SEQ ID NO. 149)
1 e	GCT A	AAG K	GCT A	GAG E	GAG E	TTC	GCT	GAA	GCT	GCT	(SEQ ID NO. 150) (SEQ ID NO. 151)
1 f	GCT A	GAC D	ATT I	GAC D	GAC D	TTC	GCT	AGA	AGT	GCT	(SEQ ID NO. 152) (SEQ ID NO. 153)

**FIG. 1A**

2 / 17

## Zone 2: codons 11 to 20

L	1 1 NWT	1 2 NAS	1 3 RNT	1 4 NYT	1 5 NAS	1 6 RNT	1 7 RNT	1 8 RNT	1 9 RNT	2 0 NAS	(SEQ ID NO. 154)
w t	TTT	AAC	TCC	CTG	CAA	GCC	TCA	CGG	ACC	GAA	(SEQ ID NO. 155)
	F	N	S	L	Q	A	S	A	T	E	(SEQ ID NO. 156)
2 a	TAT	GAG	GCT	CTT	GAG	GAT	ATT	GCT	ACT	AAC	(SEQ ID NO. 157)
	Y	E	A	L	E	D	I	A	T	N	(SEQ ID NO. 158)
2 b	TAT	GAG	GCT	CTT	GAG	GAT	ATT	GCT	ACT	AAC	(SEQ ID NO. 159)
	Y	E	A	L	E	D	I	A	T	N	(SEQ ID NO. 160)
2 c	TAT	GAG	GCT	CTT	GAG	GAT	ATT	GCT	ACT	AAC	(SEQ ID NO. 161)
	Y	E	A	L	E	D	I	A	T	N	(SEQ ID NO. 162)
2 d	TAT	GAC	GTT	CTT	CAG	ATT	GCT	GCT	ATT	AAC	(SEQ ID NO. 163)
	Y	D	V	L	Q	I	A	A	I	N	(SEQ ID NO. 164)
2e*	CTT	AAG	GAT	CTT	AAG	GCT	ACT	GTT	ATT	CAG	(SEQ ID NO. 165)
	L	K	D	L	K	A	T	V	I	Q	(SEQ ID NO. 166)
2f*	TAT	GAG	ACT	ATT	AAG	GAT	GAT	ATT	GTT	AAG	(SEQ ID NO. 167)
	Y	E	T	I	K	D	D	I	V	K	(SEQ ID NO. 168)
2g*	CTT	CAG	AAT	ATT	CAC	AGT	AGT	ATT	AGT	AAG	(SEQ ID NO. 169)
	L	Q	N	I	H	S	S	I	S	K	(SEQ ID NO. 170)
2h*	TAT	AAG	ACT	GTT	CAG	GGT	GCT	ATT	GCT	AAG	(SEQ ID NO. 171)
	Y	K	T	V	Q	G	A	I	A	K	(SEQ ID NO. 172)
2i*	TAT	AAG	ACT	ATT	AAG	AGT	ATT	GCT	AAT	AAG	(SEQ ID NO. 173)
	Y	K	T	I	K	S	I	A	N	K	(SEQ ID NO. 174)
2j*	TAT	TAG	AGT	CTT	CAG	ATT	ATT	GCT	GCT	CAG	(SEQ ID NO. 175)
	Y	Q	S	L	Q	I	I	A	A	Q	(SEQ ID NO. 176)
2k*	TTT	CAG	AGT	CTT	AAG	GAT	ACT	GCT	GAT	GAG	(SEQ ID NO. 177)
	F	Q	S	L	K	D	T	A	D	E	(SEQ ID NO. 178)
2m*	TTT	GAG	AAT	CTT	TAG	GCT	ACT	ATT	ACT	AAG	(SEQ ID NO. 179)
	F	E	N	L	Q	A	T	I	T	K	(SEQ ID NO. 180)

FIG. 1B

3/17

**Zone 3: codons 21 to 30**

	21 NWC	22 NWC	23 NKT	24 NWC	25 NYT	26 NKG	27 NYT	28 NKG	29 NWT	30 NWT	(SEQ ID NO. 181)
L	D	D	C	D	A	G	A	G	D	D	
i	F	F	F	F	F	L	F	L	F	F	
b	H	H	G	H	I	M	I	M	H	H	
r	I	I	I	I	L	R	L	R	I	I	
a	L	L	L	L	P	V	P	V	L	L	
r	N	N	R	N	S	W	S	W	N	N	
y	V	V	S	V	T		T	V	V	V	
	Y	Y	V	Y	V		V		Y	Y	
wt	TAT Y	ATC I	GGT G	TAT Y	GGG A	TGG W	GGG A	ATG M	GTT V	GTT V	(SEQ ID NO. 182) (SEQ ID NO. 183)
3 a	CTT	TTC	TTT	CTC	CTT	GGG	ACT	GIG	CAT	CTT	(SEQ ID NO. 184)
	L	F	F	L	L	G	T	V	H	L	(SEQ ID NO. 185)
3 b	TAC	TAC	CTT	AAC	ATT	TTG	GCT	GIG	TAT	GTT	(SEQ ID NO. 186)
	Y	Y	L	N	I	L	A	V	Y	V	(SEQ ID NO. 187)
3 c	TTC	ATC	CGT	GTC	ACT	TGG	ACT	ATG	TAT	GTT	(SEQ ID NO. 188)
	F	I	R	V	T	W	T	M	Y	V	(SEQ ID NO. 189)
3 d	GTC	ATC	CGT	TAC	GTT	ATG	TCT	ATG	TAT	GTT	(SEQ ID NO. 190)
	V	I	R	Y	V	M	S	M	Y	V	(SEQ ID NO. 191)

**FIG. 1C**

4 / 17




FIG. 2




FIG. 3

5/17




FIG. 4A






FIG. 4B

6/17

**FIG. 5****FIG. 6**

7/17

Link1	GAC	4	AGC	5	ACC	6	ACC	7	ATC	8	CAC	9	CAC	10	ATC	11	CAC	12	AAC	13	ATC	14	CAC (SEQ ID NO. 192)
Link2	D	2	ATC	3	AGC	4	AAC	5	S	6	T	7	H	8	P	9	R	10	N	11	R	12	R (SEQ ID NO. 193)
Link3	ACC	1	ATC	2	G	3	ATC	4	ATC	5	ATC	6	ATC	7	ATC	8	ATC	9	ATC	10	ATC	11	ATC (SEQ ID NO. 194)
Link4	ATC	1	ATC	2	ATC	3	ATC	4	ATC	5	ATC	6	ATC	7	ATC	8	ATC	9	ATC	10	ATC	11	ATC (SEQ ID NO. 195)
Link5	ATC	1	ATC	2	ATC	3	ATC	4	ATC	5	ATC	6	ATC	7	ATC	8	ATC	9	ATC	10	ATC	11	ATC (SEQ ID NO. 196)
Link6	ATC	1	ATC	2	ATC	3	ATC	4	ATC	5	ATC	6	ATC	7	ATC	8	ATC	9	ATC	10	ATC	11	ATC (SEQ ID NO. 197)
Link7	ATC	1	ATC	2	ATC	3	ATC	4	ATC	5	ATC	6	ATC	7	ATC	8	ATC	9	ATC	10	ATC	11	ATC (SEQ ID NO. 198)
Link8	ATC	1	ATC	2	ATC	3	ATC	4	ATC	5	ATC	6	ATC	7	ATC	8	ATC	9	ATC	10	ATC	11	ATC (SEQ ID NO. 199)
Link9	ATC	1	ATC	2	ATC	3	ATC	4	ATC	5	ATC	6	ATC	7	ATC	8	ATC	9	ATC	10	ATC	11	ATC (SEQ ID NO. 200)

**FIG. 7A**

8 / 17

**SUBSTITUTE SHEET (RULE 26)**

**FIG. 7B**

9/17




FIG. 8A




FIG. 8B

10/17




FIG. 9




FIG. 10

11/17




FIG. 11

12 / 17




FIG. 12A




FIG. 12B

13/17




FIG. 12C






FIG. 12D

14 / 17


**FIG. 13****FIG. 14**

	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19
	NWT	NKT	NWT	NYT	NYT	NWT	NWT	NWT	NWT	NWT	NWT	NKG	NYT	NWT	NWC	NKT	NWT	NWT (SEQ ID NO. 266)	
L	F	F	F	F	F	F	F	F	F	F	F	L	F	F	F	F	F	F	
I	L	L	L	L	L	L	L	L	L	L	M	L	L	L	L	L	L	L	
B	I	I	I	I	I	I	I	I	I	I	V	I	I	I	I	I	I	I	
R	V	V	V	V	V	V	V	V	V	V	W	W	V	V	V	V	V	V	
A	N	C	N	S	S	C	N	N	N	N	R	S	S	Y	C	N	N	N	
R	H	R	H	P	P	R	H	H	H	H	G	P	H	R	H	H	H	H	
Y	N	S	N	T	T	S	N	N	N	N	N	T	T	N	S	N	N	N	
D	G	D	A	A	G	D	D	D	D	D	A	A	A	D	G	D	D	D	
P12-1	GTT	TTT	GTT	TCT	GAT	GTT	GAT	AAT	AAT	AAT	TGG	ATT	TGG	GCT	GTC	GGT	ATT	GTT (SEQ ID NO. 267)	
P12-2	V	F	V	F	V	D	V	D	N	N	W	I	W	A	V	1	V (SEQ ID NO. 268)		
P12-3	CAT	AGT	CTT	GCT	GTT	ATT	GAT	AAT	TTT	TAT	TGG	GTT	GGG	TTT	TAC	GGT	TAT	GTT (SEQ ID NO. 269)	
P12-4	H	S	L	A	V	I	D	D	N	F	Y	W	G	F	Y	G	Y	V (SEQ ID NO. 270)	
P12-5	CTT	TTT	TAT	CCT	GTT	AGT	GTT	ATT	GTT	ATT	CGG	TTT	TTC	TCT	CTC	CTC	CTT	GTT (SEQ ID NO. 271)	
P12-6	L	F	Y	P	V	S	V	H	I	V	R	F	L	S	L	F	L	V (SEQ ID NO. 272)	
P12-7	CTT	AGT	GTT	GTT	GCT	GAT	CTT	ATT	TAT	AAT	GTC	GTT	ATG	TTT	CAC	GTT	GTT	AAT (SEQ ID NO. 273)	
P12-8	L	S	V	R	V	D	L	I	Y	N	V	M	F	H	V	V	V	N (SEQ ID NO. 274)	
P12-9	CTT	GGT	TTT	TCT	ACT	CGT	GTT	GAT	GAT	GAT	TGG	CTT	ATG	GTT	AAC	AGT	TTT	GAT (SEQ ID NO. 275)	
P12-10	L	G	F	S	T	R	V	L	V	D	W	L	M	V	N	S	F	D (SEQ ID NO. 276)	
P12-11	TAT	TTT	GCT	TTT	AGT	TTT	GAT	ATT	GAT	CTT	TGG	CTT	TAC	TTT	GTT	GTT	V	AAT (SEQ ID NO. 277)	
P12-12	Y	F	L	A	F	S	I	I	D	L	F	R	L	Y	F	V	N (SEQ ID NO. 278)		

SUBSTITUTE SHEET (RULE 26)

FIG. 15

16 / 17

**FIG. 16**




FIG. 17




FIG. 18

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 99/16596

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/10 C12N15/62 C07K14/01 C12N1/00 C12N15/86

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 94 11496 A (IXSYS INC) 26 May 1994 (1994-05-26) page 39, paragraph 3 ---	1,2,5, 7-14
X	WO 92 09690 A (GENENTECH INC) 11 June 1992 (1992-06-11) abstract ---	1,2,7-14
X	DATABASE MEDLINE [Online] AN 96105339, 1995 SMITH, G.R. ET AL.: "Expression, purification, and use as an antigen of recombinant sugarcane mosaic virus coat protein." XP002127416 abstract -----	1,3,7,9, 11,12

 Further documents are listed in the continuation of box C. Patent family members are listed in annex.

° Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

13 January 2000

Date of mailing of the international search report

27.04.00

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
 NL - 2280 HV Rijswijk  
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
 Fax: (+31-70) 340-3016

Authorized officer

Smalt, R

# INTERNATIONAL SEARCH REPORT

In. national application No.  
PCT/US 99/16596

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
  
2.  Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
  
3.  Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1.  As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
  
2.  As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
  
3.  As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
  
4.  No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Claims 1-15.

Remark on Protest

The additional search fees were accompanied by the applicant's protest.  
 No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

1. Claims: 1-15

Fusion protein comprising a heterologous polypeptide and a variant of a major viral coat protein, which enhances expression and/or surface display of said fusion protein or heterologous moiety, expression vector encoding said fusion protein, library comprising a plurality of said vectors, host cells expressing said protein, viruses displaying said protein, and a method of decreasing the detection limit of a phage display system using said fusion protein.

2. Claim : 21

Method for expressing a selected polypeptide involving screening of a phage-display library.

3. Claims: 16-20

Method of transformation of cells by electroporation.

4. Claims: 22-28, partially

Fusion protein of at least a portion of protein III with a heterologous polypeptide at its C-terminal, expression vector encoding said protein, library comprising a plurality of said proteins, host cell comprising said vector, and a virus displaying said protein.

5. Claims: 22-28, partially

Fusion protein of at least a portion of protein VIII with a heterologous polypeptide at its C-terminal, expression vector encoding said protein, library comprising a plurality of said proteins, host cell comprising said vector, and a virus displaying said protein.

## INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 99/16596

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 9411496	A 26-05-1994	CA 2148838	A	26-05-1994
		EP 0675953	A	11-10-1995
		JP 8505524	T	18-06-1996
		US 5770434	A	23-06-1998
WO 9209690	A 11-06-1992	AT 164395	T	15-04-1998
		CA 2095633	A	04-06-1992
		DE 69129154	D	30-04-1998
		DE 69129154	T	20-08-1998
		EP 0564531	A	13-10-1993
		ES 2113940	T	16-05-1998
		GR 3026468	T	30-06-1998
		JP 7503600	T	20-04-1995
		US 5750373	A	12-05-1998
		US 5534617	A	09-07-1996
		US 5688666	A	18-11-1997
		US 5780279	A	14-07-1998
		US 5846765	A	08-12-1998
		US 5821047	A	13-10-1998
		US 5834598	A	10-11-1998
		US 6022711	A	08-02-2000
		US 6040136	A	21-03-2000